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Abstract 
The purpose of this thesis was to assess long-term outcomes of the visual dysfunction 
arising from the ocular toxicity associated with the anti-epileptic drug vigabatrin 
(VGB). 
The risk of vigabatrin-associated visual field loss (VAVFL) with increasing exposure to 
VGB was modelled from retrospectively collected data from a cohort of 147 individuals 
(median exposure 7.9 years; IQR 3.6, 11.0). The modelled frequency of VAVFL 
increased with increasing exposure and plateaued at 75-80% after approximately 6 
years duration and 5kg cumulative dose. 
The relationship between the numbers of retinal ganglion cell soma and axons, derived 
by standard automated perimetry and time-domain optical coherence tomography 
(TDOCT), respectively, was evaluated in 24 individuals with VAVFL and in 16 
exposed to vigabatrin but with normal fields (VGBN). A strong linear association was 
present between the two outcomes, which was suggestive of an optic neuropathy, and 
was similar to the association for a control group of 18 individuals with open angle 
glaucoma. 
A follow-up visual field, after a median interval of 7.0 years (IQR 6.5, 7.6) was 
determined in 19 individuals with VAVFL and in 8 with VGBN, after a median 
withdrawal from VGB of 7.1 years (IQR 5.4, 8.4). No consistent trend was noted for 
either a deterioration or improvement in the field.  
A follow-up scan of the peripapillary retinal nerve fibre layer (RNFL) thickness, by 
TDOCT, after a median interval of 6.5 years (IQR 5.8, 6.9) was obtained in 13 
individuals with VAVFL and in 4 with VGBN, after a median withdrawal from VGB of 
8.0 years (IQR 5.3, 10.2). No consistent trend was noted for either a deterioration or 
improvement of the RNFL thickness.  
The macular thickness was evaluated by TDOCT in 32 individuals with VAVFL and in 
14 with VGBN. No difference in thickness was noted between the two groups. 
In conclusion, the prevalence of VAVFL, arising from the longer-term exposure to the 
drug, was substantially greater than previously recognized. The strong association 
between structural and functional outcomes, considered in terms of numbers of 
ganglion cell soma and axons, respectively, indicated that vigabatrin toxicity causes an 
optic neuropathy. Within the limits of the cohorts studied and the investigative methods 
employed, there was no evidence for either recovery or worsening of either structural or 
functional abnormality following long-term withdrawal from vigabatrin. Clinicians and 
patients should be alerted to the presence of the above findings. 
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Chapter 1. Epilepsy and vigabatrin 
1.1 Epilepsy  
Epilepsy is a diverse collection of clinical syndromes with a common characteristic of 
seizures as a consequence of abnormal synchronization and amplification of neural 
firing in electrical unstable areas of the brain (Tobias, Brodie and Brodie, 1994). The 
prevalence of epilepsy is between 5-10 cases per 1000; (Beghi, 2004; Wheless, Ramsay 
and Collins, 2007). According to the National Health Service, approximately 456,000 
people in the UK are affected by epilepsy (Medicinnet, 2013). The incidence of 
epilepsy in the United States and Europe is between 20 to 70 cases per 100,000 per year 
(Tobias et al., 1994; Brodie et al., 1997; Hesdorffer et al., 2011).  
The prevalence of epilepsy varies with age and gender. The prevalence decreases from 
early childhood to early adulthood and then steadily increases with increasing age. The 
prevalence is slightly higher in males than in females (Hauser, Annegers and Kurland, 
1993; Faught et al., 2012).  
1.2 Mortality of epilepsy  
The risk of death for an individual with epilepsy is greater compared to that for the 
general population. The overall sudden unexpected death in epilepsy (SUDEP) is 0.9-
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2.3 per 1000 person years (Hart, 2012). However, a causal relationship between 
antiepileptic drug therapy (AED) and death cannot be excluded (Ackers et al., 2011). 
1.3 Classification of epilepsy  
The most commonly used systems over the last decade for the classification of epilepsy 
have been those developed under the auspices of the International League Against 
Epilepsy (ILAE), namely, the International Classification of Epileptic Seizures (1981) 
(Berg et al., 2010; Berg and Millichap, 2013) and the International Classification of 
Epilepsies, Epileptic Syndromes and Related Seizure Disorders (1989). However, these 
classifications are gradually being superseded by a revised terminology and schema for 
the organization of seizures and epilepsies proposed by the ILAE Commission on 
Classification and Terminology in 2010 (Berg et al., 2010). Even so, the latter approach 
is the subject of on-going discussion (Byung-In, 2013). 
The ILAE Classification of 1981 and 1989 divided epilepsy into three types: Partial 
seizures, Generalized seizures, and Unclassified seizures. Partial seizures were those 
which began locally and were divided into three subtypes: Simple partial seizures, 
Complex partial seizures, and Partial seizures with secondary generalisation. 
Generalized seizures were divided into six subgroups: Absence seizures, Myoclonic 
seizures, Clonic seizures, Tonic seizures, Tonic-Clonic seizures and Atonic seizures. 
A comparison of the 1981 and 1989 ILAE classifications with the ILEA proposal of 
2010 is reproduced from Berg and Scheffer (2011) as Table  1-1. 
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Old terminology and concepts 
Recommended new terminology 
and concepts 
Focal and generalized 
For seizures 
Focal (previously “partial”): the first 
clinical and electroencephalographic 
changes indicate initial activation of a 
system of neurons limited to a part of one 
cerebral hemisphere 
Focal seizures are conceptualized as 
originating at some point within 
networks limited to one cerebral 
hemisphere 
Generalized: the first clinical changes 
indicate initial involvement of both 
hemispheres 
Generalized seizures are conceptualized 
as originating at some point within and 
rapidly engaging bilaterally distributed 
networks 
For epilepsies 
Localization-related (focal, partial): 
epilepsies with focal seizures Generalized: 
epilepsies with generalized seizures 
These terms were abandoned as 
overarching categories for classifying 
epilepsies, per se, as many syndromes 
include both seizure types; they may still 
apply in some but not all instances. 
Aetiology 
Idiopathic: there is no underlying cause 
other than a possible hereditary 
predisposition. Symptomatic: the epilepsy 
is the consequence of a known or suspected 
disorder of the central nervous system 
Cryptogenic: this refers to a disorder whose 
cause is hidden or occult. Cryptogenic 
epilepsies are presumed to be symptomatic 
Genetic: the epilepsy is, as best as 
understood, the direct result of a known 
or presumed genetic defect(s) in which 
seizures are the core symptom of the 
disorder. This attribution must be 
supported by specific forms of evidence. 
Structural/metabolic: there is a distinct 
other structural or metabolic condition or 
disease that has been demonstrated to be 
associated with a substantially increased 
risk of developing epilepsy. These 
disorders may be of acquired or genetic 
origin. When of genetic origin, there is a 
separate disorder interposed between the 
gene defect and the epilepsy unknown: 
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Old terminology and concepts 
Recommended new terminology 
and concepts 
the nature of the underlying cause is 
unknown; it may have a fundamental 
genetic basis (e.g., a previously 
unrecognized channelopathy) or it may 
be the consequence of an unrecognized 
structural or metabolic disorder not yet 
identified 
Focal seizure types 
Complex partial: with impairment of 
consciousness. Simple partial: 
consciousness not impaired. 
Secondarily generalized (note: this was not 
the terminology used in the 1981 document 
but has come into common use) 
No specific classification is 
recommended. Seizures should be 
described accurately according to their 
semiologic features without trying to fit 
them into artificial categories 
Organizational structure for epilepsies 
Hierarchically organized by localization-
related, generalized, and undetermined. 
Within those groups, by aetiology 
(idiopathic, symptomatic, cryptogenic) 
No specific organization is proposed. 
Instead a flexible approach depending on 
needs is advocated 
Table ‎1-1: The major changes between the ILAE 1981 and 1989 Classification and 
Terminology (left hand column) and the ILAE Terminology and Concepts proposed in 
2010 (right hand column) (Berg and Scheffer, 2011). 
1.4 Vigabatrin 
Vigabatrin (VGB) was first synthesized in 1974 as an analogue of gamma-aminobutyric 
acid (GABA) (Sankar and Derdiarian, 1998). The latter is the main inhibitory 
neurotransmitter in the central nervous system. The mechanism of action of vigabatrin 
is thought to occur through the selective, non-competitive and irreversible inhibition of 
GABA transaminase, the enzyme which catalyses GABA, thereby increasing whole 
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brain pre-synaptic GABA levels (Lawden, 2006; Willmore et al., 2009). In the rat 
retina, vigabatrin is accumulated in higher concentrations than in the cortex and is 
associated with an accumulation of retinal GABA (Sills et al., 2001). 
Vigabatrin (Sabril) was introduced in 1989 as add-on therapy for adults with drug-
resistant partial epilepsy (Best and Acheson, 2005) and as mono-therapy for infantile 
spasms (IS) (Chiron et al., 1990). By 2006, vigabatrin was available in at least 85 
countries (Wild et al., 2006). Vigabatrin was approved in 2009 by the United States 
Food and Drugs Administration (FDA) as add-on therapy for adults who have 
responded inadequately to alternative anti-epileptic drugs (AEDs) and in whom the 
potential benefits of the drug outweigh the risk of the visual field loss, and as mono-
therapy for children, of one month to two years of age, with IS. 
1.4.1 Efficacy of vigabatrin in adults  
The most recent Cochrane Review of the efficacy of vigabatrin, when used as add-on 
therapy for adults with drug resistant partial epilepsy, is based upon 11 short-term, 
randomised, placebo-controlled trials covering doses of between 1000mg and 6000mg 
and comprises 982 observations on 747 individuals (Hemming et al., 2013). Individuals 
treated with vigabatrin were significantly more likely to obtain a 50% or greater 
reduction in seizure frequency compared with those treated with placebo (Risk Ratio 
[RR] 2.58, 95% CI 1.87 to 3.57). Those treated with vigabatrin were also significantly 
more likely to have treatment withdrawn (RR 2.49, 95% CI 1.05 to 5.88), and were 
more likely to experience fatigue or drowsiness. Some evidence of small study effect 
bias was present, with smaller studies tending to report greater estimates of the RR than 
larger studies. The RR for a 50% reduction in seizure frequency may, therefore, be less 
than that obtained with a meta-analysis of all available studies. 
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1.4.2 Efficacy of vigabatrin in Infantile Spasms (IS)  
Infantile spasms is a rare syndrome that includes a peculiar type of seizure, a high risk 
of psychomotor retardation and, usually, a characteristic pattern to the 
electroencephalogram (EEG) known as hypsarrhythmia (Mackay et al., 2004). IS can be 
associated with cerebral palsy, Down syndrome, tuberous sclerosis, and neuronal 
migration disorders (Hancock, Osborne and Edwards, 2013). The prevalence of IS is 
0.16 to 0.42 per 1000 live births (Hancock, Osborne and Edwards, 2013). 
The most recent Cochrane Review of the efficacy of treatment for IS is based upon 18 
randomised controlled trials and comprises 916 individuals and covers a range of 12 
different pharmaceutical agents ( Hancock, Osborne and Edwards, 2013). Sixteen of the 
18 studies each contained less than 100 individuals. The majority of the studies 
exhibited poor methodology and there was insufficient evidence to recommend 
vigabatrin as a treatment for IS. 
1.5 Vigabatrin-associated visual field loss  
1.5.1 Historical Perspective 
In 1997, a case series, in the British Medical Journal, of three individuals linked the 
presence of visual field loss to the use of vigabatrin (Eke., et al 1997). The individuals 
had been exposed to 2.3kg, 3.5kg and 4.1kg of vigabatrin over 37, 28, and 38 months, 
respectively, and all presented with normal visual acuities but were symptomatic for 
their field loss which manifested as a ‘concentric’ constriction. Two of the three 
individuals exhibited bilateral optic nerve head pallor. All three exhibited abnormalities 
of the Arden Index (the ratio between the light and dark potentials) of the 
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electrooculorgram (EOG) (Arden, Barrada et al., 1962) and of the oscillatory potentials 
of the electroretinogram (ERG) but had normal visually evoked potentials to flash and 
to pattern stimuli. 
A number of additional case reports were subsequently published shortly afterwards as 
Letters to the Editor of the British Medical Journal (Blackwell, Hayllar and Kelly, 
1997; Brodie et al., 1997; Wilson and Brodie, 1997; Wong, Mawer and Sander, 1997). 
The association of vigabatrin with visual field loss was confirmed in the ensuing two 
years (Krauss, Johnson and Miller, 1998; Rao et al., 1998; Arndt et al., 1999; 
Daneshvar et al., 1999; Kalviainen et al., 1999; Lawden et al., 1999; Miller et al., 1999; 
Wild et al., 1999a; Wohlrab et al., 1999) and over the following decade and beyond.  
In the historical context, the findings of Kälviäinen and colleagues in 1999 were unique 
and particularly important in that they referred to adults exclusively treated with 
vigabatrin as monotherapy; thereby excluding the possibility of other AEDs in the 
aetiology of the field loss. Similarly, the study of Wild and colleagues in 1999 was the 
first to report the absence of field loss, other than that attributable to a known aetiology, 
in a substantial number of individuals with epilepsy who had never been treated with 
vigabatrin; thereby adding further evidence to the hypothesis that vigabatrin, alone, was 
associated with visual field loss. 
A retinal location for the toxicity associated with vigabatrin was supported by the 
findings from a case series of 4 individuals in whom the oscillatory potentials were 
absent (Krauss et al., 1998).  
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The three individuals described by Eke and colleagues (1997) subsequently formed part 
of a larger case series of eight individuals (Harding et al., 2000c) and had undergone 
more detailed visual field and visual electrophysiological examination. On withdrawal 
of vigabatrin, the Arden index of these three individuals returned to the normal range, 
indicating a metabolic effect of vigabatrin on the retinal pigment epithelium but the 
visual field loss remained (Harding et al., 2000c). The 30Hz b-wave exhibited a 
reduction in latency in five of the six eyes and the OP1 and OP2 latencies and 
amplitudes were all abnormal (Harding et al., 2000b). The results from the remaining 
ERG responses defined by the International Society for Clinical Electrophysiology of 
Vision (ISCEV) standards were normal as were the Flash and Pattern visual evoked 
potentials (VEPs).  
As of December 2013, there are approximately 200 publications which discuss 
vigabatrin-associated visual field loss in the MEDLINE (1998-2013), SCOPUS (1998-
2013) and CINAHL (1998-2013) databases. 
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1 
Krauss et al., 
(1998) 
A CS – – 38 ERG – – 10 
2 
Rao et al., 
(1998) 
A CS NA NA 15 S – – 73 
3 
Daneshvar et 
al., (1999) 
A CS NA 10 41 S – – 29 
4 
Lawden et al., 
(1999) 
A CS 16 12 31 BOTH 4.2 3,800 52 
5 
Miller et al., 
(1999) 
A L 11 Some 32 BOTH 4.2 5,118 ˜50 
6 
Kälviäinen et 
al.,( 1999) 
A L 18 N 32 S 5.7 – 40 
7 
Wild et al., 
(1999) 
A CS 42 2 88 BOTH 4.0 3,842 
29 
(95% 
CI 21 
to 
39%) 
8 
Wohlrab et al., 
(1999) 
C CS Y  12 K 2.2 – 42 
9 
Arndt et al., 
(1999) 
A CS NA 25 20 S 1.0 3,001 60 
10 
Gross-Tsur et 
al., (2000) 
C CS NA N 17 BOTH – – 65 
11 
Iannetti et al. 
(2000) 
C CS N NA 21 BOTH – – 19 
12 
Manuchehri et 
al. (2000) 
A L 11 20 20 BOTH 4.9 2,894 45 
13 
Midelfart et al., 
(2000) 
A CS 5 NA 18 BOTH – – 44 
14 
Russell-Eggitt 
et al., (2000) 
C CS NA NA 14 K – – 71 
15 
European 
Medicines 
Agency, (1999) 
A L NA NA 335 K 5.0 5,080 
31 
(95% 
CI 
26to 
36%) 
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16 
Malmgren, 
Ben-Menachem 
and Frisén, 
(2001) 
A CS 56 NA 99 K – – 19 
17 
Paul et al., 
(2001) 
A CS NA 9 22 BOTH – 1,186 41 
18 
Pelosse et al., 
(2001) 
C CS NA NA 11 K 3.4 – 55 
19 
Roccella et al., 
(2001) 
C L NA – 12 S – – 33 
20 
Toggweiler & 
Weiser, (2001) 
A CS 11 NA 15 K 3.9 3,062 60 
21 
Besch et al., 
(2002) 
A CS NA NA 20 ERG – – 90 
22 
Jensen et al., 
(2002) 
A CS 10 N 10 K – – 30 
23 
Newman et al., 
(2002) 
A L NA NA 100 K 5.0 4,029 - 
24 
Nicolson et al., 
(2002) 
A CS NA NA 98 S – 5,530 43 
25 
Schmitz et al., 
(2002) 
A L 31 62 29 K – – 45 
26 
Van Der 
Torren et al., 
(2002) 
A L NA NA 29 BOTH 4.6 3,012 68 
27 
Vanhatalo et 
al., (2002) 
C L NA NA 91 K 2.2 1,842 19 
28 
Ascaso et al., 
(2003) 
C L NA NA 15 S 3.5 1,600 20 
29 
McDonagh et 
al., (2003) 
A L Y NA 32 S 7.0 5,865 59 
30 
Fledelius, 
(2003) 
A L 9 Y 26 K 8.5 – 92 
31 
Riise et al., 
(2003) 
A CS NA NA 31 K – – 80 
32 
Moreno et al., 
(2005) 
A CS 15 N 18 S 3.7 – 89 
33 
Pojda-Wilczek 
et al., (2005) 
C L NA NA 19 S – – 53 
34 
Kinirons et al., 
(2006) 
A L NA NA 131 K 6.7 5,879 64 
35 
Tseng et al., 
(2006) 
A CS NA Y 34 S 3.8 3,674 59 
36 
Werth & 
Schadler, 
(2006) 
C CS 70 NA 30 K – – 27 
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37 
You et al., 
(2006) 
C L NA NA 67 S 4.0 1,554 22 
38 
Hui et al., 
(2008) 
A CS 19 NA 18 S 2.0 – 80 
41 
Gaily, Jonsson 
and Lappi, 
(2009) 
C CS NA NA 16 K 1.75 655 6 
42 
Gonzalez et al., 
(2009)  
A L 105 NA 105 K&ERG 2 – 51 
43 
Wild et al., 
(2009) 
A&C L 210 – 
301/ 
85 
BOTH 2.9 1,970 
34/ 
20 
44 
Sergott et al., 
(2010) 
C L 83 NA 258 BOTH – – 19 
45 
Clayton et al., 
(2013) 
A L NA NA 14 K 10 – 93 
A, Adult population; C, Child population; L, Longitudinal study; CS, Cross-sectional 
study; S, Static perimetry; K, Kinetic perimetry; BOTH, Static and Kinetic perimetry; 
ERG, Electroretinogram; NA, Not applicable, VAVFL, vigabatrin-associated visual 
field loss. 
Table ‎1-2: The frequency of vigabatrin-associated visual field loss. The studies 
highlighted in bold indicate those containing individuals with five or more years of 
exposure to vigabatrin.  
1.5.2 The Frequency of vigabatrin-associated visual field loss  
The various estimates of the frequency of vigabatrin-associated visual field loss are 
summarised, by study, in Table  1-2. Aside from the issues associated with the 
representative nature of a given cohort, the determination of the prevalence of 
vigabatrin-associated visual field loss is influenced by the sensitivity and specificity of 
the perimetric technique to identify the vigabatrin-associated visual field loss, by the 
ability of the individual to produce a reliable result, and by the experience of the 
clinician to interpret, correctly, the result from the examination. In addition, it should 
also be noted that approximately 20% to 25% of adult individuals exposed to vigabatrin 
are unable to perform perimetry reliably (Harding et al., 2000c). 
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The frequency of vigabatrin-associated visual field loss ranges from 6% (Gaily, Jonsson 
and Lappi, 2009) to 93% (Clayton et al., 2013). A pooled analysis of 335 individuals, 
from all available studies at the time, yielded a frequency estimate of 32% (95% CI 28, 
36%) (EMEA, 1999). However, the only systematic review of the prevalence of 
vigabatrin-associated visual field loss, which is based upon 32 studies and includes 
1,678 individuals exposed to vigabatrin and 406 controls, found that the median for 
visual field loss was 45% [interquartile range (IQR) 33–60] (Maguire et al., 2010). For 
a mean cumulative dose of 1000g of vigabatrin, the estimated proportion with field loss 
was 34%, compared to 53% for those receiving a cumulative dose of 5000g. For the 
nine studies reporting vigabatrin-associated visual field loss, specifically, the median 
value for vigabatrin-associated visual field loss was 31% (IQR 21–52) and the median 
value of field loss attributed to other causes was 10% (IQR 5–13). Adults yielded a 
higher median proportion with visual field loss than children [55% (IQR 40, 63) 
compared to 33% (IQR 22, 56)]. The studies described within the systematic review 
were based upon relatively short-term exposures to vigabatrin (mean duration 3.9 years; 
standard deviation [SD] 1.5; mean cumulative dose 3.5 kg; SD 1.5 kg).  
The lower prevalence of vigabatrin-associated visual field loss in children may simply 
arise from an under reporting due to an inability to perform perimetry under the age of 
approximately 9 to 10 years. To overcome this latter problem, a field-specific VEP was 
developed which utilised a central stimulus (0° to 5° radius) and a peripheral stimulus 
(30° to 60° radius) (Harding et al., 2000c). Both stimuli consisted of black and white 
checks which increased in size with eccentricity. The checks reversed at different rates, 
allowing separate central and peripheral responses to be recorded. In a limited case 
series of 12 children, the field-specific VEP identified 3 of 4 abnormal visual fields, and 
7 of 8 normal fields, designated by perimetry (Harding et al., 2000c). Alternatively, 
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aspects of the full field ERG can be utilised, such as the outcome to the 30Hz flicker 
(Harding, Robertson and Holliday, 2000a). 
Although it is possible that the prevalence of vigabatrin-associated visual field loss may 
be lower in children, there is no evidence of vigabatrin toxicity in children exposed to 
vigabatrin in utero (Sorri et al., 2005; Lawthom, Smith and Wild, 2008).  
1.5.3 Characteristics of vigabatrin-associated visual field loss  
The visual field loss associated with vigabatrin is, typically, a bilateral and clinically 
symmetrical, ‘concentric’ constriction of the peripheral field which is generally more 
pronounced nasally than temporally, both in terms of area and depth, and which, in 
almost all cases, encroaches upon at least the nasal region of the central field (i.e. out to 
a radius of 27º from fixation) (Wild et al., 2009). By static perimetry, using Goldmann 
stimulus size III, the field loss manifests as a steep sided bi-nasal annulus extending to 
varying degrees, vertically across the horizontal midline and also centripetally. In 
severe manifestations, the defect by static perimetry manifests as a concentric 
constriction to within approximately 15º from fixation (Wild et al., 2009).  
The nasal to temporal asymmetry in the magnitude of the field loss is less apparent by 
kinetic perimetry (Lawden, 2006).  
The frequency of vigabatrin-associated visual field loss is higher with static threshold 
perimetry of the central field and suprathreshold perimetry of the peripheral field 
compared to that with kinetic perimetry of both the central and peripheral field (Odds 
Ratio [OR] 2.32; CI 1.33, 4.16) or the peripheral field only (OR 2.86; CI 0.30, 25.0) 
(Wild et al., 2009). Equally, the results from the systematic review of Maguire et al., 
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(2010) indicated that the median proportion of field loss was higher for a combination 
of static and kinetic perimetry (55% IQR 37, 60) compared either to static perimetry, 
alone, (50%; IQR 30, 62) or to kinetic perimetry, alone, (42% IQR 33, 64).  
The degree of symmetry of vigabatrin-associated visual field loss was used by Conway, 
Cubbidge and Hosking, (2008) to develop a Vigabatrin Severity index and a Defect 
Symmetry Index. 
The visual field loss associated with vigabatrin is initially asymptomatic (Eke et al., 
1997; Lawden et al., 1999; Wild et al., 1999a). The visual acuity is normal, or near 
normal, and the relative sparing of the temporal field in one eye compensates for the 
predominantly nasal defect in the contralateral eye (Wild et al., 1999a). Field loss 
becomes symptomatic as the temporal field becomes increasingly affected, i.e., as the 
field loss becomes a bilateral concentric constriction within approximately 15° 
eccentricity.  
1.5.4 Risk factors for vigabatrin-associated visual field loss 
1.5.4.1 Gender  
Male preponderance is generally considered to be the major risk factor for vigabatrin-
associated visual field loss (Wild et al., 1999a; Hardus et al., 2000b; Hardus et al., 
2000c; Kalviainen and Nousiainen, 2001; Newman, Tocher and Acheson, 2002; Wild et 
al., 2009). The risk of vigabatrin-associated visual field loss is 2 to 2.5 times greater for 
males (OR 2.1, 95% CI 1.20, 4.6%) (Wild et al., 1999a). However, most smaller scale 
studies have failed to show such an association (Manuchehri et al., 2000; Comaish et 
al., 2002; Gonzalez et al., 2009) and, therefore, the lack of an association is reflected in 
the results of the systematic review of (Maguire et al., 2010). 
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1.5.4.2 Age 
Although many studies have not specifically addressed the issue of age, the frequency 
of vigabatrin-associated visual field loss is considered to be lower in children than in 
adults. As was discussed earlier, the systematic review of Maguire et al., (2010), for 
example, found the median proportion of adults with field loss of all types was 55% 
IQR 40, 63) compared to that for children of 33% (IQR 40, 63). As was also discussed 
earlier, the lower frequency of vigabatrin-associated visual field loss in children is most 
likely to reflect the difficulties in obtaining a reliable result from the visual field 
examination.  
1.5.4.3 Smoking 
Smoking exhibits borderline significance as a risk factor for developing vigabatrin-
associated visual field loss (Wild et al., 1999a; Kalviainen and Nousiainen, 2001).  
1.5.4.4 Cumulative dose of vigabatrin  
The association of larger cumulative doses of vigabatrin with a higher frequency of 
cases of vigabatrin-associated visual field loss is equivocal. However, as discussed 
previously, the systematic review of Maguire et al., (2010) found a prevalence of 34% 
with visual field loss (of all types) for a mean cumulative dose of 1000g compared to 
53% for a mean cumulative dose of 5000g. However, in a study not included in the 
systematic review, the prevalence of vigabatrin associated visual field loss was 4% (2 of 
51 individuals) for cumulative doses of less than 1000g and 71% (10 of 14 individuals) 
for cumulative doses of greater than 3000g (Malmgren, Ben-Menachem and Erisén, 
2001). The latter study was unusual in that the cohort comprised a relatively large 
number of individuals who had low cumulative doses of vigabatrin but the composition 
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highlighted the clear distinction between low and higher cumulative doses of vigabatrin 
in the evolution of vigabatrin associated visual field loss. Similar findings were reported 
by Lawden et al., (1999); the mean cumulative dose for those without vigabatrin-
associated visual field loss was 1.7kg compared to 4.4kg for those with vigabatrin-
associated visual field loss.  
Interestingly, in the largest study to date and which involved 734 individuals of whom 
421 were exposed to vigabatrin and based upon the 524 individuals who were able to 
undertake a visual field examination reliably (386 exposed to vigabatrin and 138 
exposed to other AEDs), the presence of vigabatrin-associated visual field loss was 
associated with mean daily dose of vigabatrin (OR 26.4; 95% CI 2.4, 291.7) (Wild et 
al., 2009). Other studies have reported that cumulative vigabatrin exposure is positively 
correlated with the prevalence of vigabatrin-associated visual field loss (Manuchehri, 
2000; Hardus et al., 2001b; Malmgren et al., 2001) and with the severity of the field 
loss (Manuchehri, 2000; Hardus et al., 2001b;  Frisen, 2004). Alternatively, increasing 
cumulative dose of vigabatrin has not been found to be associated with a higher 
frequency of vigabatrin-associated visual field loss (Kalviainen et al., 1999; Newman et 
al., 2002; Nicolson et al., 2002; Kinirons et al., 2006). 
1.5.4.5 Duration of vigabatrin therapy 
The association of longer durations of vigabatrin therapy with a higher frequency of 
vigabatrin-associated visual field loss is also equivocal. The systematic review of 
Maguire et al., (2010) failed to find any association between duration of vigabatrin 
therapy and the presence of visual field loss. The studies were based upon relatively 
short-term exposures to vigabatrin (mean duration 3.9 years; standard deviation [SD] 
1.5; mean cumulative dose 3.5 kg; SD 1.5).  
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However, the study by Wild and colleagues in 2009, which is described in above, found 
that the frequency of vigabatrin-attributed visual field loss increased substantially with 
increase in the duration of vigabatrin therapy (OR 15.2; 95% CI 4.4 to 51.7). Such 
findings are in accord with those of (Lawden et al., 1999; Hardus et al., 2001b; 
Malmgren et al., 2001; Toggweiler and Wieser, 2001; Schmitz et al., 2002). 
Individual cases of vigabatrin associated visual field loss have been reported after 6 
weeks (Schmitz, 1999), and 6 months (cumulative dose 365g) (Kiratli and Türkçüoğlu, 
2001) of vigabatrin. However, the field loss (confirmed as that attributable to vigabatrin 
toxicity) was only illustrated for the individual described in the latter study.  
1.5.5 Cumulative dose/ duration of vigabatrin and the severity of 
vigabatrin-associated visual field loss 
The association between cumulative dose and/ or duration of vigabatrin therapy and the 
severity of vigabatrin-associated visual field loss has received relatively little attention. 
Most studies have utilised inappropriate perimetric methodology to determine the full 
range of the depth of the field loss, i.e., examination with two-zone age-corrected 
suprathreshold perimetry (Manuchehri, 2000), with the Esterman Test (Hardus et al., 
2001ab) with the II4e and V4e (Frisen, 2004) with the I4e (Newman et al., 2002) or 
with the V4e isopter (Hardus et al., 2001ab; Malmgren et al., 2001). However, the latter 
study found modest relationships, accounting for 25% to 45% of the variance, between 
the extent of the V4e isopter and mean daily dose, cumulative dose and duration of 
vigabatrin, respectively, in a cohort of 92 individuals with a maximum cumulative dose 
approaching 7 to 8kg (Hardus et al., 2001ab). A similar level of association was found 
by Frisen, (2004) for 10 individuals (with a maximum cumulative dose of 
approximately 4kg) for the extents of the nasal (R
2
=0.29) and temporal (R
2
=0.53) II2e 
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isopters and the cumulative dose of vigabatrin. In the same study, however, the 
association for the outcome of Rarebit perimetry was higher (R2=0.85 and R2=0.68, 
respectively). Rarebit perimetry uses short (200msec) presentations of pairs of light 
spots (with a diameter equal to one-half of the normal minimum angle of resolution) 
presented against a dark background. The two spots are separated by 4º. The observer is 
required to indicate the number of spots seen (0-2) on each presentation. The visual 
field is sampled in 5º circular test areas.  
A more modest correlation may be present between cumulative dosage and the mean 
radial degree for the I4e isopter (Clayton et al., 2011) or there may be no correlation at 
all between either cumulative dosage or duration of treatment and radial extent of the 
I4e isopter (r
2
=0.04 and r
2
=0.04, respectively) (Newman et al., 2002).  
Interestingly, the two indices based upon the between-eye symmetry of vigabatrin-
associated visual field loss, the Vigabatrin Severity Index and the Defect Symmetry 
Index developed by Conway et al., (2008) each correlated with the maximum dose. 
1.5.6 The evolution of vigabatrin-associated visual field loss following 
withdrawal of vigabatrin  
There are relatively few studies which have evaluated the subsequent outcome of 
vigabatrin-associated visual field loss following withdrawal from vigabatrin and those 
studies which have been undertaken have involved relatively few individuals over 
relatively short follow-up periods. The definition, and severity, of vigabatrin-associated 
visual field loss are not stated; the sensitivity and specificity of the perimetric technique 
for the detection of change in the visual field, and the definition of change in the field 
loss varies, between the various studies. Nevertheless, it would appear that vigabatrin-
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attributed visual field loss remains stable following withdrawal from vigabatrin (i.e., it 
neither worsens nor improves) over follow-up periods of up to 9 months (Johnson et al., 
2000); 18 months (Newman et al., 2002); more than 24 months (Hardus et al., 2000a; 
Hardus et al., 2000b); 38 months (Nousiainen, Mantyjarvi and Kalviainen, 2001); 4 
years (Hardus et al., 2003) and 4–6 years (Kjellström et al., 2008).  
It should be noted, however, that a number of studies have suggested that the visual 
field improves following withdrawal of vigabatrin (Krakow et al., 2000; Vanhatalo et 
al., 2001). The majority of these reports involve case studies of children (Krakow et al., 
2000; Krämer, Ried and Landau, 2000) and it has been speculated that children are 
more able to repair the retinal damage arising from vigabatrin toxicity. A more 
plausible explanation for the improvement in the visual field is the perimetric learning 
effect, whereby the differential light sensitivity improves over the initial visual field 
examinations, and which would be expected as the child becomes older and more 
capable of performing perimetry. Indeed, the baseline visual field ‘defect’ of a 10 year 
old girl exposed to vigabatrin, illustrated by Versino and Veggiotti, (1999) is clearly 
that attributable to the perimetric fatigue effect. 
1.5.7 The evolution of the normal visual field following withdrawal of 
vigabatrin  
The outcome of the normal visual field following withdrawal of vigabatrin has not been 
studied. Therefore, the potential for, and the time period of, any vigabatrin toxicity 
following withdrawal of the drug is unknown. 
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1.5.8  The evolution of vigabatrin-associated visual field loss with 
continued exposure to vigabatrin 
It is generally accepted that, once established, vigabatrin-associated visual field loss is 
stable and does not progress with continued usage of vigabatrin at least over the short-
term, i.e., 11 months (Lawden et al., 1999); 12 months (Paul et al., 2001); 18 months 
(Graniewski-Wijnands and van der Torren, 2002); 24 months (Schmidt et al., 2002); 38 
months (Nousiainen et al., 2001); 43 months (Best and Acheson, 2005) or between 18 
and 66 months (Kinirons et al., 2006) Table  1-2. Nevertheless, the sensitivity and 
specificity of the perimetric technique for the detection of a progressive worsening of 
vigabatrin-associated visual field loss, and the definition of a worsening of the field 
loss, together with the severity of the field loss again varies between studies.  
A single case report, published after the start of the research for this thesis, described a 
significant worsening of vigabatrin-associated visual field loss, in terms of the extent 
(mean radial degrees) of the I4e isopter over ten years of treatment with vigabatrin 
(Clayton et al., 2010). A subsequent publication from the same group evaluated the 
visual fields of 14 individuals (including the individual from the earlier publication) 
from the baseline visual field (which had been undertaken, on average, 5 years after the 
commencement of vigabatrin) over a follow-up ranging from 104 to 144 months 
(Clayton et al., 2013). Visual field progression for the I4e isopter was present in six 
individuals; however, in 5 of these 6 individuals, progression was from a normal field to 
vigabatrin-associated visual field loss.  
21 
 
1.5.9 The evolution of the normal field with continued exposure to 
vigabatrin 
With the exception of the study by Clayton et al., (2013), the outcome of the normal 
visual field with continuation of longer-term vigabatrin treatment has not been studied. 
Therefore, the potential for, and the time period of, any vigabatrin dysfunction remains 
unknown. 
1.5.10 Electrophysiological abnormalities associated with vigabatrin  
1.5.10.1 Electroretinography 
The outcome of electroretinography (ERG) in individuals exposed to vigabatrin is 
equivocal and no consistent association has been established between any of the ERG 
abnormalities and vigabatrin-associated visual field loss. Initially, the whole-field ERG 
was thought to be normal in individuals with vigabatrin-associated visual field loss 
(Blackwell et al., 1997; Harding, 1997; Lawden et al., 1999).  
1.5.10.1.1  Photopic b-wave  
Subsequently, a reduction in the adult photopic b-wave amplitude was found to be 
present with vigabatrin monotherapy (Coupland et al., 2001), with vigabatrin therapy 
and current or previous exposure to other AEDs (Miller et al., 1999; Coupland et al., 
2001; Comaish et al., 2002) and in individuals withdrawn from vigabatrin with current 
or previous exposure to other AEDs (Coupland et al., 2001; Graniewski-Wijnands and 
van der Torren, 2002; van der Torren et al, 2002). Surprisingly, the association of these 
findings to the presence of vigabatrin-associated visual field loss was not reported in 
two (Coupland et al., 2001; Graniewski-Wijnands and; van der Torren et al., 2002) of 
these studies. However, Miller et al., (1999) found a positive correlation (the magnitude 
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of which was unspecified) between the amplitude of the photopic b-wave and the extent 
of the visual field to an unspecified isopter. In a separate study of 32 individuals 
receiving vigabatrin as monotherapy, 13 exhibited vigabatrin-associated visual field 
loss; three of the 13 exhibited severe field loss and all manifested a reduced photopic b-
wave amplitude (Kalviainen et al., 1999). Similarly, (Hardus et al., 2001a) reported a 
decreased photopic b-wave amplitude to be present with more extensive vigabatrin-
associated visual field loss. Conversely, the photopic b-wave can seemingly be 
unaffected by current vigabatrin therapy even in cases of severe vigabatrin-associated 
visual field loss (Arndt et al., 1999). Interestingly, Harding et al., (2000b) found that, in 
those with severe vigabatrin-associated visual field loss, the photopic b-wave amplitude 
was significantly smaller (p<0.05) for those withdrawn from vigabatrin, and currently 
being treated with carbamazepine, compared to those receiving vigabatrin. This latter 
outcome, was consistent that the finding that the photopic b-wave amplitude is reduced 
in adult individuals with epilepsy receiving carbamazepine who had never been 
exposed to vigabatrin (Harding et al., 2000a; Harding et al., 2000b). A deterioration in 
the photopic b-wave amplitude has been used as a measure for monitoring the 
progression of vigabatrin dysfunction (Cohen et al., 2000). Eleven of 14 individuals 
(78%) with vigabatrin-associated visual field loss showed progressive reduction of the 
photopic b-wave amplitude; however, the specificity was poor in that 23 of 46 
individuals without vigabatrin-associated visual field loss also manifested such changes.  
In infants (median age 7.6 months; range 1.5 to 24 months), the photopic b-wave 
amplitude has been shown to initially increase (p = 0.04) after 6 months and then to 
decrease by 18 months (Morong et al., 2003) either with vigabatrin monotherapy or 
with vigabatrin multitherapy (Westall et al., 2003).  
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Occasional reports suggest that an increase in the implicit time of the photopic b-wave 
can be associated with vigabatrin-associated visual field loss (Besch et al., 2002) 
However; the implicit time of the photopic b-wave is also increased with short duration 
vigabatrin therapy in normal individuals and indicates a metabolic effect resulting from 
an increase in GABA (Harding et al., 1998a). It can also be present in some individuals 
exposed to vigabatrin with normal fields (Jensen et al., 2002).  
1.5.10.1.2  Scotopic b-wave  
Several studies have found a reduction in the amplitude of the scotopic b-wave in 
association with a reduction in the amplitude of the photopic b-wave (Kalviainen et al., 
1999; Miller et al., 1999; Coupland et al., 2001; Hardus et al., 2001a; Comaish et al., 
2002). The reduction in the amplitude of the scotopic b-wave is present in individuals 
receiving vigabatrin monotherapy (Kalviainen et al., 1999; Coupland et al., 2001) in 
individuals receiving vigabatrin monotherapy with severe vigabatrin-associated visual 
field loss; in individuals receiving vigabatrin therapy and current or previous exposure 
to other AEDs (Coupland et al., 2001) with either normal fields (Jensen et al., 2002) or 
with vigabatrin-associated visual field loss (Daneshvar et al., 1999; Miller et al., 1999; 
Hardus et al., 2001a; Comaish et al., 2002; Jensen et al., 2002); and in individuals 
withdrawn from vigabatrin with current or previous exposure to other AEDs (Coupland 
et al., 2001). Interestingly, Graniewski-Wijnands and van der Torren (2002) found that 
six of nine individuals exhibited abnormalities of the scotopic b-wave amplitude and 
implicit time immediately prior to withdrawal of vigabatrin and that, following 
withdrawal, the appearance returned to the normal range in 4 of the 6 individuals. 
However, the proportion of these 6 individuals with vigabatrin-associated visual field 
loss was not given. Conversely, other groups have found no abnormality of either the 
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scotopic b-wave amplitude or implicit time with exposure to vigabatrin (Arndt et al., 
1999; Harding et al., 2000b).  
1.5.10.1.3  30 Hz flicker 
The 30 Hz flicker ERG is considered to be the most effective electrophysiological 
technique for the detection of vigabatrin-associated visual field loss: a reduced 30Hz 
flicker b-wave amplitude predicted vigabatrin-associated visual field loss with 100% 
sensitivity at a specificity of 75% (Harding et al., 2000b). An abnormal 30Hz flicker 
amplitude and an abnormal implicit time has also been shown to be present with 
vigabatrin-associated visual field loss (McDonagh et al., 2003). In addition, a reduction 
in the 30Hz flicker b-wave amplitude correlates (r = 0.64, and r = 0.72) with the degree 
of visual field constriction by kinetic perimetry (Miller et al., 1999). Conversely, no 
correlation has been found between either 30Hz flicker implicit time (r=0.22) or 
amplitude (r=0.21) and cumulative dose of vigabatrin (McDonagh et al., 2003). The 
reduction in the 30Hz flicker b-wave amplitude has been found in a modest number of 
individuals receiving, variously, vigabatrin monotherapy; vigabatrin therapy and current 
or previous exposure to other AEDs; and previous vigabatrin with current or previous 
exposure to other AEDs (Coupland et al., 2001). Interestingly, in a case series of eight 
individuals, vigabatrin-associated visual field loss and abnormal 30Hz flicker b-wave 
amplitude, present whilst receiving vigabatrin therapy, were still present in all eight 
individuals at follow-up 4–6 years after discontinuation of vigabatrin (Kjellström et al., 
2008). Conversely, in a separate study of vigabatrin-associated visual field loss, at 
100% sensitivity, Cohen et al., (2000) was only able to demonstrate a specificity of 
50% for the 30Hz flicker b-wave amplitude.  
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In children, the 30Hz flicker amplitude declines between 6 months and 1 year of 
vigabatrin treatment (Westall et al., 2003). Indeed, the 30 Hz flicker cone b-wave 
amplitude was abnormal in each of seven children with vigabatrin-associated visual 
field loss and normal in each of five children with normal fields (Ponjavic and 
Andréasson, 2001). Conversely, an abnormal 30Hz flicker amplitude occurred 
infrequently in 114 paediatric individuals (median age at test 22.9 months; range 2.4 to 
266.1; and median duration of vigabatrin (9.7 months; range 0.3 to 140.7) (Moskowitz 
et al., 2012). In a subset of 39 children who underwent perimetry, there was no 
significant association between visual field loss and any ERG parameter (Moskowitz et 
al., 2012).  
1.5.10.1.4  Photopic and Scotopic a-waves 
Normal photopic and scotopic a-waves are present with vigabatrin monotherapy 
(Coupland et al., 2001), with vigabatrin therapy and current or previous exposure to 
other AEDs (Coupland et al., 2001) and in individuals withdrawn from vigabatrin with 
current or previous exposure to other AEDs (Coupland et al., 2001). However, 
individuals receiving vigabatrin monotherapy with severe visual field loss exhibit a 
reduced photopic and scotopic a-wave amplitude (Kalviainen et al., 1999). Indeed, a 
reduction in the photopic a-wave amplitude can be found in some individuals with 
vigabatrin-associated visual field loss (Jensen et al., 2002). However, in individuals 
with severe vigabatrin-associated visual field loss, the implicit time of the scotopic a-
wave is prolonged in those receiving vigabatrin compared to those withdrawn from the 
drug (Harding et al., 2000c). This latter finding suggests that scotopic a-wave implicit 
time is more related to current vigabatrin therapy than to the presence of the field loss. 
Increases in the implicit times of either the scotopic or photopic a-waves are also 
present in individuals currently treated with vigabatrin irrespective of the presence of 
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vigabatrin-associated visual field loss (Miller et al., 1999). Interestingly, Harding et al., 
(2000c) also found that the photopic a-wave latency increased with increasing severity 
of the visual field defect. Conversely, the photopic and scotopic a-waves (Arndt et al., 
1999; Daneshvar et al., 1999) or the photopic a-wave (Comaish et al., 2002) are also 
normal in individuals exposed to vigabatrin irrespective of the presence of vigabatrin-
associated visual field loss. 
In children, the amplitude and implicit time of the a-wave for the combined rod-cone 
response have been found to be abnormal (Kjellstrom, Andreasson and Ponjavic, 2011). 
Similarly, the amplitude of the a-wave for the combined rod-cone response is abnormal 
in adults with vigabatrin-associated visual field loss (Kjellstrom, Andreasson and 
Ponjavic, 2013). 
1.5.10.1.5  Oscillatory potentials  
Reduced photopic oscillatory potentials were found in all four individuals in the case 
series describing the electrophysiological characteristics of vigabatrin-associated 
dysfunction (Krauss et al., 1998). Reduced amplitudes of the photopic oscillatory 
potentials were also present in all 32 individuals who were currently receiving 
vigabatrin, irrespective of the status of the visual field (Miller et al., 1999). Indeed, 
similar frequencies of abnormality of the summed amplitude of the photopic oscillatory 
potentials were found in those treated with vigabatrin monotherapy, those treated with 
vigabatrin multitherapy and those withdrawn from vigabatrin, respectively; although the 
relationship to the presence of vigabatrin-associated visual field loss was not stated 
(Coupland et al., 2001). However, in the case series of 18 individuals receiving 
vigabatrin described by Arndt et al., (1999) the oscillatory potentials were absent in all 
five individuals with severe loss but were also present in 4 of 7 individuals with mild 
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loss and absent in 2 of 7 individuals with normal visual fields. Similarly, in the case 
series of individuals receiving vigabatrin monotherapy described by Kalviainen et al., 
(1999), the oscillatory potentials were absent in all three individuals with severe loss 
and in 6 of the 10 individuals with mild loss. However, Harding et al., (2000b) found 
that the latency of the second oscillatory potential was prolonged in current compared 
to previous vigabatrin users, all with advanced visual field loss, suggesting that the 
increase was more related to current vigabatrin use than to the presence of the visual 
field loss. The association between abnormality of the oscillatory potentials and 
vigabatrin-associated visual field loss, particularly in those with advanced loss, was also 
reported by Besch et al., (2002) and by Comaish et al., (2002). The latter group found a 
strong correlation (r = 0.83) between the averaged amplitude for the first three 
oscillatory potentials and the area of the remaining field. A correlation has also been 
found between the implicit time of the second and third oscillatory potentials and the 
presence of vigabatrin-associated visual field loss (van der Torren et al., 2002). 
However, whilst the latency of the first oscillatory potential is associated with severe 
vigabatrin-associated visual field loss the second oscillatory appears to be affected by 
the presence of current vigabatrin therapy (Harding et al., 2000c). However, the 
reduction in the amplitude of the first and of the second oscillatory potentials remained 
in all 8 individuals with vigabatrin-associated visual field loss 4–6 years after 
withdrawal of vigabatrin (Kjellstrom et al., 2013). Conversely, the oscillatory potentials 
were normal in all 9 individuals with vigabatrin-associated visual field loss in the case 
series of (Daneshvar et al., 1999).  
In infants, the early oscillatory potentials showed a significant reduction after 6 months 
and remained as such for the duration of treatment (Westall et al., 2003). 
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1.5.10.2 Multi-Focal Electroretinogram (mfERG) 
Relatively few studies have utilised the mfERG to investigate vigabatrin-associated 
dysfunction and the results are equivocal. In a case presentation of an individual with 
vigabatrin-associated visual field loss, the second oscillatory potential of the full field 
ERG was abnormal and the mfERG normal (Ruether et al., 1998). However, in four 
individuals with vigabatrin-associated visual field loss, two from each of two separate 
case series, a marked overall reduction in amplitude of the mfERG was present 
peripherally which correlated with the appearance of the visual field; the implicit times 
were normal (Mackenzie and Klistorner, 1998; Lawden et al., 1999). A subsequent case 
history described the outcome of the wide-field (90°) mfERG in an individual with 
vigabatrin-associated visual field loss (McDonagh et al., 2003). Normal retinal function 
was recorded in the central 40° of both eyes; however, a delay in implicit time occurred 
with increase in eccentricity together with a marked reduction in peripheral b-wave 
amplitudes. Nevertheless, in another study, a reduced amplitude was only found in 12 
of 20 individuals exposed to vigabatrin; however, the mfERG oscillatory potentials 
were delayed in all 18 individuals with vigabatrin-associated visual field loss (Besch et 
al., 2002).  
In a case series of 12 children exposed to vigabatrin, 7 of whom exhibited vigabatrin-
associated visual field loss, 6 had a reduced amplitude of the peripheral mfERG 
although there was little correlation with the visual field loss (Ponjavic and Andréasson, 
2001).  
The wide-field mfERG exhibits a reduced peripheral amplitude and an increased 
implicit time compared to the central amplitude response in individuals with vigabatrin-
associated visual field loss (McDonagh et al., 2003). Of the 32 individuals exposed to 
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vigabatrin, all 19 with vigabatrin-associated visual field loss were identified whilst 2 of 
the 13 individuals with a normal field were classified as abnormal, i.e., 100% sensitivity 
and 86% specificity. However, of the 21 individuals who had never received vigabatrin 
all 21 exhibited a normal field but, of these, 8 manifested a reduction of the peripheral 
amplitude mfERG. 
A later, and more extensive, study, from the same centre (Gonzalez et al., 2009), 
comprised 56 individuals currently treated with vigabatrin (Group 1), 49 previously 
treated with vigabatrin (Group 2), 46 with no previous exposure to vigabatrin but 
receiving GABAergic anti-epileptic drugs (Group 3) and 53 individuals treated with 
non-GABA-ergic anti-epileptic drugs but with no prior exposure to any GABAergic 
drug (Group 4). Bilateral visual field constriction was present in 59% of individuals in 
Group 1, in 43% of individuals in Group 2, in 24% of individuals with no exposure to 
vigabatrin (Groups 3 and 4). Wide-field mfERG abnormalities were present in 48% of 
individuals in Group 1 and in 22% of individuals in Group 2. A total of 21 vigabatrin 
exposed individuals (current and previous) exhibited visual field loss in the presence of 
a normal mfERG whereas only 3 vigabatrin exposed individuals manifesting a normal 
visual field exhibited an abnormal mfERG. However, the results of the full-field ERG 
were equivocal. Bilateral reductions in the amplitude of rod, oscillatory potential, cone 
a-wave, cone b-wave, and 30Hz flicker responses were noted in individuals with visual 
field loss compared to those without. However, such reductions were also present in 
individuals in Group 3 i.e., those with no previous exposure to vigabatrin but receiving 
GABAergic anti-epileptic drugs. Notably, the reduction in the amplitude of the 
photopic b-wave correlated with the presence of wide-field mfERG abnormalities for 
individuals in Group 1.  
30 
 
Interestingly, Kjellstrom et al., (2013) found significant positive correlations, in 12 
individuals with vigabatrin-associated visual field loss and previously exposed to 
vigabatrin, between the total averaged retinal nerve fibre layer thickness derived by 
optical coherence tomography (see Section 1.5.12) and the amplitudes of the b-waves of 
the combined rod-cone response (rho r = +0.60; p = 0.04), and the 30Hz flicker 
response (rho r = +0.64; p = 0.026). These correlations were maintained for the retinal 
nerve fibre layer thickness of the superior quadrant and of the inferior quadrant and the 
b-wave amplitude of the combined rod-cone response (superior: rho = +0.66; p = 0.019; 
inferior: rho = +0.73; p = 0.007) and for the 30Hz flicker response (superior: rho = 
+0.73; p = 0.007, inferior: rho = +0.75; p = 0.005). No correlations were present for the 
retinal nerve fibre layer thickness of the temporal quadrant and any of the ERG 
outcomes. 
1.5.10.3 Electrooculogram (EOG) 
Two out of the 3 individuals in the original case series of (Eke et al., 1997) exhibited an 
abnormal Arden Index of the EOG; however, following withdrawal of vigabatrin, the 
Arden Index returned to the normal range in both individuals (Harding, 1997).  
The link between an abnormal EOG and vigabatrin-associated visual field loss, in 
current vigabatrin users, was also reported by others; however, in these studies, 
individuals with normal visual fields also had an abnormal EOG (Arndt et al., 1999; 
Daneshvar et al., 1999; Lawden et al., 1999; van der Torren et al., 2002). In the study 
by Lawden et al., (1999), the Arden Index was abnormal in all individuals who were 
currently receiving vigabatrin but was reversible upon withdrawal of the drug; the 
improvement in the Arden index, where present, was unrelated to the severity of the 
vigabatrin-associated visual field loss. 
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The improvement in the Arden Index, and/ or the lower frequency of abnormality, 
following withdrawal of vigabatrin has since been confirmed by others (Harding et al., 
1998b; Coupland et al., 2001; Comaish et al., 2002; Graniewski-Wijnands and van der 
Torren, 2002). Furthermore, the Arden Index has been shown to be reduced in young 
normal individuals at nine days of exposure to vigabatrin without any alteration to the 
visual field (Harding et al., 1998a). Collectively, the results from these various studies 
indicate a metabolic effect of vigabatrin on the retinal pigment epithelium and/ or the 
retinal pigment epithelial-outer segment complex.  
1.5.10.4 Visual Evoked Potential  
The majority of studies have found a normal visually evoked potential (VEP) in adults 
(Liegeois-Chauvel et al., 1989; Eke et al., 1997; Mauguiere et al., 1997; Wilson and 
Brodie, 1997; Ruether et al., 1998; Lawden et al., 1999) and in children with vigabatrin-
attributed visual field loss (Uldall et al., 1995). 
However, an abnormal VEP has been found in 22% of 32 individuals exposed to 
vigabatrin (Miller et al., 1999). A similar prevalence (30%) has also been found in 
adults, the majority of whom exhibited advanced vigabatrin-associated visual field loss 
(Daneshvar et al., 1999) and also in children (33%) (Gross-Tsur et al., 2000). The 
reduction in the VEP reflects the central dominance of the traditional summed VEP 
responses and it can be postulated that mfVEP technology may identify vigabatrin 
toxicity more peripherally (Lawthom, Smith and Wild, 2009). 
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1.5.11 Fundal abnormalities and vigabatrin-associated visual field loss 
The fundal abnormalities, visible by ophthalmoscopy, in individuals with vigabatrin-
associated visual field loss, if present, are subtle and include retinal nerve fibre layer 
(RNFL) attenuation (Miller et al., 1999; Frisen and Malmgren, 2003; Buncic et al., 
2004) ‘inverse’ or nasal, optic nerve head atrophy, i.e. that sparing the temporal sector 
which contains the papillomacular bundle  (Frisen and Malmgren, 2003; Buncic et al., 
2004); an abnormal macular reflex (Krauss et al., 1998; Buncic et al., 2004); epi-retinal 
membrane formation (Krauss et al., 1998); peripheral vessel irregularity (Krauss et al., 
1998; Wild et al., 1999a) and peripheral pigmentary disturbances (Lawden et al., 1999; 
Wild et al., 1999a). However, the various fundal abnormalities are not sufficiently 
common, or consistent, to make a diagnosis of vigabatrin toxicity, based upon the 
ophthalmoscopic appearance, alone (Lawden, 2006). The optic nerve head atrophy is a 
late presentation of vigabatrin-associated visual field loss. 
1.5.12 Digital Imaging of the retinal nerve fibre layer 
The imaging of an attenuated peripapillary retinal nerve fibre layer in an individual with 
vigabatrin-associated visual field loss was first described by Viestenz, Viestenz and 
Mardin (2003) using both scanning laser ophthalmoscopy (Heidelberg Retinal 
Tomography) and nerve fibre layer polarimetry (Retinal Nerve Fibre Layer Analyzer 
GDx). The case history described a 70-year-old male exposed to a cumulative dose 
3.7kg of vigabatrin who exhibited bilateral moderate visual field loss, optic disc pallor, 
reduced photopic and scotopic b-wave amplitudes and delayed VEPs.  
The use of optical coherence tomography (OCT) to image the retinal nerve fibre layer 
in an individual with vigabatrin-associated visual field loss was first described by Choi 
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and Kim, (2004). In a land mark case description, an 18 year old male with a 
cumulative dose of approximately 6.0 kg vigabatrin over seven and a half years 
manifested the typical bilateral nasal annular defect present with vigabatrin-associated 
visual field loss. The peripapillary retinal nerve fibre layer thickness by OCT was 
attenuated in all quadrants except for the temporal quadrant in both eyes and the inferior 
quadrant in the right eye. The preservation of the temporal quadrant, i.e., that which 
contains the papillomacular bundle was compatible with the inverse optic atrophy (i.e., 
that sparing the temporal region of the optic nerve head) independently described by 
Frisen and Malmgren, (2003) and Buncic et al., (2004). In the following year, the 
results from a case series of 8 individuals confirmed the presence of an attenuated 
retinal nerve fibre layer in individuals with vigabatrin-associated visual field loss 
(Rebolleda et al., 2005). Twelve eyes had abnormal visual fields, and 4 eyes showed 
normal electrophysiology and normal visual fields. The peripapillary retinal nerve fibre 
layer thickness was attenuated in at least one quadrant in 12 eyes (75%), and in at least 
two quadrants in 9 eyes (56.3%). The most frequently attenuated quadrants were the 
nasal and superior (83%), and inferior (41.7%). The temporal quadrant peripapillary 
retinal nerve fibre layer thickness was normal in all eyes despite the inclusion of cases 
of very advanced (sic) visual field loss. The characteristics of the attenuation and the 
preservation of the temporal quadrant peripapillary retinal nerve fibre layer thickness 
was in accord with that of Choi and Kim, (2004) and entirely compatible with the 
concept of inverse optic atrophy (Frisen and Malmgren, 2003; Buncic et al., 2004). 
In a case-controlled study (Wild et al., 2006), which was accepted for publication prior 
to publication of the commentary by Rebolleda et al., (2005), and which used an OCT 
scan based upon the vertical diameter of the optic nerve head, an attenuated total 
peripapillary retinal nerve fibre layer thickness was found in all 13 adults with 
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vigabatrin-associated visual field loss. Of the 8 individuals who were exposed to 
vigabatrin but who manifested normal fields, 3 exhibited an attenuated total 
peripapillary retinal nerve fibre layer thickness. All but two of the 14 individuals who 
had been exposed to carbamazepine monotherapy (a non-GABAergic anti-epileptic 
drug) and all 7 of the individuals treated with sodium valproate monotherapy (a mildly 
GABAergic anti-epileptic drug) exhibited a total peripapillary retinal nerve fibre layer 
thickness within the normal range. Subsequent studies have confirmed that lack of 
peripapillary retinal nerve fibre layer thinning in individuals exposed to other anti-
epileptic drugs (Lawthom et al., 2009; Akçakaya et al., 2010; Clayton et al., 2011; 
Moseng et al., 2011; Clayton et al., 2012).  
The characteristic pattern of peripapillary retinal nerve fibre layer attenuation unique to 
vigabatrin-attributed toxicity, namely superior and/ or inferior quadrant thinning, either 
with or without nasal quadrant thinning and a normal temporal quadrant thickness was 
subsequently confirmed in other cohorts (Lawthom et al., 2009; Akçakaya et al., 2010; 
Moseng et al., 2011; Clayton et al., 2012; Kjellstrom et al., 2013).  
Apart from the initial case report by Viestenz et al., (2003), imaging of the retinal nerve 
fibre layer in individuals exposed to vigabatrin by scanning laser ophthalmoscopy and 
by nerve fibre layer polarimetry has received little attention. However, the results from 
the case series of 8 individuals with vigabatrin-associated visual field loss (mean 
cumulative dose of vigabatrin 5.4 kg; mean duration 81 months) described by Durnian 
and Clearkin, (2008) were compatible with those derived by OCT. All eight individuals 
had a significantly reduced peripapillary retinal nerve fibre layer (mean 
TSNIT=36.5μm), particularly superiorly (mean 42.7μm), and inferiorly (mean 39.2μm), 
i.e., an attenuation of the long nerve fibres, which was consistent with the nasal 
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predominance of the field loss. Conversely, in their case control study described above, 
Wild et al., (2006) found that scanning laser ophthalmoscopy exhibited a poorer 
sensitivity (77%) compared to OCT for the detection of vigabatrin-associated visual 
field loss.  
1.5.13 The renaissance of vigabatrin? 
1.5.13.1 Epilepsy 
As was discussed in Section 1.4, vigabatrin gained approval from the US Food and 
Drug Administration (FDA) in August 2009 as monotherapy for individuals from 1 
month to 2 years of age with IS, and as adjunctive therapy for adults with refractory 
complex partial seizures whose seizures have inadequately responded to several 
alternative treatments and for whom the potential benefits outweigh the risk of vision 
field loss (Pellock et al., 2011).  
The FDA approval of vigabatrin was accompanied by the implementation of a Risk 
Evaluation and Mitigation Strategy (REMS) which is a programme designed to reduce 
the risk of vigabatrin-associated visual field loss whilst, at the same time, providing 
risk–benefit analyses for appropriate individual populations The programme is a 
administered through the Support, Help, and Resources for Epilepsy (SHARE) scheme 
administered by the Marketing Authorisation Holder for vigabatrin in the USA, 
Lundbeck Inc (Pellock et al., 2011). The REMS programme included the establishment 
of a registry of individuals in the USA treated with vigabatrin, and which is mandatory 
for prescribers and individuals, to assess the incidence, prevalence, time to onset, 
progression, and severity of vision loss (Pellock et al., 2011). As part of the Registry, 
benefit–risk assessments are required early in the course of vigabatrin therapy: 
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ophthalmological assessments, including visual acuity and perimetry and/ or optical 
coherence tomography, are required at baseline (≤4 weeks after therapy initiation), 
every 3 months during therapy, and at 3 to 6 months after discontinuation (Sergott, 
2010; Sergott et al., 2010; Pellock et al., 2011). 
Following the approval by the FDA, numerous medical-marketing papers, sponsored by 
the Marketing Authorisation Holder for vigabatrin in the USA, have been published, in 
a Supplement to Acta Neurologica Scandanavica (Ben-Menachem, 2011; Ben-
Menachem and Sander, 2011; Carmant, 2011; Faught, 2011; Pellock, 2011; Pellock et 
al., 2011; Plant and Sergott, 2011; Walker and Kalviainen, 2011), but also elsewhere 
(Sergott, 2010; Sergott et al., 2010; Sergott, Foroozan and Pellock, 2012a). 
1.5.13.2  Substance abuse 
Vigabatrin has recently received Fast Track designation from the FDA for the treatment 
of cocaine and/ or methamphetamine dependence (Buddy, 2008). Fast Track is a 
process designed to facilitate the development, i.e. to expedite the review of drugs to 
treat serious conditions and fill an unmet medical need (FDA, 2014). 
GABA suppresses both the firing rate and the amount of dopamine released in the 
brain. As was discussed in Section 1.4, vigabatrin is thought to selectively, non-
competitively and irreversibly, inhibit GABA transaminase, the enzyme which 
catalyses the breakdown (catabolism) of GABA, thereby increasing whole brain pre-
synaptic GABA levels. As a consequence, vigabatrin has been trialled in two open-label 
studies (Brodie, Figueroa and Dewey, 2003; Brodie et al., 2005) and two double-blind 
placebo-controlled studies (Brodie et al., 2009; Somoza et al., 2013) for the treatment of 
cocaine dependence. The efficacy of vigabatrin to induce abstinence is beyond the 
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scope of this review. The treatment regime for the study by Brodie et al., (2009) 
involved a cumulative dose of 131.5g over 9 weeks and that of Berezina et al., (2012) 
and of Somoza et al., (2013) involved escalation of vigabatrin to a maximum of 3g of 
vigabatrin per day after two weeks, which was maintained for nine weeks, and tapered 
to zero at week 12, i.e. a total dose of 218g.  
No cases of vigabatrin-associated visual field loss have been reported in safety studies 
at either the lower (Fechtner et al., 2006) or higher level (Berezina et al., 2012; Somoza 
et al., 2013) of dosing. However, the peripheral field (HFA Program 60-4) was utilized 
in these studies. The definition of visual field change was defined either as a change in 
the Mean Sensitivity by 2SDs of that obtained for the study cohort at baseline in one or 
more quadrants (Fechtner et al., 2006) or, rather liberally, as a reduction in sensitivity 
either of ≥15dB at each of 5 or more stimulus locations or of ≥33% in one or more of 
the three peripheral annuli (Berezina et al., 2012). Interestingly, no definition for the 
change in the visual field was described by Somoza et al., (2013) whilst the definition 
for change in any wave form of the ERG was defined as a ≥50% reduction in amplitude 
or as a ≥50% increase in implicit time, or both.  
1.5.13.3 Migraine Prophylaxis 
Vigabatrin has been trialled as a prophylactic therapy for migraine. However, the latest 
Cochrane review finds that vigabatrin is no better than a placebo in reducing headache 
frequency per 28 day period during treatment (Linde et al., 2013). 
1.5.13.4 Other uses 
GABA-ergic mechanisms are important in the development and maintenance of alcohol 
dependence. However, the efficacy, safety and tolerability of vigabatrin for the 
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treatment of alcohol withdrawal syndrome needs further study (Caputo and Bernardi, 
2010). Vigabatrin may also suppress the craving for nicotine (Wickelgren, 1998).  
Vigabatrin has been shown to be a candidate for cerebral microdialysis in individuals 
with severe head injury (Carpenter et al., 2012). Vigabatrin and GABA levels increased 
more in abnormal brain than in sites further from the lesion(s) (Sergott et al., 2010). 
It has been speculated that a deficiency of the amino acid taurine is associated with 
vigabatrin ocular toxicity (Jammoul et al., 2009).  
In the mammalian retina, taurine is the most abundant amino acid during both 
development and adulthood (Macaione et al., 1974). The concentration in adults is 
higher compared to other parts of the eye and to the brain and to all other organs in all 
species examined (Pasantes-Morales and Cruz 1985). Within the retina the 
concentration is highest in the photoreceptors (Huxtable, 1989) and in the outer nuclear 
layer (Pasantes-Morales et al., 1972). The physiological concentrations of taurine 
cannot occur from endogenous synthesis, alone, and must occur from exogenous 
synthesis of food. Uncooked meat and seafood (Zhao, 1994) and milk and eggs (Hayes 
and Sturman, 1981) are major sources of taurine. Dietary taurine uptake is dependent 
upon transportation across the intestinal barrier to the blood. In human, two intestinal 
transport mechanisms mediate the transport of taurine: a high affinity, low capacity 
NA
+
 and Cl
-
 dependent transporter (Tau-T) and a low-affinity transport for amino acids 
(Anderson et al., 2009). The latter represents the major uptake for taurine. The 
topographical distribution of Tau-T within the mammalian retina suggests that dietary 
taurine in the plasma is taken up by the retinal pigment epithelium and the outer retina 
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to supply the photoreceotors and by the capillary endothelium in the inner retina to 
supply the ganglion cells (Vinnakota et al., 1997). 
The role of taurine, particularly in the retina is unclear. Taurine is considered to be an 
anti-oxidant (Froger et al., 2014). It is also a mediator of cellular Ca
2+ 
influx and may be 
cytoprotective by preventing excitotoxicity due to excess glutamate release and 
glutamate receptor activation (El Idrissi and Trenkner, 1999) particularly in NMDA-
exposed retinal ganglion cells. Taurine is considered to be an agonist of all the GABA 
receptors (Albrecht and Schousboe, 2005; Jones and Palmer, 2009) although there is no 
clear evidence of GABAB activation (Froger et al., 2013). It may also activate the 
strychnine-sensitive glycine ionotropic receptors in retinal ganglion cells (Bulley and 
Shen, 2010) and in cones (Balse et al., 2006) and be responsible for 5HT receptor 
activation in ganglion cells (Bulley et al., 2013).  
Dietary deprivation of taurine, as expressed by depletions both in plasma and in retinal 
concentrations, in cat (Hayes et al., 1975; Aguirre, 1978), in infant primate  (Imaki et 
al., 1998) and in children and adult humans (Ament et al., 1986; Milea et al., 2000) 
leads to extensive photoreceptor degeneration.  Taurine depletion, with the consequent 
photoreceptor degeneration, can also be induced by pharmacological agents such as 
guanidoethane and Β-alanine which can be used to block Tau-T activity and therefore 
decrease the synthesis of exogenous taurine and subsequent uptake  (Lake et al., 1988; 
Pasantes Morales et al., 1983). Guanidoethane treated mice also exhibit ganglion cells 
loss which was initially considered to be secondary to the photoreceptor degeneration as 
with retinitis pigmentosa (Lake and Malik et al., 1988; Imaki et al., 1998)  but is now 
considered to occur concomitantly with the photoreceptor degeneration  (Gaucher et al., 
2012). Similarly, taurine depletion induced in knockout mice by disruption of the gene 
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encoding Tau-T leads to photoreceptor degeneration (Heller-Stilb et al., 2002; Rascher, 
Servos et al., 2004). 
Vigabatrin exposed rats exhibit depleted plasma levels of taurine compared to controls 
and the extent of the taurine depletion negatively correlates with the photopic ERG 
amplitudes and with cone density (Jammoul et al., 2009). In the same study, vigabatrin-
treated rats who received taurine supplementation via drinking water exhibited higher 
plasma taurine levels, a greater cone density and greater photopic ERG amplitudes than 
those vigabatrin exposed rats who did not receive supplementation. However, these 
measures were lower than untreated rats indicating that taurine may have a 
cytoprotective role in vigabatrin toxicity.  
Clearly, the role of taurine depletion in the development of vigabatrin ocular toxicity in 
human requires investigation. 
1.6 Summary 
Vigabatrin is a well-tolerated anti-epileptic drug which is used as add-on therapy for 
adults with drug-resistant partial epilepsy and as monotherapy for infantile spasms.  
Vigabatrin causes retinal toxicity which results in vigabatrin-associated visual field 
loss; a bilateral and clinically symmetrical, ‘concentric’ constriction of the field which 
is generally more pronounced nasally than temporally, particularly within the central 
field. 
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The frequency of vigabatrin-associated visual field loss varies from 6% for exposures 
up to 1.75 years to 93% for exposures up to 10 years with an ‘accepted’ frequency of 
between 30% and 40%. However, the frequency for longer-term exposures, such as the 
latter, remains to be confirmed. The frequency in children is thought to be lower than in 
adults. The frequency of vigabatrin-associated visual field loss is higher with standard 
automated perimetry than with kinetic perimetry. 
Male gender is a risk factor for vigabatrin-associated visual field loss. The association 
between duration and cumulative dose of vigabatrin-associated visual field loss is 
equivocal.  
No consistent association has been established between abnormality of the various 
ERGs and the presence of vigabatrin-associated visual field loss. The 30Hz flicker 
exhibits the strongest association with the presence of vigabatrin-associated visual field 
loss. An abnormality of the photopic oscillatory potentials may be associated with a 
metabolic effect of vigabatrin. The Arden Index of the EOG is also associated with the 
use of vigabatrin. 
The fundal signs of vigabatrin toxicity using ophthalmoscopy are subtle but include 
retinal nerve fibre layer thinning and an associated inverse optic atrophy. The retinal 
nerve fibre layer thinning is also present by optical coherence tomography. 
The progressive nature of vigabatrin-associated visual field loss with continued therapy, 
or following withdrawal of the drug, are both equivocal. Given the extent of the 
structural abnormality of the retinal nerve fibre layer, recovery of visual function is 
unlikely.  
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Chapter 2. Rationale for the Research 
2.1 Introduction 
The work described in this thesis is a natural consequence of the previous work 
undertaken on vigabatrin ocular toxicity at Aston University, Birmingham, and, 
subsequently, in the Cardiff School of Optometry and Vision Sciences, Cardiff 
University. 
The initial work undertaken by Professor Wild and colleagues at Aston University had 
contributed to the understanding of the prevalence of the visual field loss associated 
with vigabatrin (Lawden et al., 1999; Wild et al., 1999a); had described the 
characteristics of the visual field loss associated with vigabatrin, namely the bilateral, 
clinically symmetrical, concentric constriction which was more marked nasally than 
temporally (Wild et al., 1999a); and had identified the visual electrophysiological 
abnormalities associated with vigabatrin (Harding et al., 2000b; Harding et al., 2000c).  
The subsequent phases of the work undertaken by Professor Wild and colleagues at 
Cardiff University had concentrated on developing an objective technique for the 
detection of vigabatrin-associated visual field loss using either visual electrophysiology 
(Harding et al., 2002) or ocular imaging of the retinal nerve fibre layer (Wild et al., 
2006; Lawthom et al., 2009); and establishing more accurate estimates of the 
prevalence of vigabatrin associated visual field loss either through an observational 
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study of the largest, to date, cohort exposed to vigabatrin (Wild et al., 2007; Wild et al., 
2009) or by systematic review (Maguire et al., 2010).  
It can be seen from the literature review in Chapter One that, at the commencement of 
this thesis in 2009, the estimates of the prevalence of vigabatrin-associated visual field 
loss varied widely but were taken to be ‘in the region’ of 30-40%. The validity of this 
clinical approximation, in individuals with exposures of up to approximately four years, 
was subsequently confirmed by Maguire et al., (2010). It was also accepted in the 
literature that the field loss was both irreversible (Johnson et al., 2000; Newman, 
Tocher and Acheson, 2002; Hardus et al., 2000a; Hardus et al., 2000b; Nousiainen, 
Mantyjarvi and Kalviainen, 2001; Hardus et al., 2003; Kjellström et al., 2008) and also 
non-progressive upon withdrawal of vigabatrin (Lawden et al., 1999; Paul et al., 2001; 
Graniewski-Wijnands and van der Torren, 2002; Nousiainen et al., 2001; Schmidt et al., 
2002; Best and Acheson, 2005; Kinirons et al., 2006) over a maximum period ranging 
from 4 to 6 years following withdrawal of vigabatrin (Kjellström et al 2008).  
The literature on the outcome of visual electrophysiology was equivocal. It was 
generally accepted that the abnormalities of the electrooculogram which reversed on 
withdrawal of the drug (Harding et al., 1998a; Harding et al., 1998b; Coupland et al., 
2001; Comaish et al., 2002; Graniewski-Wijnands and van der Torren, 2002) were 
indicative of a metabolic effect of vigabatrin and that the abnormalities in the 
electroretinagram were indicative of a retinal location for vigabatrin toxicity which was 
most likely attributable to a cone pathway abnormality (Harding et al., 2000c).  
The literature on the fundal appearance associated with vigabatrin toxicity was limited. 
However, two separate and independent studies had noted the presence of an ‘inverse’ 
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optic atrophy (Buncic et al., 2004) or ‘C-shaped or ‘temporal sparing’ optic atrophy 
(Frisen and Malmgren, 2003) which was associated with vigabatrin-associated visual 
field loss. In addition, attenuation of the retinal nerve fibre layer had, initially, also been 
observed by fundoscopy (Miller et al., 1999; Frisen and Malmgren, 2003; (Buncic et al., 
2004) and, subsequently, by optical coherence tomography (Viestenz, Viestenz and 
Mardin, 2003). A single study had noted the presence of an abnormal macular 
appearance in some cases of vigabatrin-associated visual field loss (Krauss et al 2003). 
The risk factors for vigabatrin-associated visual field loss were generally considered to 
be male gender (Wild et al., 1999a; Hardus et al., 2000b; Hardus et al., 2000c; 
Kalviainen and Nousiainen, 2001; Newman et al., 2002; Wild et al., 2009) and, as 
would be expected, either cumulative dose (Malmgren et al., 2001; Lawden et al., 1999) 
or duration (Lawden et al., 1999; Hardus et al., 2001b; Malmgren et al., 2001; 
Toggweiler and Wieser, 2001; Schmitz et al., 2002) of vigabatrin or mean daily dose of 
vigabatrin (Lawden et al., 1999; Hardus et al., 2001b).  
Clearly, a number of clinically important issues concerning vigabatrin toxicity were 
unknown. In particular, the prevalence of vigabatrin-associated visual field loss arising 
from longer-term usage of the drug was not known. Equally, the relation between the 
structural and/ or functional outcome measures at any given time point was also 
unknown. Moreover, the nature of any progression (i.e. a worsening) in the structural 
and/ or functional outcome measures of vigabatrin toxicity for those either remaining 
on, or withdrawn from, the drug were also unknown. 
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2.2 Primary Aims of the Study 
The Primary aims of the work contained in this thesis were to: 
Model the risk (frequency), by means of a cross-sectional approach, of vigabatrin-
associated visual field loss, in terms of cumulative dose and duration of vigabatrin, with 
particular reference to long-term usage of vigabatrin.  
Determine the relationship between the structural (i.e. retinal nerve fibre layer 
thickness) and functional (visual field severity) outcomes, evaluated in terms of retinal 
ganglion cell count, arising from vigabatrin toxicity. 
Evaluate any progressive nature (i.e. a worsening) of the functional and of the structural 
outcome measures in individuals withdrawn from vigabatrin and in those with 
continuing exposure to the drug.  
Investigate any difference in macular thickness between those with vigabatrin-
associated visual field loss and those exposed to vigabatrin but with normal fields. 
2.3 Clinical Studies and Outcomes 
The various studies described in this thesis were based upon individuals recruited from 
the Alan Richens Unit, Welsh Epilepsy Centre, University Hospital of Wales. The 
appropriate data sets had either been collected previously and were used retrospectively 
or were collected prospectively. All participants conformed to rigid inclusion/ exclusion 
criteria. The study protocols were considered by the National Institute for Social Care 
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and Health Research to lie within the category of clinical audit and, as such, placed the 
work outside of the remit of the National Health Service Research and Ethics 
Committees (Scott, 2009).  
The experimental work was divided into five separate studies.  
2.4 Modelling the risk of visual field loss arising from long-
term exposure to vigabatrin  
The study, described in Chapter 3, involved modelling, from the cross-sectional 
evidence, the risk of visual field loss arising from the long-term usage of vigabatrin. 
The study was a retrospective cohort study of 147 individuals treated with vigabatrin 
for refractory complex partial (focal) seizures. The median duration of vigabatrin 
exposure was 7.9 years (IQR 3.6 to 11.0; range 0.2 to 16.1 years). Eighty-seven 
individuals exhibited vigabatrin-associated visual field loss. The modelling was 
undertaken jointly by an epidemiologist, Professor David Fone, Epidemiologist, and by 
Professor Robert Newcombe, Medical Statistician, both of whom were from the 
Institute of Public Health at Cardiff University. Standard and plateau univariate logistic 
regression techniques were explored. The plateau model for duration and for cumulative 
dose exhibited a better fit than the standard model. The study was published in the 
academic journal CNS Drugs (Appendix). 
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2.5 The structure-function relationship in vigabatrin toxicity 
The study described in Chapter 4 explored the relationship between the structural 
outcome (i.e. the extent of the retinal nerve fibre layer attenuation derived by optical 
coherence tomography) and the functional outcome (i.e. the visual field derived by 
threshold perimetry) in terms of the remaining retinal ganglions cells calculated by each 
technique based upon the model developed by (Harwerth et al., 2010). Such an 
approach, i.e., in terms of remaining ganglion cells, converts the logarithmic scale used 
in perimetry to a linear scale, thereby simplifying the type of potential relationship with 
a linear structural outcome, and is also more appropriate for quantifying residual 
function. The study was undertaken on 40 individuals treated with vigabatrin for 
refractory complex partial (focal) seizures of whom 24 had vigabatrin-associated visual 
field loss. A group of 22 normal individuals and a group of 18 individuals with open 
angle glaucoma were used as controls.  
2.6 Long-term follow-up of vigabatrin-associated visual field 
loss  
The literature suggests that vigabatrin-associated visual field loss neither reverses nor 
progresses over a maximum period ranging from 4 to 6 years following withdrawal of 
vigabatrin (Kjellström et al., 2008). The study described in Chapter 5 evaluated the 
longer-term follow-up of the visual field in 27 individuals exposed to vigabatrin. 
Nineteen of the 27 individuals had vigabatrin-associated visual field loss; of these, 13 
were receiving vigabatrin at the time of their initial visual field examination and the 
remaining six had been withdrawn from vigabatrin prior to their initial examination. Of 
8 individuals with normal fields, 6 had been withdrawn from vigabatrin prior to the 
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initial visual field examination. The median interval between the two visual field 
examinations was 7.02 years (IQR 6.49, 7.61). All individuals had withdrawn from 
vigabatrin prior to the second visual field examinations. 
2.7 The long-term follow-up of vigabatrin-associated retinal 
nerve fibre layer thinning  
To date, there have been no studies evaluating the status of the retinal nerve fibre layer 
thickness following withdrawal of vigabatrin. The study described in Chapter 6 
evaluated the long-term follow-up of the retinal nerve layer thickness in 17 individuals 
exposed to vigabatrin. Thirteen of the 17 individuals had vigabatrin-associated visual 
field loss. Of these, 11 were receiving vigabatrin at the time of the initial optical 
coherence tomography examination and two had been withdrawn from vigabatrin prior 
to the initial examination. Of the four individuals with normal fields, all 4 had been 
withdrawn from vigabatrin prior to the initial optical coherence tomography 
examination. The median interval between the two optical coherence tomography 
examinations was 6.5 years (IQR 5.8, 6.9). 
2.8 The macular thickness in individuals exposed to 
vigabatrin  
Epiretinal membrane formation and either an irregular sheen or abnormal pigmentation 
at the macular have been found in some individuals with vigabatrin ocular toxicity 
(Krauss et al., 2003). The study described in Chapter 7 evaluated the macular thickness, 
determined by time-domain optical coherence tomography, in 62 individuals exposed to 
vigabatrin, of whom 45 exhibited vigabatrin-associated visual field loss. 
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2.9  Logistics 
The visual field and optical coherence tomographic examinations for the studies 
described in Chapters 4, 5, 6 and 7 were undertaken during normal clinic hours in the 
Welsh Epilepsy Clinic and in the Cardiff Eye Unit, respectively, and were, therefore, 
dependent upon the goodwill of the study participants, and of individuals and staff, 
alike. The visual field examinations were undertaken by the Author and the optical 
coherence tomographic examinations by a Senior Medical Photographer, Ms Belinda 
Colton, who was experienced in the technique. The concomitant ophthalmological and 
neurological examinations were undertaken as part of the routine clinical care of the 
given individual. 
In total, a maximum of 147 individuals with refractory partial (focal) epilepsy who were 
exposed to vigabatrin and who had yielded reliable fields were involved in the study 
described in Chapter 3. A total of 72 individuals were examined by the Author during 
the development of this thesis. Of these 72 individuals, 9 yielded unreliable outcomes to 
the visual field examination. The remaining 63 individuals took part in at least one of 
the studies described in Chapters 4, 5, 6 and 7. 
The Author was responsible to Professor John Wild, as supervisor, for the compilation, 
and the quality control, of the data files.  
.   
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Chapter 3. Modelling the risk of visual field loss 
arising from the long-term exposure to 
vigabatrin: a cross-sectional approach 
3.1 Introduction 
It was shown in Chapter One that, although the estimate of the frequency of vigabatrin-
associated visual field loss ranges from 6% (Gaily, Jonsson and Lappi, 2009) to 93% 
(Clayton et al., 2013), the frequency is generally considered to be approximately 32% 
(95% CI 28, 36%) (EMEA, 1999) and is based upon the visual fields of 335 individuals 
submitted to the Committee for Proprietary Medicinal Products (CPMP) of the 
European Medicines Agency in 1999 by the Marketing Authorisation Holder (EMEA, 
1999). The cumulative incidence of vigabatrin-associated visual field loss, derived from 
the cross-sectional data, and modelled for the time to onset, rather than the time to 
detection, of the field loss, increased rapidly in the first two years of treatment and then 
stabilised at three years of exposure (EMEA, 1999). The corresponding model for 
cumulative dose increased steeply within the first 2kg of intake and reached a plateau 
after 3kg.
 
However, the models were limited by the lack of treatment durations in 
excess of 5-6 years and the CPMP noted that there was no reliable evidence to indicate 
that the risk of developing vigabatrin-associated visual field loss lessened after three 
years of treatment (EMEA, 1999).  
It was also shown in Chapter One that a reliable estimate of the prevalence of 
vigabatrin-associated visual field loss could also be gained from the systematic review 
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by Maguire et al., (2010) of 32 observational studies of individuals exposed to 
vigabatrin. This review generated a median of 45% (IQR 33 to 60) for the proportion of 
individuals with field loss. For a mean cumulative dose of 1kg of vigabatrin, the 
estimated proportion with field loss was 34% compared to 53% for 5kg. However, only 
nine studies specifically reported vigabatrin-associated visual field loss as opposed to 
field loss, in general. The median for vigabatrin-associated visual field loss was 31% 
(IQR 21 to 52) and that for field loss attributable to other causes 10% (IQR 5 to 13). 
The studies were also based upon relatively short-term exposures to vigabatrin (mean 
duration 3.9 years; standard deviation [SD] 1.5; mean cumulative dose 3.5kg; SD 1.5) 
(Maguire et al., 2010).  
The longer-term safety profile of vigabatrin in relation to the associated visual field loss 
is unknown. It is, therefore, essential to determine the rate and magnitude of any 
increase in the frequency of vigabatrin-associated visual field loss arising from longer-
term usage.  
3.2 Aim 
The purpose of the study was to assess the risk (frequency) of vigabatrin-associated 
visual field loss, in terms of duration and cumulative dose of vigabatrin, with particular 
reference to long-term usage of vigabatrin in individuals with refractory complex partial 
(focal) seizures.  
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3.3 Methods 
3.3.1 Cohort 
The study was a retrospective cohort study. The cohort was derived from the case notes 
of individuals attending the Alan Richens Unit Welsh Epilepsy Centre, University 
Hospital of Wales, Cardiff, UK, who had been treated with vigabatrin for refractory 
complex partial (focal) seizures. It comprised 147 unselected consecutive individuals 
(80 females, 67 males) who had all yielded a reliable outcome to an identical and robust 
perimetric protocol and for whom a full anti-epileptic drug history was available. All 
individuals had undergone an ophthalmological examination and 145 individuals had 
met predefined inclusion criteria in each eye; namely, a distance refractive error of less 
than or equal to 5 dioptres mean sphere and less than 2.5 dioptres cylinder; a visual 
acuity of 20/30 or better in each eye; normal pupil reactions; an intraocular pressure of 
≤ 21mmHg; open angles; crystalline lens integrity defined by LOCS III (Chylack et al., 
1993) as less than, or equal to, nuclear opalescence grade 2 and nuclear colour grade 2, 
cortical cataract less than or equal to grade C1 and posterior subscapsular cataract less 
than C1; no optic nerve head or fundal abnormalities characteristic of a known disease 
other than vigabatrin toxicity; no previous ocular surgery or trauma; no visual field loss 
other than that attributable either to vigabatrin toxicity or to cortical lesions; no topical 
ocular therapy other than ocular lubricants; no systemic medication known to affect the 
visual field other than vigabatrin; no history of diabetes mellitus and no family history 
of glaucoma. The remaining two individuals had bilateral open-angle glaucoma and 
unilateral central serous retinopathy, respectively. However, in the first individual, the 
vigabatrin-associated visual field loss could be clearly distinguished from the 
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glaucomatous field loss and in the second individual, the vigabatrin-associated visual 
field loss was clearly evident in the contralateral eye. 
Of the 147 individuals, 124 were under the care of the Welsh Epilepsy Unit and 23 had 
been referred from other hospitals for perimetry. Almost all the individuals had 
received vigabatrin in tablet formulation. 
Of the 147 individuals, 137 had commenced treatment with vigabatrin between 1989, 
the year of its licensing, and 1997 inclusive, the year of the first publication linking 
vigabatrin to visual field loss. A further 4 individuals had begun treatment prior to 1989 
on an off-label compassionate basis. Of the remaining 6 individuals, 4 had begun 
treatment in 1998 and one each in 1999 and 2000, respectively. Fifty eight of the 147 
individuals (39.4%) had commenced vigabatrin between 1986 and the end of 1991.  
3.3.2 Visual field examination 
A systematic programme of visual field examination of individuals exposed to 
vigabatrin had been initiated in the Welsh Epilepsy Unit from 2000 onwards as a 
consequence of the then emerging consensus on the association of vigabatrin with 
visual field loss (Eke et al., 1997; Kalviainen et al., 1999; Miller et al., 1999; Wild et 
al., 1999a).
 
All individuals had been/ were withdrawn from vigabatrin, as a safety 
measure, either prior to, or immediately following, the visual field examination.  
Examination of the full field had been undertaken with three-zone age-corrected 
suprathreshold (Humphrey Field Analyzer 750 Full Field 135 Screening Test with 
Goldmann stimulus size III). For the assessment of the central field, each individual 
wore their distance correction in trial lens form together with the appropriate near 
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correction for the viewing distance of the perimeter bowl, where necessary. Individuals 
with visual field results deemed to be abnormal, or to be suspicious of abnormality, had 
then undergone threshold static perimetry of the central field on a separate occasion 
(HFA Program 30-2: Goldmann stimulus size III and the FASTPAC algorithm).  
Each individual had received extensive instruction and practice on the requirements of 
the given visual field examination. Rest periods of one minute had been given after a 
maximum of three minutes of perimetry, during which time the individual had been 
required to continue looking into the bowl of the perimeter. A rest period of 10 to 15 
minutes, in the waiting area of the clinic, had taken place between the examinations of 
the two eyes. Visual field examinations which had yielded greater than 15% incorrect 
responses to the false-positive and/ or greater than 20% incorrect responses to the 
fixation loss catch trials and/ or poor quality outcomes to the gaze tracking had been 
repeated on a separate occasion. Individuals who had manifested such an outcome to 
the repeat examination were not included in the cohort. A similar approach was adopted 
for incorrect responses to the false-negative catch trials: the repeat criterion was greater 
than 30% incorrect responses but the tolerance widened with increase in severity of the 
field loss (Bengtsson and Heijl, 2000). Any examination deemed to have initially 
yielded an equivocal diagnostic outcome, including an apparent learning effect, had 
also been repeated on a subsequent occasion. 
The visual fields of the 147 individuals were reviewed, masked to anti-epileptic drug 
history, by Dr Charlotte Lawthem, Consultant Neurologist, Mr Gareth Lewis, Specialist 
Registrar in Ophthalmology, and Professor John Wild. The visual fields from 15 
individuals with epilepsy who had never been treated with vigabatrin were randomly 
interposed within the series of visual fields for review. These visual fields all exhibited 
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a normal appearance and were included such that the reviewers were aware that not all 
the visual fields for review emanated from patients exposed to vigabatrin. The 
definition of vigabatrin-associated visual field loss followed that previously described, 
namely, a bilateral clinically symmetrical, ‘concentric’ constriction of the peripheral 
field which, by static perimetry using Goldmann stimulus size III, is generally more 
pronounced nasally than temporally (Wild et al., 2009) and which, in almost all cases, 
encroaches upon at least the nasal region of the central field (i.e. out to a radius of 27º 
from fixation) (Wild et al., 2009). In severe manifestations, the defect by static 
perimetry manifests as a concentric constriction to within approximately 15º from 
fixation (Wild et al., 2009). The vigabatrin-associated visual field loss was required to 
exhibit a consistent appearance between suprathreshold and threshold perimetry. The 
perimetric algorithms, and the definition of vigabatrin-associated visual field loss, were 
those approved by the Committee for Proprietary Medicinal Products (CPMP) for the 
investigation of the association between vigabatrin and visual field loss (Wild et al., 
2009). Illustrations of typical vigabatrin-associated visual field loss are given in Wild et 
al (1999). 
The severity of the vigabatrin-associated visual field loss was expressed, objectively, in 
terms of the Mean Deviation (MD) visual field index, averaged across the two eyes. 
The MD is the weighted mean of the difference, across each stimulus location within 
the central field, between the measured value of sensitivity and the age-corrected 
normal value (Heijl, Lindgren and Olsson, 1987b). It enables a continuous (ratio) scale 
of measurement, is used universally in the clinical and in the research setting, and, in 
the context of the current study, expresses the extent of the vigabatrin-associated visual 
field loss within the functionally important central field. Individuals with concomitant 
field loss were omitted from this sub-analysis.  
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3.3.3 Statistical analysis 
Gender; age at the time of the visual field examination; age at onset of epilepsy; age at 
onset of treatment with vigabatrin; duration and cumulative dose of vigabatrin at the 
time of the visual field examination; and anti-epileptic drugs used prior to, and 
concurrently with, vigabatrin were each evaluated as explanatory variables. The extent 
of GABA-ergic activity of each of the other anti-epileptic drugs was expressed, on a 
four point scale, in descending order of empirically assigned magnitude. Tiagabine was 
graded as level 1; the benzodiazepines as level 2; valproate, phenobarbital and 
primodone as level 3; and the remainder as level 4 (Wild et al., 2009). 
The characteristics of the cohort were described with descriptive statistics. Independent 
t-tests for continuously distributed variables, and chi-square tests for categorical 
variables, were used to assess univariate associations between vigabatrin-associated 
visual field loss and the duration and the dose of vigabatrin and between vigabatrin-
associated visual field loss and each of the other explanatory variables. Statistical 
analysis was undertaken using SPSS Statistics 20 (IBM Corporation, Armonk, NY). 
A confidence interval for the relative risk of vigabatrin-associated visual field loss by 
gender was calculated by the score method (Miettinen and Nurminen, 1985). 
The degree of associations between duration and cumulative dose of vigabatrin and the 
severity of vigabatrin-associated visual field loss was characterised by the Spearman 
rank correlation, rs.  
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3.3.4 Modelling 
The increase in the risk (frequency) of individuals with vigabatrin-associated visual 
field loss (p) with increasing exposure to vigabatrin (x) was evaluated by logistic 
regression. In addition to the standard logistic regression model, a plateau model was 
utilised: 
p = k / (1 + exp (- - x)) 
where k denotes a plateau value lower than 1 (100%), and where  and  are intercept 
and slope parameters, respectively. For the plateau model, the risk of vigabatrin-
associated visual field loss at the highest exposures approaches k, not 1, whereas for the 
standard regression model, k  1. The standard and plateau models were fitted by 
maximum likelihood with profile likelihood CIs for the parameters. Comparisons 
between the standard and plateau models were performed by referring the difference in 
deviance to the Chi-square distribution. The two models were each applied separately 
for duration and for cumulative dose. Models of these two exposure variables, 
considered together, were also evaluated. 
3.4 Results 
3.4.1 Demographics of the cohort.  
The age at visual field examination (Table  3-1) ranged from 12.6 to 75.9 years with a 
mean of 40.3 years (SD 13.7), median 39.6, (IQR 30.4 to 50.6); females 40.5 years (SD 
13.4, median 40.1, IQR 30.5 to 50.7), males 40.0 years (SD 14.2, median 38.8, IQR 
30.4 to 50.6).  
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Age Mean (SD) Median (IQR) Min  Max  
All individuals  40.3 (13.7) 39.6 (30.4, 50.6) 12.6 75.9 
Male 40.0 (14.2) 38.8 (30.4, 50.6) 16.1 75.9 
Female 40.5 (13.4) 40.1 (30.5, 50.7) 12.6 66.5 
Table ‎3-1: The summary statistics for the distribution of age amongst the 147 
individuals in the study and for the distribution of age by gender. 
Overall, 87 individuals (59%) exhibited vigabatrin-associated visual field loss; 44 / 67 
(66%) were males and 43 / 80 (54%) females (relative risk 1.22, 95% CI 0.93 to 1.61, p 
= 0.14). 
Gender                                    Status VAVFL (%) 
Vigabatrin exposed 
with normal field (%) 
Total 
Male 44 (51%) 23 (39%) 67 
Female 43 (49%) 37 (61%) 80 
Total 87 (59%) 60 (41%) 147 
Table ‎3-2: The frequency of vigabatrin-associated visual field loss (VAVFL) by 
gender. 
Eleven individuals exhibited superior homonymous quadrantanopia secondary to 
neurosurgery for seizure control; of these, seven exhibited vigabatrin-associated visual 
field loss. Twelve others had homonymous hemianopia or quadrantanopia secondary to 
other causes; of these, eight had vigabatrin-associated visual field loss. No cases of field 
loss were designated in any of the visual fields from the 15 individuals with epilepsy 
who had never received vigabatrin.  
3.4.2 Evaluation of the explanatory variables for vigabatrin-
associated visual field loss  
Individuals exhibiting vigabatrin-associated visual field loss were slightly older at the 
onset of epilepsy and at the time of perimetry, but younger at the onset of treatment 
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with vigabatrin, than those without vigabatrin-associated visual field loss (Table  3-3); 
however, the differences in the mean ages were not statistically significant (1.4 years, 
95% CI -2.9 to 5.8; 0.2 years, 95% CI -4.3 to 4.7; and -3.4 years, 95% CI –8.0 to 1.1, 
respectively).  
The mean duration of vigabatrin therapy, 7.4 years (SD 4.1, median 7.9, range 0.2 to 
16.1 years, IQR 3.6 to 11.0), was not significantly different for gender: females 7.2 
years (SD 4.2) and males 7.6 years (SD 4.0); difference between means 0.5 years (95% 
CI -0.9 to 1.8). Similarly, the mean cumulative dose, 6.4 kg (SD 4.6, median 5.8, range 
0.2 to 19.8, IQR 2.5 to 8.7), was not significantly different for gender: females 6.0 kg 
(SD 4.5) and males 6.8 kg (SD 4.8); difference between means 0.8 kg (95% CI -0.8 to 
2.3).  
Characteristics  Mean (SD) Median (IQR) Min. Max. 
Duration of VGB (yr) 7.4 (4.1) 7.9 (3.6, 11.0) 0.2 16.1 
Cumulative dose of VGB at  
follow-up (kg) 
6.4 (4.6) 5.8 (2.5, 8.7) 0.2 19.8 
Table ‎3-3: The summary statistics for the distribution of duration of vigabatrin therapy 
and the distribution of cumulative dose of vigabatrin amongst the 147 individuals in the 
study. 
The duration and cumulative dose of vigabatrin therapy were highly correlated (rS = 
+0.86, p<0.001) (Figure 3-1).  
The mean duration and mean cumulative dose of vigabatrin therapy (Table  3-4) for 
those with vigabatrin-associated visual field loss was 8.9 years (SD 3.1) and 8.0 kg (SD 
4.4), respectively, compared to 5.2 years (SD 4.3) and 4.0 kg (SD 3.9) for those without 
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vigabatrin-associated visual field loss (difference between means 3.7 years, [95% CI: 
2.5, 4.9] and 4.0 kg, [95% CI: 2.6, 5.5]).  
Duration of vigabatrin (years) 
 Mean (SD) Median (IQR) Min. Max. 
VAVFL 8.9 (3.2) 9.24 (6.8, 11.7) 0.2 15.3 
Normal field  5.3 (3.9) 4.0 (1.4, 9.1) 0.3 16.1 
Cumulative dose of vigabatrin (kg) 
VAVFL 8.0 (4.4) 6.94 (4.7, 9.9) 0.2 19.84 
Normal field 4.0 (4.0) 2.42 (1.1, 6.9) 0.2 16.1 
Table ‎3-4: The summary statistics for the distribution of duration of vigabatrin therapy 
(top) and of cumulative dose of vigabatrin (bottom) by presence or absence of 
vigabatrin-associated visual field loss (VAVFL). 
Vigabatrin-associated visual field loss was not significantly associated with the level of 
GABAergic activity of other anti-epileptic drugs taken either before, or concurrently 
with, vigabatrin. 
The summary statistics of the Mean Deviation visual field index (Table  3-5) for those 
with vigabatrin-associated visual field loss (excluding those with other concomitant 
field loss) were mean -8.12dB (SD 4.9); median -6.5dB (IQR -4.26 to -10.5; range -0.8 
to -29.0dB). The corresponding summary statistics for the MD for those without 
vigabatrin-associated visual field loss (excluding those with other concomitant field 
loss) were mean -1.5dB (SD 1.7); median-1.5dB (IQR -0.06 to -2.6; range -4.8 -1.4dB).  
  
61 
 
 
Figure ‎3-1: The scatter plot of cumulative dose of vigabatrin (kg) against duration of 
vigabatrin therapy (yr) for the individuals with (filled symbols) and without (open 
symbols) vigabatrin-associated visual field loss. 
Characteristics Mean (SD) Median (IQR) Min. Max. 
VAVFL -8.12 (4.9) -6.5 (-4.3, -10.5) -0.8 -29.0 
Normal field -1.5 (1.7) -1.5 (-2.6, -0.06) 1.4 -4.8 
Table ‎3-5: The summary statistics for the Mean Deviation visual field index, averaged 
between the two eyes, by the presence or absence of vigabatrin-associated visual field 
loss (VAVFL). 
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No evidence was found for an association between the severity of the vigabatrin-
associated visual field loss, as expressed by the MD, and either duration (rs +0.22, 95% 
CI -0.03 to +0.45) or cumulative dose of vigabatrin (rs +0.02, 95% CI -0.24 to +0.28). 
Severe vigabatrin-associated visual field loss was noted even at very low exposures. 
Three outlier individuals exhibited severe vigabatrin-associated visual field loss of more 
than two SDs from an assumed linear fitted line of best fit, which was associated with 
durations of 3, 6 and 13 years and cumulative doses of 3, 7, and 19kg, respectively. 
3.4.3 The risk (frequency) of vigabatrin-associated visual field loss 
with increasing exposure to vigabatrin 
The outcome of the visual field examination by decile group of exposure, by current or 
previous vigabatrin therapy at the time of the visual examination, and by severity of the 
vigabatrin-associated visual field loss, expressed in terms of the MD averaged between 
the two eyes, is given in Table  3-6 for duration of vigabatrin therapy and in Table  3-7 
for cumulative dose of vigabatrin. 
The risk (frequency), derived by the plateau model, of developing vigabatrin-associated 
visual field loss according to duration (Figure  3-2) top and to cumulative dose (Figure 
 3-2) bottom of vigabatrin was expressed as the proportion of individuals with 
vigabatrin-associated visual field loss, by decile group of exposure to vigabatrin, plotted 
against the median exposure for the corresponding decile group. The relevant parameter 
estimates are given in Table  3-8. The plateau, towards which the frequency of 
vigabatrin-associated visual field loss increased with increasing exposure, was 76% 
(95% CI 67 to 85) beyond approximately six years duration and 79% (95% CI 70 to 87) 
after approximately 5kg cumulative dose.  
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In comparison to the plateau model, the standard model with k  100% was a highly 
significantly poorer fit to the data (χ2 = 12.75 for duration, χ2 = 18.93 for cumulative 
dose, both p<0.001). The standard model failed to express the very steep rise in the 
proportion of individuals with vigabatrin-associated visual field loss between exposures 
of approximately 2 and 6 kg. It fitted a proportion of 20 - 25% at zero exposure, which 
rose to over 90% for the highest exposures in the cohort; both these modelled 
proportions were much higher than the observed proportions. The observed proportion 
at minimal exposure in the plateau model was very low, but not zero: one individual 
had developed vigabatrin-associated visual field loss after taking 0.189 kg of vigabatrin 
over 9 weeks. A model which incorporated a plateau and constrained the proportion to 
be zero at zero exposure was a slightly poorer fit than the unconstrained plateau model. 
The modelled frequency of individuals with vigabatrin-associated visual field loss 
assumes that the field loss in those who had discontinued vigabatrin prior to the visual 
field examination was not reversible (Johnson et al., 2000; Nousiainen et al., 2001; 
Newman et al., 2002). Seventy-one (48%) individuals were receiving vigabatrin at the 
time of the visual field examination. Visual field loss was marginally significantly more 
common in these latter individuals (48 / 71, 68%) than in those who had discontinued 
treatment (39 / 76, 51%; p = 0.045). However, the individuals who were currently 
receiving vigabatrin had significantly longer durations of use (mean 8.6 years compared 
to 6.2 years, p < 0.001) and significantly greater cumulative doses (mean 7.3kg 
compared to 5.5kg, p = 0.017) compared to those who were not. The incorporation of 
an additional term in the plateau model for current vigabatrin therapy did not give an 
appreciably better fit (χ2 = 0.46, p = 0.50 for duration; χ2 = 0.04, p = 0.84 for 
cumulative dose). 
64 
 
Decile 
Number of 
individuals 
Duration of vigabatrin therapy 
Vigabatrin therapeutic status at the  
perimetric examination  
and corresponding visual field outcome 
Severity of vigabatrin-associated 
visual field loss (MD [ dB]) 
1
 
Min. Max. Mean Median 
ON  
Normal 
OFF Normal ON VAVFL 
OFF  
VAVFL 
Mean Median Min. Max. 
1 14 0.2 1.3 0.9 1.0 2 11 0 1 
 
2 15 1.3 2.8 2.0 1.9 4 10 1 0 -4.2 
3 15 2.9 4.7 3.7 3.6 3 3 4 5 -10.5 -9.7 -4.2 -20.1 
4 15 4.7 6.5 5.7 6.0 3 4 2 6 -11.1 -10.5 -2.6 -20.2 
5 15 6.6 7.9 7.4 7.4 0 1 5 9 -6.5 -5.9 -3.3 -9.8 
6 14 8.0 9.0 8.5 8.4 2 2 5 5 -6.2 -5.7 -2.4 -9.3 
7 15 9.0 10.2 9.6 9.4 4 0 8 3 -11.6 -12.0 -0.8 -16.9 
8 15 10.2 11.6 10.9 11.0 2 2 8 3 -7.1 -6.5 -4.2 -11.6 
9 15 11.6 12.3 12.0 12.0 1 3 7 4 -6.5 -6.1 -1.6 -11.9 
10 14 12.4 16.1 13.4 13.0 2 1 8 3 -6.8 -4.3 -3.0 -22.2 
Table ‎3-6: The summary statistics for duration of vigabatrin therapy for each decile group by vigabatrin therapeutic status, visual field outcome 
and severity of the vigabatrin-associated visual field loss (VAVFL). 1The severity of the vigabatrin-associated visual field loss is expressed in 
terms of the visual field index, Mean Deviation (MD), averaged between the two eyes. An increasingly negative MD represents a worsening of 
the visual field. Note individuals with concomitant visual field loss are excluded from the distributions of the MD. 
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Decile 
Number of 
individuals 
Cumulative dose of vigabatrin (kg) 
Vigabatrin therapeutic status at the 
perimetric examination and 
corresponding visual field outcome 
Severity of vigabatrin-attributed 
visual field loss (MD [dB])
1
 
Min. Max. Mean Median 
ON 
Normal 
OFF 
Normal 
ON 
VAVFL 
OFF 
VAVFL 
Mean Median Min. Max. 
1 14 0.1 1.0 0.5 0.5 3 10 0 1 
 
2 15 1.0 1.5 1.2 1.1 3 11 1 0 
 
3 15 1.5 3.1 2.5 2.5 6 3 2 4 -9.2 -5.6 -2.6 -20.1 
4 15 3.2 4.6 3.9 3.9 1 4 4 6 -9.0 -9.1 -4.2 -13.9 
5 15 4.7 5.8 5.2 5.0 2 1 8 4 -8.2 -7.4 -2.5 -16.5 
6 14 6.0 6.9 6.4 6.4 1 1 6 6 -8.1 -6.3 -2.4 -20.2 
7 15 6.9 8.0 7.5 7.5 3 2 5 5 -7.6 -5.8 -3.0 -16.6 
8 15 8.3 9.7 8.9 8.7 1 1 8 5 -6.8 -6.3 -3.5 -10.4 
9 15 9.9 12.9 11.8 11.9 2 3 7 3 -7.7 -7.4 -4.2 -11.9 
10 14 13.1 19.8 15.9 15.1 1 1 7 5 -8.5 -5.7 -0.8 -22.2 
Table ‎3-7: The summary statistics for cumulative dose of vigabatrin therapy (kg) for each decile group by vigabatrin therapeutic status, visual field 
outcome and severity of the vigabatrin-attributed visual field loss (VAVFL). 1The severity of the vigabatrin-associated visual field loss is expressed in 
terms of the visual field index, Mean Deviation (MD), averaged between the two eyes. An increasingly negative MD represents a worsening of the 
visual field. Note individuals with concomitant visual field loss are excluded from the distributions of the MD. 
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Figure ‎3-2: The risk of developing vigabatrin-associated visual field loss according to 
duration (top) and cumulative dose (bottom) of vigabatrin. In each panel, the 10 
symbols each represent decibel groups defined by the relevant exposure, and show the 
proportions of individuals in each exposure group with vigabatrin-associated visual 
field loss, plotted against the median exposure for the group. The smooth curves are 
fitted by a logistic regression model incorporating a plateau. The middle curve shows 
the estimated cumulative risk of vigabatrin-associated visual field loss at each 
exposure. The lower and upper curves represent the 95% confidence interval. 
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Parameter  Model by duration 
(years) 
  Model by cumulative  
dose (kg) 
Intercept   -3.28 -3.36 
Slope  0.98 (0.48 to 2.38) 1.29 (0.71 to 2.28) 
Odds ratio per unit exposure, e
 
2.67 (1.61 to 10.79) 3.63 (2.03 to 9.74) 
Plateau k 0.76 (0.67 to 0.85) 0.79 (0.70 to 0.87) 
Table ‎3-8: Parameter estimates for the plateau logistic regression models for the risk 
(frequency) of developing vigabatrin-associated visual field loss by duration and by 
cumulative dose of vigabatrin. The plateau parameter, k, may be regarded as the 
proportion of the caseload of individuals treated with vigabatrin who would develop 
vigabatrin-associated visual field loss following a high degree of exposure to the drug. 
95% confidence limits are shown for the plateau k, for the slope parameter  and the 
corresponding odds ratio, e, representing the increase in the odds of developing 
vigabatrin-associated visual field loss for an additional unit of exposure among those 
susceptible to developing it. 
3.5 Discussion 
The current study describes the risk (frequency) of vigabatrin-associated visual field 
loss at higher exposures to vigabatrin than previously evaluated: over half the 
individuals (85 / 147; 58%) had received vigabatrin for more than 7 years and almost 
one third (31%) for more than 10 years. The two novel plateau models indicate that the 
frequency of vigabatrin-associated visual field loss, compiled from the cross-sectional 
evidence, rises steeply up to approximately 6 years or 5kg cumulative dose, then levels 
out at a plateau of between 75-80%. The plateau is substantially higher than frequencies 
at lower exposures to vigabatrin (EMEA, 1999; Wild et al., 2009; Maguire et al., 2010) 
yet it is firmly well below 100%. 
Duration and cumulative dose of vigabatrin were highly correlated, and exhibited 
similar patterns of increasing frequency of vigabatrin-associated visual field loss with 
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increasing exposure. A plateau model incorporating duration and dose, together, 
described the data significantly better than the model by duration, alone (χ2 = 9.02, p = 
0.003) but not appreciably better than the model by cumulative dose, alone (χ2 = 0.09, p 
= 0.77). This suggests that the risk of developing vigabatrin-associated visual field loss 
is determined by cumulative dose rather than by duration. It can also be seen from  
Figure  3-1 that, for any given duration (i.e. for any vertical slice), the data points 
representing individuals with vigabatrin-associated visual field loss tend to lie above 
(i.e. at greater cumulative doses) than those points representing individuals with no 
vigabatrin-associated visual field loss. Conversely, for any horizontal slice, there is no 
apparent tendency for the data points representing individuals with vigabatrin-
associated visual field loss to lie to the right (i.e. at greater durations) of those points 
representing individuals with no vigabatrin-associated visual field loss. The greater 
influence of cumulative dose compared to duration is also consistent with that of the 
only systematic review of vigabatrin-associated visual field loss (Maguire et al., 2010).  
The main limitation of the study is that the estimate of the increase in the frequency of 
vigabatrin-associated visual field loss with increased expose to vigabatrin was based 
upon a cross-sectional evaluation of the effects of duration and of cumulative dose. 
Ethical considerations of the potential risk for vigabatrin-associated visual field loss 
with continuing exposure to vigabatrin prevent a formal prospective longitudinal 
clinical trial over an equivalent time period. Even for such a study, the precision of the 
estimate of the increase in frequency would be dependent upon the number of, and 
interval between, the perimetric examinations. In the USA, approval for vigabatrin was 
conditional upon implementation of a Risk Evaluation and Mitigation Strategy (REMS) 
which is currently administered via the USA Marketing Authorisation Holder’s 
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programme (Pellock et al., 2011; SHARE, 2013). As part of this programme, the 
outcomes from ophthalmological testing of all individuals treated with vigabatrin in the 
USA are mandatorily collated in a registry. Analysis of the registry could eventually 
provide some longitudinal perspective as to the increase in the frequency of vigabatrin-
associated visual field loss with increased exposure to vigabatrin. However, the registry 
will be only be analysed for the first six years and the outcome will not approach the 
level of evidence from prospective clinical trial data (Pellock et al., 2011). The most 
recent analysis of the registry, at three years, has yielded little in regard to the frequency 
of vigabatrin-associated visual field loss. The registry comprised 4292 individuals: of 
these, 62% had infantile spasms; 55% of all individuals had discontinued vigabatrin; 
and only 7% had undergone a visual field examination at baseline (Sergott et al., 
2012a). A current, small-scale, prospective study, over one year, of approximately 80 
adult individuals, de novo to vigabatrin and undergoing regular perimetry and optical 
coherence tomography, of whom it is estimated 20 will complete the study, may provide 
some evidence as to the short-term onset of vigabatrin-associated visual field loss 
(Sergott, Laxter and Torri, 2012b). 
In the current study, the modelled frequency of individuals with vigabatrin-associated 
visual field loss at 3 years of exposure, 31.7%, is identical to that, submitted to the 
CPMP, for an equivalent exposure (EMEA, 1999). The latter estimate was based upon 
the modelled time to onset of the field loss whilst that of the current study was derived 
from the time to detection of the field loss. The modelled frequency is also in agreement 
with the median frequency of 31% derived by the systematic review for a similar 
exposure (Maguire et al., 2010). 
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Vigabatrin-associated visual field loss is largely initially asymptomatic unless the field 
loss is concentric within the central field (Lawden et al., 1999; Miller et al., 1999; 
Coupland et al., 2001). The visual acuity remains normal or near-normal and, in less 
severe cases, the predominantly nasal loss in the ipsilateral eye is compensated by the 
relatively well-preserved temporal field in the contralateral eye (Wild et al., 1999a). As 
a consequence of the asymptomatic nature, it is likely that, for most individuals, the 
time to detection will have preceded the time to self-referral on the basis of symptoms.  
The marked difference in the distributions of the Mean Deviation visual field index 
between the two cohorts (i.e. those with, and those without, vigabatrin-associated visual 
field loss) clearly indicates the high sensitivity and high specificity both of the 
perimetric protocol and of the definition of vigabatrin-associated visual field loss. 
The established literature on vigabatrin-associated visual field loss, evidenced by the 
outcome of the systematic review (Maguire et al., 2010), is contrary to the findings of 
Sergott et al., (2010), the latter were derived from a subset of the cohort described by 
Wild et al., (2009). Based upon an evaluation of the outcome of kinetic perimetry in 
terms of the angular extent of the V4e or IVe isopter along the temporal meridian, and 
an empirical definition for normality (Sergott et al., 2010)
 
the
 
approach yielded poor 
sensitivity (72% of those exposed to vigabatrin, exhibited field loss) and poor 
specificity (45% of those with no exposure to vigabatrin, exhibited field loss) when 
compared to the outcome in the same cohort based upon the CPMP accepted protocol 
and classification system of static perimetry (Wild et al 2009).
 
The extremities of the 
temporal field exhibit the largest between- and within-individual variability in response 
to kinetic perimetry and is the least affected by vigabatrin-associated visual field loss. 
The efficient detection of visual field loss by good quality kinetic perimetry can only be 
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undertaken in terms of a comparison of the shape and extent of a number of isopters 
across all meridians. The guidelines provided by the Marketing Authorisation Holders 
of vigabatrin outside of the USA stipulate that, when undertaken, kinetic perimetry of 
individuals exposed to vigabatrin should examine the III4e, I4e and I2e or I1e isopters. 
However, Wild et al., (2009) also showed that, in the full data set, vigabatrin-associated 
visual field loss was more frequently detected with static than with kinetic perimetry 
(OR, maximum, 3.3; 95% CI: 0.8 to 13.5) at a specificity of 99.2%. Sergott et al., 
(2010) also failed to undertake any quality control of the data subset: the output from 
many of the visual field examinations by kinetic perimetry had been of such poor 
quality that Wild et al., (2009) had introduced a protocol amendment which had 
replaced the technique, wherever possible, with static perimetry.  
The severity of the vigabatrin-associated visual field loss, as expressed by the Mean 
Deviation visual field index, was not significantly associated with either the duration or 
the cumulative dose of vigabatrin. Clearly, the absence of a correlation between the 
Mean Deviation and either the cumulative dose, or the duration, of vigabatrin cannot be 
explained by any restriction in the range of severity of the vigabatrin-associated visual 
field loss. The absence of any correlation is in agreement with some shorter-term 
exposure studies (Nousiainen et al., 2001; Kinirons et al., 2006)
 
but not with others 
(Hardus et al., 2000b; Koller et al., 2001) and is consistent with the concept of an 
idiosyncratic drug reaction. 
The lack of an association of vigabatrin-associated visual field loss with any other anti-
epileptic drug either prior to, or concurrently with, vigabatrin is consistent with most 
studies. The absence of any association may arise from the insufficient number of cases 
with vigabatrin-associated visual field loss to accommodate the multiplicity of 
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therapeutic combinations. However, sodium valproate has been implicated with more 
severe vigabatrin-associated visual field loss (Arndt et al., 2002). 
Vigabatrin-associated visual field loss is considered by some to be, principally, a defect 
of the peripheral field (Frisen and Malmgren, 2003), i.e., that beyond a radius of 27º 
from fixation. However, all but one of the individuals manifested vigabatrin-associated 
visual field loss within the central field. Such a finding underlines the importance of 
threshold perimetry of the central field out to 27º eccentricity, in conjunction with three-
zone age-corrected suprathreshold static perimetry of the peripheral field, for 
delineating vigabatrin-associated visual field loss and which, together with a robust 
definition of vigabatrin-associated visual field loss based upon abnormality exhibiting at 
least nasal encroachment within the central field, would reduce false-positive outcomes 
such as those clearly evident in the illustrations of Gonzalez et al., (2009). 
The visual field examination of individuals receiving vigabatrin can often be 
inconclusive due to the inherent cognitive demands. The frequent requirement for one 
or more confirmatory repeat examinations further increases the cost of management of 
such individuals. However, even after repeated examinations, the results often remain 
equivocal. In the compilation of this cohort of 147 individuals, a further 20 competent 
adult individuals (12%) had been unable to produce a reliable result. This figure 
compares with estimates of approximately 25% in similar individuals (Wild et al., 2006; 
Wild et al., 2009). However, assessment of the retinal nerve fibre layer thickness by 
optical coherence tomography shows promise either as an alternative, or as an adjunct, 
to perimetry (Wild et al., 2006; Clayton et al., 2011; Clayton et al., 2012) and is 
acceptable for REMS in individuals who are unable to undertake perimetry (Pellock et 
al., 2011).  
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The earliest onset of vigabatrin-associated visual field loss (0.189kg over a treatment 
period of 8 weeks) is compatible with onsets of between 4 (Malmgren et al., 2001)
 
and 6 
months (Kiratli and Türkçüoğlu, 2001). The obvious rapid manifestation of vigabatrin-
associated visual field loss in some individuals; the continued increase in the frequency 
of vigabatrin-associated visual field loss up to six years of exposure, reported here; and 
the potential for longer-term worsening of existing vigabatrin-associated visual field 
loss (Clayton et al., 2010; Clayton et al., 2013) is compatible with the REMS stipulation 
for perimetry at baseline and at a minimum of three monthly intervals (Pellock et al., 
2011)
 
throughout the treatment period and within 3 to six months following withdrawal. 
These requirements are more stringent than others; which advocate a baseline 
examination followed by six-monthly examinations either for the entire treatment period 
(Aventis, 2010) or for the first five years of exposure followed by yearly examinations 
for those without vigabatrin-associated visual field loss (Hawker and Astbury, 2008). 
Based upon the results of the current study, these latter two recommendations should be 
brought into line with those of REMS. The resultant increased economic cost for the 
provision of the ensuing additional visual investigations will need to be considered in 
the use of vigabatrin outside of the USA. 
GABA elevation dampens the increase in brain dopamine responsible for drug ‘highs’ 
(Gerasimov et al., 2001)
 
and a maximum cumulative dose of vigabatrin of between 
0.137kg (Fechtner et al., 2006) and 0.218kg (Berezina et al., 2012) over 9 to 12 weeks, 
respectively, has been proposed as anti-addiction therapy for misuse of stimulant drugs. 
The early onset case of vigabatrin-associated visual field loss in the current study was 
associated with a cumulative dose of 0.189kg.  
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Vigabatrin can induce clinically profound bilateral peripheral visual field loss which 
encroaches into the central field, to varying degrees, as evidenced by the range of the 
MD index encountered in the study (Table  3-6). There are no staging systems for 
vigabatrin-associated visual field loss in terms of the Mean Deviation; a recent study of 
individuals with glaucomatous visual field loss designated Mean Deviation of better 
than -6.00dB as mild, of between -6.00dB and -12.00dB as moderate and worse than -
12.00dB as severe (Pillai et al., 2013). From an ophthalmological perspective, any 
vigabatrin-associated visual field loss is unacceptable, regardless of severity, and is a 
major concern when superimposed upon existing loss e.g., that from cortical 
involvement. Even if such individuals are excluded from treatment with vigabatrin, a 
proportion of those who are treated and who develop vigabatrin-associated visual field 
loss will go on to develop field loss secondary to conditions concomitant with aging 
such as open angle glaucoma and/ or macular degeneration. From a neurological 
perspective, where the goal is a reduction in seizure frequency, the vigabatrin-associated 
visual field loss may be of secondary concern; however, it should be noted that most 
individuals are initially asymptomatic but can subsequently attribute difficulties in 
particular activities of daily living to their vigabatrin-associated visual field loss. The 
psychological and sociological ramifications of the vigabatrin-associated visual field 
loss should also not be underestimated. For example, one individual in the cohort was 
dismissed from his employment as a result of vigabatrin-associated visual field loss, 
subsequently required a guide dog and enlisted on a course of visual rehabilitation at a 
college for individuals with severe sight impairment.  
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3.6 Conclusion 
The increasing frequency of vigabatrin-associated visual field loss with long-term 
exposure to vigabatrin substantially increases the risk-benefit for visual field loss and, 
with the requirement for an increased number of perimetric and/ or optical coherence 
tomographic examinations, the cost-benefit for therapy. Clinicians, individuals and 
carers should be aware of these findings to enable an informed choice as to the benefit 
of vigabatrin.  
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Chapter 4. Topographical variation in the 
retinal ganglion cell structural and functional 
association in vigabatrin toxicity  
4.1 Introduction  
The association between the extent of the exposure to vigabatrin and the severity of 
vigabatrin-associated visual field loss is equivocal. Most studies have utilised a 
perimetric methodology, and/ or analysis, inappropriate for describing the full 
topographical extent of the field loss, e.g., the Esterman test (Hardus et al., 2001a;b), 
Two Zone age-corrected suprathreshold perimetry (Manuchehri et al., 2000), or the 
radial extent of a given isopter (Best and Acheson, 2005). Other studies involving 
threshold perimetry, which expresses the full topographical extent of the field loss, have 
used outcomes based upon the logarithmic (dB) representation of perimetric sensitivity 
(Conway, Cubbidge and Hosking, 2008; Wild et al., 2013). This latter measure 
generates a curvilinear association, if present, with a variable, such as drug exposure, 
considered on a linear scale. A curvilinear association can be more difficult to recognize 
than a linear trend when excessive variability is associated with the measurement of one 
or both variables. 
The association between the extent of the retinal nerve fibre layer thickness and the 
severity of the vigabatrin-associated visual field loss has received relatively little 
attention. The reduction in thickness exhibits a weak linear association with the 
reduction in the extent of the I4e isopter, expressed either linearly in mean radial 
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degrees (Clayton et al., 2011) or qualitatively (Clayton et al., 2012) and a weak 
exponential association with the reduction in the Mean Sensitivity of the central field (a 
measure based upon the logarithmic representation of sensitivity) derived by threshold 
perimetry (Wild et al., 2006). However, these studies failed to account for the presence 
of the non-axonal component of reflectance in the retinal nerve fibre layer, i.e., that 
arising from glial cells and blood vessels etc, which remains in advanced disease, and 
which results in a floor effect of approximately 35-55μm (Sihota et al., 2006). The 
presence of a floor effect will both hinder the identification, and diminish the strength, 
of any association between the retinal nerve fibre layer thickness and a given variable. 
In addition, the studies also failed to evaluate the influence on any association of the 
topographic/ regional variation in the distribution of the ganglion cell axons. As a 
consequence, the extent to which vigabatrin-associated visual field loss is influenced by 
retinal ganglion cell soma and/ or axonal dysfunction remains unknown. 
A linear association between the retinal nerve fibre layer thickness and the severity of 
the visual field loss derived by threshold perimetry, when expressed on a linear scale, 
can be successfully modelled in diseases involving/ implicating the retinal ganglion 
cells, e.g., glaucoma (Hood et al., 2007; Hood and Kardon, 2007), ischaemic optic 
neuropathy (Hood et al., 2008) and optic neuritis (Cheung et al., 2008). In addition, two 
models have been proposed which, respectively, enable calculation, at each stimulus 
location, of the number of residual retinal ganglion cells based upon the outcome of 
standard automated perimetry and the number of residual retinal ganglion cell axons 
based upon the outcome of Time-domain optical coherence tomography (Harwerth et 
al., 2010). These models were developed from experimental glaucoma induced in 
primate and were subsequently refined for clinical use in human. The models generate 
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clinically similar/ identical numbers of residual ganglion cells in open angle glaucoma 
(Medeiros et al., 2012a; Medeiros et al., 2012b). 
Given the apparent involvement of the retinal ganglion cells in the pathogenesis of 
vigabatrin-associated visual field loss, either as a primary or as a secondary process, it 
would seem appropriate to investigate the structural and functional association, 
expressed on linear scales in terms of residual ganglion cell characteristics. By these 
means, the extent to which the characteristic pattern of vigabatrin-associated visual field 
loss is influenced by retinal ganglion cell soma and/ or axonal dysfunction can be 
further investigated. 
4.2  Aim 
The aim of the study was to determine, as a function of retinal location, the association 
between the number of residual ganglion cell soma derived by standard automated 
perimetry and the number of residual ganglion cell axons derived by Time-domain 
optical coherence tomography in individuals with vigabatrin-associated visual field loss 
and in individuals previously exposed to vigabatrin but with normal fields.  
4.3 Methods 
The study utilised a prospective cross-sectional design. 
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4.3.1 Cohort 
The primary cohort comprised 40 individuals consecutively presenting to the Alan 
Richens Unit of the Welsh Epilepsy Centre, University Hospital of Wales, Cardiff, UK, 
who had previously been treated with vigabatrin for refractory complex partial (focal) 
seizures, who conformed to pre-defined inclusion criteria, and who had volunteered to 
take part in the study. The 40 individuals had been exposed to a variety of AEDs prior 
to treatment with vigabatrin. None of the individuals had received tiagabine which was 
considered to exhibit a level one category of GABAergic activity when expressed on 4- 
point scale in descending order of empirically assigned magnitude (Chapter 3). One 
individual had received clobazam and 15 had received sodium valproate (levels 2 and 3 
GABAergic activity, respectively).  
The secondary cohorts, used for control purposes, comprised 18 individuals with open 
angle glaucoma and 22 normal individuals. The individuals with open angle glaucoma 
were consecutively presenting individuals to the Glaucoma Clinics of the Cardiff Eye 
Unit, University Hospital of Wales, Cardiff, UK who had participated in a previous 
study which had employed an identical methodology. The normal individuals had 
participated in the same previous study and were consecutive volunteers recruited from 
those attending the Cardiff University Eye Clinic. All conformed to inclusion criteria 
identical to that of the cohort exposed to vigabatrin with the exception that none were 
epileptic and those with open angle glaucoma exhibited glaucomatous optic neuropathy, 
glaucomatous visual field loss and a medically treated intraocular pressure of ≤ 
21mmHg. 
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4.3.2 Perimetry 
The individuals exposed to vigabatrin underwent standard automated perimetry in each 
eye using Program 30-2, Goldmann size III, and the FASTPAC algorithm of the 
Humphrey Field Analyser 750 (software revision 12.6/14.0) (Carl Zeiss, Meditec, 
Dublin, CA). They were all experienced in standard automated perimetry having 
previously undergone Program 30-2 and the FASTPAC algorithm, reliably, on at least 
two previous occasions. In addition, they had also undergone Three Zone 
suprathreshold perimetry of the central and peripheral field using the Full Field 135 
Point Screening Test of the Humphrey Field Analyzer. The field of the right eye was 
examined before that of the left eye. 
The individuals with open angle glaucoma and the normal individuals all underwent 
standard automated perimetry in each eye using Program 24-2, Goldmann size III, and 
the SITA Standard algorithm of the Humphrey Field Analyser 750 (software revision 
12.6/12.6). The individuals with open angle glaucoma were experienced in standard 
automated perimetry having undergone Program 24-2 and either the SITA Fast or the 
SITA Standard algorithms on at least three previous occasions. Most of the normal 
individuals had previously undergone standard automated perimetry as part of their 
routine clinical care. 
All individuals from all cohorts wore their refractive correction appropriate for the 
viewing distance of the perimeter. The field of the right eye was examined before that of 
the left eye. Rest periods of one minute were given to the individuals in each cohort 
after a maximum of three minutes of perimetry during which time each individual was 
required to continue looking into the bowl of the perimeter. A further rest period, 
ranging from 10 minutes to 30 minutes depending upon the individual, was given 
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between the examination of the two eyes. Visual field examinations which had yielded 
greater than 15% incorrect responses to the false-positive and/ or greater than 20% 
incorrect responses to the fixation loss catch trials and/ or poor quality outcomes to the 
gaze tracking were repeated on a separate occasion. Two individuals with vigabatrin-
associated visual field loss who had manifested such an outcome to the repeat 
examination were not included in the cohort. A similar approach was adopted for 
incorrect responses to the false-negative catch trials: the repeat criterion was greater 
than 30% incorrect responses but the tolerance widened with increase in severity of the 
field loss (Bengtsson and Heijl, 2000). 
The visual field examination of the individuals exposed to vigabatrin was undertaken by 
the Author and that of the individuals with open-angle glaucoma and the normal 
individuals by an experienced technician. 
The fields of each individual were reviewed at the end of the study, masked to the given 
cohort, in random sequence by Professor John Wild who is highly experienced in 
interpreting the visual fields derived by automated perimetry in individuals exposed to 
vigabatrin and also in individuals with glaucoma. 
4.3.3 Optical Coherence Tomography 
Following perimetry, all individuals underwent measurement of the peripapillary retinal 
nerve fibre layer using the standard 3.4 Scan protocol of the Time-domain StratusOCT 
(Software Version 3.0) (Carl Zeiss, Meditec, Dublin, CA). The pupil was dilated, if 
necessary, with one drop of 0.5% tropicamide and one drop of 2.5% phenylephrine 
hydrochloride. Individuals were instructed to fixate the external fixation target which 
was suitably positioned by the operator to ensure optimum centration of the scan on the 
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optic nerve head. The polarization and Z-axis offset were optimised to gain maximum 
reflection of the signal. Between three and six images were retained for each individual. 
All retained images were free from blink or movement artefacts and had a signal to 
noise ratio of ≥ 33dB. All images were acquired by a senior medical photographer, Ms 
Belinda Colton, who is highly experienced in optical coherence tomography. The image 
possessing the most optimal placement of the scan centre, compatible with the 
maximum signal to noise ratio, was then selected for each individual by the Author and 
by Professor John Wild independently of each other and masked to the visual field 
status. Both the Author and Professor Wild are experienced in the interpretation of 
optical coherence tomography. In cases of discordance between the two assessors for 
any given individual, a consensus was subsequently reached. 
4.3.4 Ganglion cell calculation 
The differential light sensitivity, in dB, at each stimulus location corresponding to the 
Program 24-2 stimulus configuration was extracted from the Single Field Analysis 
print-out for each individual; and entered into an Excel 2007 spreadsheet. Similarly, the 
global, quadrant and sector retinal nerve fibre layer thicknesses, automatically 
calculated by the StatusOCT analysis software, were separately extracted from the print-
out of the selected image of each individual and entered into the spreadsheet. 
4.3.4.1 Calculation of ganglion cell soma quantity from standard 
automated perimetry 
The ganglion cell soma quantity for standard automated perimetry was calculated for 
each stimulus location of the Program 24-2 grid using the equations of (Harwerth et al., 
2010): 
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m = [0.054*(ecc*1.32)] + 0.9 (1) 
b = [-1.5*(ecc*1.32)] -14.8 (2) 
gl = {[(s - 1) – b] / m} + 4.7 (3) 
and 
gcsap= Σ 10⋀
 
(gl*0.1) (4) 
where m and b represent the slope and intercept, respectively, of the linear function of 
ganglion cell density by differential light sensitivity at the given eccentricity (ecc); and 
where the ganglion cell density (gl), defined as the number of somas per mm
2
 of retina,
and the differential light sensitivity (s) are both expressed in dBs; and where gcSAP is the 
total number of retinal ganglion cells across the given number of stimulus locations. 
The constant, -1, in Equation (3) accounts for the approximate 1dB higher sensitivity of 
the SITA Standard algorithm compared to the Full Threshold algorithm (Bengtsson and 
Heijl, 1998; Wild et al., 1999b; Wild et al., 1999c) and was used for the calculation of 
the ganglion cell quantity for the individuals with open angle glaucoma. The constant 
was omitted for the calculation of the ganglion cell soma quantity for the individuals 
exposed to vigabatrin since the differential light sensitivities obtained with the Full 
Threshold and FASTPAC algorithms are clinically identical (Wild et al., 1999b; Wild et 
al., 1999c). The constant 4.7 in Equation (3) converts retinal ganglion cell soma density 
to the total number of retinal ganglion cell somas at the given stimulus location based 
upon the 6˚ square stimulus grid of Program 24-2. 
The ganglion cell soma quantities derived by standard automated perimetry at each 
stimulus location were then summed, as appropriate, to give the separate global, 
quadrant and sector totals corresponding to that of the StratusOCT, based upon the 
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topographical map of Wirtschafter et al., (1982) and as described by Garway-Heath et 
al., (2000) (Figure  4-1) which relates the axons of the retinal ganglion cells sub-serving 
the given perimetric stimulus location to their entry point at the optic nerve head. 
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Figure ‎4-1: The sectors of the optic nerve head, for the right eye, after Wirtschafter et 
al., (1982) and as described by Garway-Heath et al., (2000) (Top) and the stimulus 
locations of the visual field (Program 24-2) for the right eye corresponding to the given 
sectors of the optic nerve head (Bottom). The black shading indicates the blind spot. 
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4.3.4.2 Calculation of ganglion cell axon quantity from optical coherence 
tomography 
The ganglion cell axon quantity derived by optical coherence tomography was 
calculated for the optic nerve head, as a whole, and for each of the quadrants and the 
sectors derived by the StratusOCT using the additional equations of Harwerth et al., 
(2010) developed with the StratusOCT: 
 
 d = (-0.007*age) + 1.4   (5)   
 a = mh*px*21.2*d    (6) 
 c = (-0.26*MD) + 0.12   (7) 
 and  
 axoct = 10 ⋀ [(log a)*10] – c   (8) 
 
where d is the axonal density, i.e. the number of axons per μm2; age is in years, a is the 
number of axons for a section of the retinal nerve fibre layer scan with a mean height 
(mh) in μm over px number of pixels; 21.2 is the length per pixel in μm for the 10.87 
mm scan length of the standard retinal nerve fibre layer (3.4) Scan protocol of the 
StratusOCT; c is a correction factor in dBs for the non-axonal component of the 
measured retinal nerve fibre layer thickness at the given stage of the disease, expressed 
by the un-weighted Mean Deviation (MD) index for the given visual field sector; and 
axoct is the age-corrected and non-axonal component-corrected total number of retinal 
ganglion cell axons in the given sector of the peripapillary retinal nerve fibre layer.  
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4.3.5 Statistical Analysis 
The characteristics of the cohort were described with descriptive statistics using 
independent t-tests for continuously distributed variables, and the chi-square tests or 
Fisher’s exact tests for categorical variables. 
The degree of association between duration and cumulative dose of vigabatrin was 
characterised by the Pearson correlation coefficient, r. 
The degree of association between residual ganglion cell soma quantity derived by 
standard automated perimetry and residual ganglion cell axon quantity derived by 
optical coherence tomography was illustrated by the use of separate scatter graphs for 
the entire scan, for each of the four quadrants and for each of the 12 sectors. 
The degree of association between the residual ganglion cell soma quantity derived by 
standard automated perimetry and the duration of vigabatrin therapy and between the 
residual ganglion cell axon quantity derived by optical coherence tomography and the 
duration of vigabatrin therapy was characterised by the Spearman rank correlation, rs. 
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4.4 Results 
4.4.1 Demographics of the cohort exposed to vigabatrin 
The demographic characteristics of the cohort exposed to vigabatrin are shown in Table 
 4-1.  
The cohort contained a greater number of females than males (χ2 = 6.4; p<0.011). The 
males were slightly older than the females at the time of the study; however, the 
differences in the mean ages were not statistically significant (difference between means 
1.7 years 95% CI -9.75 to 13.13; p=0.762). 
Twenty-four of the 40 individuals exhibited vigabatrin-associated visual field loss. The 
individuals with vigabatrin-associated visual field loss were slightly older at the time of 
the study than those exposed to vigabatrin but with normal fields; however, the 
difference in the mean ages was not statistically significant (difference between means 
1.6 years, 95% CI -9.7 to 6.5; p=0.690).  
The between-gender difference in the proportion with vigabatrin-associated visual field 
loss, 8 out of 12 males and 16 out of 28 females, was not statistically significant 
(p=0.729).  
The exposure to vigabatrin for the individuals with vigabatrin-associated visual field 
loss, 8.9kg (SD 4.3) cumulative dose and 10.3 years (SD 3.5) duration, respectively, 
was statistically significantly greater than that for the individuals with normal fields, 
3.9kg (SD 4.5) and 5.4 years (SD 4.9), (difference between means 4.93kg, 95% CI 2.05 
to 7.81, p<0.001; and 4.10 years, 95% CI 1.53 to 6.68; p<0.003).   
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Characteristic 
Visual field outcome  
Normal VAVFL Combined 
Number of 
individuals 
 
16 24 40 
Gender 
Male  4 8 12 
Female  12 16 28 
Age (yrs) 
Mean (SD) 
Median (IQR) 
Range 
42.6 (11.6) 
43.5 (32.7, 48.5) 
19.6 – 65.5 
44.2 (12.8) 
44.5 (35.7, 54.2) 
22.8 – 68.6 
43.5 ( 12.2) 
44.5 (35.0, 51.2) 
19.6 – 68.6 
Cumulative dose of 
vigabatrin (kg) 
Mean (SD) 
Median (IQR) 
Range 
3.9 (4.5) 
1.5 (1.0, 6.0) 
0.27 – 14.2 
8.9 (4.3) 
8.5 (6.1, 12.7) 
2.14 –18.9 
7.0 (5.0) 
6.7 (2.2, 11.6) 
0.27 – 18.9 
Duration of vigabatrin 
(yrs) 
Mean (SD) 
Median (IQR) 
Range 
7.3 (5.8) 
5.5 (2.0, 13.5) 
0.04 – 18.2 
10.3 (3.5) 
10.2 (7.0, 12.9) 
4.8 – 17.9 
9.1 (4.7) 
9.2 (5.5, 12.9) 
0.04 – 18.2 
Interval from withdrawal 
of vigabatrin (yrs) 
Mean (SD) 
Median (IQR) 
Range 
9.3 (4.5) 
9.0 (5.9, 11.9) 
2.0-17.4 
6.7 (3.5) 
7.1 (5.1, 8.9) 
1.8-12.57 
7.7 (4.1) 
7.8 (5.2, 10.7) 
1.8-17.4 
MD average of both 
eyes (dB) 
Mean (SD) 
Median (IQR) 
Range 
-2.0 (2.4) 
-1.05 (-3.7, -.09) 
-5.6 – 0.46 
-7.8 (5.1) 
-5.9 (-12.8, -4.1) 
-21.5 – (-0.80) 
-5.3 (5.1) 
-4.2 (-8.6, -1.4) 
-21.5 – (- 0.46) 
PSD averaged of both 
eyes (dB) 
Mean (SD) 
Median (IQR) 
Range 
2.56 (0.8) 
2.2 (2.0, 3.0) 
1.77 – 5.1 
7.7 (3.5) 
7.8 ( 4.5, 11.2) 
2.4 – 13.49 
5.6 (3.7) 
4.4 (2.4, 8.5) 
1.77 – 13.49 
Table ‎4-1: The summary statistics, mean, standard deviation (SD) median, interquartile 
range (IQR) and range, for the demographic characteristics of the 40 individuals exposed 
to vigabatrin by visual field outcome (VAVFL indicates vigabatrin-associated visual field 
loss. MD indicates Mean Deviation, PSD indicates Pattern Standard Deviation).  
The two parameters describing the severity of the visual field loss, the Mean Deviation 
and the Pattern Standard Deviation, each averaged across the two eyes, were each 
statistically significantly worse for the individuals with vigabatrin-associated visual 
field loss -7.8dB (SD 5.1) and 7.7dB (SD 3.5) compared to the individuals with normal 
fields, -2.0dB (SD 2.4) and 2.56dB (SD 0.8), (difference between means -5.70dB 95% 
CI -2.83 to -8.56; p<0.001; and 5.15 95% CI 3.31 to 7.00 (p<0.001), respectively.  
The duration and cumulative dose of vigabatrin therapy were highly correlated (rs = 
0.69; p<0.001).  
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4.4.2 Demographics of the cohort with open angle glaucoma 
The demographic characteristics of the cohort with open angle glaucoma and of the 
cohort of normal individuals are shown in Table  4-2.  
The field loss of the individuals with open angle glaucoma was predominantly focal.  
Characteristic  Open angle glaucoma Normal 
Gender 
Male  8 8 
Female 10 14 
Age at enrolment 
Mean (SD) 
Median (IQR) 
Range 
68.9 (9.0) 
68.4 (62.3, 77.2) 
54.2-84.4 
64.8 (12.0) 
64.7 (58.7, 72.8) 
31.3-81.5 
  Designated Eye Average of both eyes 
Mean Deviation (dB) 
Mean (SD) 
Median (IQR) 
Range 
-3.0 (4.5) 
-1.5 (-0.23, -4.5) 
-18.23 – -0.66 
0.02 (1.4) 
-0.29 (1.4, -0.9) 
-2.54 – -2.2 
Pattern Standard 
Deviation (dB) 
Mean (SD) 
Median (IQR) 
Range 
4.32 (3.0) 
2.82 (2.24, 6.67) 
1.64 – 13.3 
1.63 (0.29) 
1.5 (1.4, 1.78) 
1.24 – 2.53 
Table ‎4-2: The summary statistics, mean, standard deviation (SD) median, interquartile 
range (IQR) and range, for the demographic characteristics of the 18 individuals with 
open angle glaucoma and of the 22 normal individuals (MD indicates Mean Deviation, 
and PSD indicates Pattern Standard Deviation). Note the MD and PSD are given for the 
designated eye of the individuals with open angle glaucoma. 
 
4.4.3 Demographics of the cohort of normal individuals 
The demographic characteristics of the cohort of normal individuals are shown in Table 
 4-2. 
4.4.4 Retinal ganglion cell structural and functional association 
The summary statistics for the estimated number of ganglion cell soma and axons for 
the individuals exposed to vigabatrin with normal fields are given in Table  4-3 for the 
right eye and in Table  4-4 for the left eye. The corresponding data for the individuals 
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with vigabatrin-associated visual field loss are given in Table  4-5 and Table  4-6; for the 
designated eye of the individuals with open angle glaucoma in Table  4-7 and the normal 
individuals in Table  4-8 and Table  4-9. 
4.4.5 Global Evaluation 
The associations between the number of remaining ganglion cell soma derived from 
perimetry and the number of remaining ganglion cell axons derived from the complete 
circular OCT scan for each eye of the individuals exposed to vigabatrin are represented 
as separate scatter plots in Figure  4-2.  
The corresponding associations for each eye of the individuals with open angle 
glaucoma and for each eye of the normal individuals are shown together in Figure  4-3 
and for the designated eye of the individuals with open angle glaucoma in Figure  4-4.  
The association for those exposed to vigabatrin superimposed upon that for the 
designated eye of those with open angle glaucoma is shown in Figure  4-5. 
The association for those exposed to vigabatrin superimposed upon that for the 
designated eye of those open angle glaucoma and upon that for the normal individuals is 
shown in Figure  4-6.   
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Right Eye Global Quadrant Sector 
  
Inferior Superior Nasal Temporal 6 11 
Mean 1,185,347 435,222 348,591 31,938 355,919 154,525 108,864 
SD 259,500 95,953 75,393 5,600 116,147 29,629 26,370 
Median 1,216,382 452,074 338,741 32,848 340,642 151,646 118,587 
Q1 933,768 376,545 292,298 27,351 291,180 132,485 87,574 
Q3 1,327,246 490,690 413,618 35,831 388,466 184,035 127,906 
Minimum 786,446 242,744 240,370 21,332 215,056 100,255 59,833 
Maximum 1,609,421 581,029 466,731 40,245 634,679 191,179 141,758 
        
Mean 876,522 274,272 234,620 187,186 185,147 79,880 99,082 
SD 170,000 70,630 77,950 53,843 53,311 25,297 30,787 
Median 919,055 279,503 227,562 179,334 174,540 75,664 99,366 
Q1 746,400 236,338 184,260 144,638 150,583 64,477 77,598 
Q3 994,128 324,416 288,745 215,206 215,917 92,224 125,732 
Minimum 551,824 117,512 99,887 119,305 87,057 25,486 51,524 
Maximum 1,144,865 375,836 342,942 306,039 292,735 124,083 150,496 
Table ‎4-3: The summary statistics, by quadrant, for the estimated number of retinal 
ganglion cell soma (top) and axons (bottom) in the right eye for the individuals exposed 
to vigabatrin with normal fields. 
 
Left Eye Global Quadrant Sector 
  
Inferior Superior Nasal Temporal 6 11 
Mean 1,241,236 525,956 471,129 23,509 199,038 171,039 67,649 
SD 292,047 143,388 108,841 4,563 52,396 33,852 15,800 
Median 1,201,933 522,368 451,325 23,241 206,726 170,995 70,052 
Q1 1,052,449 439,370 384,665 20,490 166,227 149,776 57,618 
Q3 1,448,700 645,300 503,614 25,299 226,085 186,385 78,472 
Minimum 754,597 314,042 324,231 16,370 85,418 104,481 42,841 
Maximum 1,807,690 799,189 697,033 34,246 292,791 234,177 92,411 
        
Mean 853,351 257,204 264,553 150,748 180,263 80,673 95,035 
SD 194,144 64,138 68,831 52,960 45,731 27,816 29,740 
Median 873,801 275,628 263,444 168,118 178,490 75,314 101,224 
Q1 761,931 241,258 230,230 108,702 140,538 68,957 76,325 
Q3 959,108 306,308 282,955 191,951 201,563 83,370 112,792 
Minimum 463,541 109,039 140,414 39,969 117,457 37,109 29,538 
Maximum 1,231,153 328,896 462,120 216,699 273,713 163,429 152,106 
Table ‎4-4: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the left eye 
for the individuals exposed to vigabatrin with normal fields. 
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Right Eye Global Quadrant Sector 
  
Inferior Superior Nasal Temporal 6 11 
Mean 983,085 331,694 279,383 25,655 354,251 104,305 67,831 
SD 318,821 108,855 85,560 10,287 125,657 47,806 32,248 
Median 931,774 304,882 267,717 26,453 331,540 94,224 71,099 
Q1 799,195 256,384 228,821 19,194 266,553 71,829 45,711 
Q3 1,182,282 434,945 334,730 32,652 403,598 145,119 84,767 
Minimum 437,420 156,650 112,860 2,289 190,683 17,468 6,262 
Maximum 1,607,984 518,089 452,971 41,237 702,727 195,535 137,418 
        
Mean 492,361 144,957 110,451 122,273 157,233 37,134 40,309 
SD 200,967 80,531 62,949 51,969 51,815 20,932 30,967 
Median 478,516 128,644 113,579 109,600 148,392 35,345 29,004 
Q1 360,278 91,758 55,813 93,108 132,478 20,229 23,474 
Q3 612,287 181,258 149,893 158,809 167,476 48,611 50,592 
Minimum 115,431 27,845 5,937 22,219 70,616 4,152 7,833 
Maximum 942,753 368,226 237,491 225,402 257,529 78,685 134,369 
Table ‎4-5: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the right eye 
for the individuals with vigabatrin-associated visual field loss. 
 
Left Eye Global Quadrant Sector 
  
Inferior Superior Nasal Temporal 6 11 
Mean 918,761 379,702 340,889 13,796 164,833 110,035 34,927 
SD 321,504 154,963 130,496 7,405 51,587 47,958 22,240 
Median 967,825 421,418 329,642 12,023 166,190 111,921 26,904 
Q1 702,269 274,441 273,090 9,128 142,794 75,974 17,889 
Q3 1,114,201 474,377 422,894 18,460 182,496 151,853 51,543 
Minimum 280,974 89,495 71,787 2,381 49,330 15,584 4,764 
Maximum 1,583,883 651,783 625,578 28,088 282,630 198,317 75,079 
        
Mean 518,443 148,817 136,573 85,440 153,760 41,192 48,202 
SD 191,365 76,390 61,604 41,541 41,355 24,037 31,504 
Median 486,948 139,786 123,701 83,967 153,839 39,960 37,529 
Q1 388,325 89,524 93,242 63,864 134,601 22,299 20,353 
Q3 642,669 198,193 187,668 104,146 169,302 54,360 76,333 
Minimum 125,317 33,731 26,674 15,445 66,390 4,941 10,549 
Maximum 900,333 311,928 236,787 162,599 248,657 90,697 112,284 
Table ‎4-6: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the left eye 
for the individuals with vigabatrin-associated visual field loss. 
  
94 
 
 
Global Quadrant Sector 
  
Inferior Superior Nasal Temporal 6 11 
Mean 903,005 349,427 294,164 208,055 21,577 113,787 81,408 
SD 319,977 140,403 100,782 125,282 8,458 34,415 33,474 
Median 904,361 362,312 307,361 155,101 20,809 124,912 77,324 
Q1 735,405 272,087 224,753 108,098 14,932 88,068 65,111 
Q3 1,190,853 476,674 377,965 305,672 27,059 139,120 100,221 
Minimum 270,534 50,785 85,506 70,747 10,779 42,557 11,058 
Maximum 1,417,993 564,935 443,844 509,678 38,288 154,948 135,287 
        
Mean 611,032 177,928 192,035 132,113 123,310 64,491 62,077 
SD 184,368 60,060 79,725 43,326 37,180 26,186 23,645 
Median 644,063 191,454 217,028 133,065 118,146 74,777 60,064 
Q1 470,480 125,796 105,067 111,373 102,394 47,790 46,406 
Q3 739,379 228,371 240,399 164,647 157,366 82,094 76,923 
Minimum 238,893 41,530 30,245 33,944 54,364 9,156 16,880 
Maximum 1,160,972 319,562 334,032 190,695 353,892 100,429 123,701 
Table ‎4-7: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the 
designated eye for the individuals with visual field loss due to open angle glaucoma. 
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Right Eye Global Quadrant Sector 
Inferior Superior Nasal Temporal 6 11 
Mean 1,200,214 431,557 364,385 384,872 27,716 143,353 103,052 
SD 242,343 95,716 65,256 89,824 5,238 23,714 22,836 
Median 1,211,778 428,297 370,036 408,890 27,613 146,261 99,600 
Q1 1,057,920 383,080 331,873 317,533 25,465 128,616 86,238 
Q3 1,380,619 500,823 407,954 446,530 30,753 158,203 118,255 
Minimum 626,949 226,512 212,160 175,004 18,573 90,615 62,615 
Maximum 1,616,910 623,124 476,069 502,960 40,288 180,642 154,692 
Mean 994,915 312,747 292,112 194,961 186,688 115,512 91,987 
SD 218,200 68,283 81,679 63,223 46,719 31,154 31,155 
Median 995,807 303,191 283,393 183,190 194,358 108,842 86,475 
Q1 847,824 265,951 243,435 148,934 149,049 97,072 68,945 
Q3 1,133,039 366,324 358,071 237,145 221,177 129,929 108,396 
Minimum 626,064 187,885 142,084 105,612 106,939 53,060 35,822 
Maximum 1,292,528 363,510 433,364 287,332 252,090 152,252 140,026 
Table ‎4-8: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the right 
eye for the normal individuals. 
Left Eye Global Quadrant Sector 
Inferior Superior Nasal Temporal 6 11 
Mean 1,115,065 427,240 362,908 356,423 28,682 144,328 106,611 
SD 201,723 78,223 68,528 96,786 4,482 23,372 20,912 
Median 1,160,026 444,259 360,149 374,589 27,933 140,914 104,425 
Q1 1,039,610 373,225 317,534 288,177 26,443 128,003 87,285 
Q3 1,281,988 479,948 394,558 423,659 31,053 157,427 120,806 
Minimum 406,095 292,951 246,393 170,322 20,809 104,459 79,429 
Maximum 1,491,837 559,568 508,884 512,324 39,286 201,831 146,271 
Mean 965,857 295,886 291,508 177,156 187,493 108,126 97,325 
SD 186,248 63,681 94,656 59,813 36,706 22,054 30,745 
Median 915,176 282,517 288,573 171,396 193,320 104,663 94,421 
Q1 829,139 257,995 250,096 136,560 155,766 96,783 77,336 
Q3 1,070,439 349,272 339,358 204,318 220,986 119,631 106,643 
Minimum 702,248 193,297 32,435 90,653 121,866 65,874 41,995 
Maximum 1,350,330 439,406 477,670 357,749 244,660 158,185 169,066 
Table ‎4-9: The summary statistics, by quadrant and by Sectors 6 and 11, for the 
estimated number of retinal ganglion cell soma (top) and axons (bottom) in the left eye 
for the normal individuals. 
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Figure ‎4-2: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for the right (left column) and left (right column) eyes of the 
individuals exposed to vigabatrin. Filled circles represent individuals with vigabatrin-
associated visual field loss and open squares represent individuals exposed to vigabatrin 
but with normal visual fields. The line of unity is given for comparison. 
  Right Eye       Global           Left Eye 
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Figure ‎4-3: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for the right (left column) and left (right column) eyes of the 
individuals with open angle glaucoma. Filled circles represent individuals with bilateral 
glaucomatous visual field loss; filled triangles, individuals with glaucomatous field loss 
in the represented eye; open triangles, individuals with glaucomatous field loss in the 
fellow eye; and open circles normal individuals. The line of unity is given for 
comparison. 
Right Eye       Global Left Eye 
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Figure ‎4-4: Scatter plot illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for the designated eye of the individuals with open angle 
glaucoma. The line of unity is given for comparison.  
Global 
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Figure ‎4-5: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for the right (left column) and left (right column) eyes of the 
individuals exposed to vigabatrin and for the designated eye of the individuals with open 
angle glaucoma. Filled circles represent individuals with vigabatrin-associated visual 
field loss; open squares represent individuals exposed to vigabatrin but with normal 
visual fields; and filled triangles represent individuals with open angle glaucoma in the 
designated eye. The line of unity is given for comparison. 
Right Eye Global Left Eye 
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Figure ‎4-6: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for the right (left column) and left (right column) eyes of the 
individuals exposed to vigabatrin and for the designated eye of the individuals with open 
angle glaucoma. Filled circles represent individuals with vigabatrin-associated visual field 
loss; open squares represent individuals exposed to vigabatrin but with normal visual 
fields; filled triangles represent individuals with open angle glaucoma and open circles 
represent normal individuals. The line of unity is given for comparison. 
Right Eye Global  Left Eye 
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4.4.5.1 Quadrant Evaluation 
The summary characteristics, by quadrant and by sector, for the number of remaining 
ganglion cell axons and the corresponding remaining number of retinal ganglion cell 
soma for each eye of the individuals exposed to vigabatrin but with normal fields and 
for the individuals with vigabatrin-associated visual fields loss are given in Table  4-3 to 
Table  4-4, respectively. 
The associations for each eye of the individuals exposed to vigabatrin for the superior 
and inferior quadrants are given in Figure  4-7 and for the nasal and temporal quadrants 
in Figure  4-8. 
Similarly, the association for each eye of the individuals with open angle glaucoma and 
for each eye of the normal individuals, for the superior and inferior quadrants and for 
the nasal and temporal are given in Figure  4-9 and Figure  4-10, respectively. The 
association for the designated eye of the individuals with open angle glaucoma for the 
superior and inferior quadrants and for the nasal and temporal quadrants are given in 
Figure  4-11 and Figure  4-12, respectively. 
The associations, for each eye, of the individuals exposed to vigabatrin, combined with 
the designated eye of the individuals with open angle glaucoma and the normal 
individuals are given for the superior and inferior quadrants and for the nasal and 
temporal quadrants in Figure  4-13 and Figure  4-14, respectively. 
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Figure ‎4-7: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the superior (top) and inferior (bottom) quadrants for the right (left column) and left 
(right column) eyes of the individuals exposed to vigabatrin. Filled circles indicate 
individuals with vigabatrin-associated visual field loss and open squares indicate 
individuals exposed to vigabatrin but with normal visual fields. The line of unity is given 
for comparison. Note the scaling of the axes is different to that in Figure 4-2. 
Right Eye Superior Quadrant   Left Eye 
Right Eye Inferior Quadrant Left Eye 
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Figure ‎4-8: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the nasal (top) and temporal (bottom) quadrants for the right (left column) and left (right 
column) eyes of the individuals exposed to vigabatrin. Filled circles indicate individuals 
with vigabatrin-associated visual field loss and open squares indicate individuals exposed 
to vigabatrin but with normal visual fields. The line of unity is given for comparison. Note 
the scaling of the axes is different to that in Figure 4-2 to Figure 4-6. 
Right Eye Nasal Quadrant Left Eye 
Right Eye Temporal Quadrant Left Eye 
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Figure ‎4-9: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the superior (top) and inferior (bottom) quadrants for the right (left column) and left 
(right column) eyes of the individuals with open angle glaucoma and of the normal 
individuals. Filled circles represent individuals with bi-lateral glaucomatous visual field 
loss; filled triangles, individuals with glaucomatous field loss in the given eye; open 
triangles, individuals with glaucomatous field loss in the fellow eye; and open circles, 
normal individuals. The line of unity is given for comparison. 
Right Eye Inferior Quadrant Left Eye 
Right Eye Superior Quadrant Left Eye 
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Figure ‎4-10: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the nasal (top) and temporal (bottom) quadrants for the right (left column) and left (right 
column) eyes of the individuals with open angle glaucoma and of the normal individuals. 
Filled circles represent individuals with bi-lateral glaucomatous visual field loss; filled 
triangles, individuals with glaucomatous field loss in the given eye; open triangles, 
individuals with glaucomatous field loss in the fellow eye; and open circles, normal 
individuals. The line of unity is given for comparison. 
Right Eye       Nasal Quadrant Left Eye 
Right Eye Temporal Quadrant Left Eye 
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Figure ‎4-11: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the superior (top) and inferior (bottom) quadrants of the designated eye of the individuals 
with open angle glaucoma. The line of unity is given for comparison. Note the scaling of 
the axes is different to that in Figure 4-2 to Figure 4-6. 
Superior Quadrant 
Inferior Quadrant 
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Figure ‎4-12: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the nasal (top) and temporal (bottom) quadrants of the designated eye of the individuals 
with open angle glaucoma. The line of unity is given for comparison. Note the scaling of 
the axes is different to that in Figure 4-2 to Figure 4-6. 
Temporal Quadrant 
Nasal Quadrant 
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Figure ‎4-13: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the superior (top) and inferior (bottom) quadrants of the right (left column) and left 
(right column) eyes of the individuals exposed to vigabatrin and of the designated eye of 
the individuals with open angle glaucoma. Filled circles represent individuals with 
vigabatrin-associated visual field loss; open squares represent individuals exposed to 
vigabatrin but with normal visual fields; filled triangles represent individuals with open 
angle glaucoma, and open circles represent normal individuals. The line of unity is given 
for comparison. Note the scaling of the axes is different to that in Figure 4-2 to Figure 4-6. 
Right Eye Superior Quadrant Left Eye 
Right Eye Inferior Quadrant Left Eye 
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Figure ‎4-14: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by Time-domain optical coherence tomography (OCT) (axons) for 
the nasal (top) and temporal (bottom) quadrants of the right (left column) and left (right 
column) eyes of the individuals exposed to vigabatrin and of the designated eye of the 
individuals with open angle glaucoma. Filled circles represent individuals with 
vigabatrin-associated visual field loss; open squares represent individuals exposed to 
vigabatrin but with normal visual fields; filled triangles represent individuals with open 
angle glaucoma; and open circles normal individuals. The line of unity is given for 
comparison. Note the scaling of the axes is different to that in Figure 4-2 to Figure 4-6. 
Right Eye Nasal Quadrant Left Eye 
Right Eye Temporal Quadrant Left Eye 
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4.4.5.2 Sector Evaluation 
The associations for each eye of the individuals exposed to vigabatrin by each of the 8 
sectors are given in Figure 4-15 to Figure 4-18, inclusive and for each eye of the 
individuals with open angle glaucoma of the normal individuals in Figures 4-19 to 
Figures 4-22. The combined data set for Sectors 6 and 11 are given in Figure 4-23 and 
Figure 4-24. 
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Figure ‎4-15: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 7 (top) and 10 (bottom) of the right (left column) 
and left (right column) eyes of the individuals exposed to vigabatrin. Filled circles 
represent individuals with vigabatrin-associated visual field loss and open squares 
represent individuals exposed to vigabatrin but with normal visual fields. The line of 
unity is given for comparison. 
Right Eye  Sector Seven Left Eye 
Right Eye Sector Ten Left Eye 
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Figure ‎4-16: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 6 (top) and 11 (bottom) of the right (left column) 
and left (right column) eyes of the individuals exposed to vigabatrin. Filled circles 
represent individuals with vigabatrin-associated visual field loss and open squares 
represent individuals exposed to vigabatrin but with normal visual fields. The line of 
unity is given for comparison. 
Right Eye Sector Six Left Eye 
Right Eye Sector Eleven  Left Eye 
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Figure ‎4-17: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 4 and 5 (top) and Sectors 12 and 13 (bottom) of 
the right (left column) and left (right column) eyes of the individuals exposed to 
vigabatrin. Filled circles represent individuals with vigabatrin-associated visual field loss 
and open squares represent individuals exposed to vigabatrin but with normal visual 
fields. The line of unity is given for comparison. 
Right Eye Sectors Four and Five Left Eye 
Right Eye   Sectors Twelve and Thirteen Left Eye 
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Figure ‎4-18: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 1 and 14 of the right (left column) and left (right 
column) eyes of the individuals exposed to vigabatrin. Filled circles represent individuals 
with vigabatrin-associated visual field loss and open squares represent individuals 
exposed to vigabatrin but with normal visual fields. The line of unity is given for 
comparison. Filled circles represent individuals with vigabatrin-associated visual field 
loss; open squares represent individuals exposed to vigabatrin but with normal visual 
fields; filled triangles represent individuals with open angle glaucoma; and open circles 
normal individuals. 
Right Eye Sector One Left Eye 
Right Eye Sector Fourteen Left Eye 
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Figure ‎4-19: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 7 and 10 of the right (left column) and left (right 
column) eyes of the individuals with open angle glaucoma and of the normal individuals. 
Filled circles represent individuals with bi-lateral glaucomatous visual field loss; filled 
triangles, individuals with glaucomatous field loss in the given eye; open triangles, 
individuals with glaucomatous field loss in the fellow eye; and open circles represent 
normal individuals. The line of unity is given for comparison. 
Right Eye Sector Seven Left Eye 
Right Eye Sector Ten Left Eye 
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Figure ‎4-20: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) for Sectors 6 and 11 of the right (left column) and left (right 
column) eyes of the individuals with open angle glaucoma and of the normal individuals. 
Filled circles represent individuals with bi-lateral glaucomatous visual field loss; filled 
triangles, individuals with glaucomatous field loss in the given eye; open triangles, 
individuals with glaucomatous field loss in the fellow eye; and open circles represent 
normal individuals. The line of unity is given for comparison. 
Right Eye Sector Six Left Eye 
Right Eye Sector Eleven  Left Eye 
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Figure ‎4-21: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) (top) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) (bottom) for Sectors 4 and 5 and 12 and 13 of the right (left 
column) and left (right column) eyes of the individuals with open angle glaucoma and of 
the normal individuals. Filled circles represent individuals with bilateral glaucomatous 
visual field loss; filled triangles, individuals with glaucomatous field loss in the given eye; 
open triangles, individuals with glaucomatous field loss in the fellow eye; and open circles 
represent normal individuals. The line of unity is given for comparison. 
Right Eye Sectors Four and Five Left Eye 
Right Eye Sectors Twelve and Thirteen Left Eye 
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Figure ‎4-22: Scatter plots illustrating the association between the estimated number of 
remaining retinal ganglion cells derived from standard automated perimetry (SAP) (cell 
soma) (top) and that derived by the circular scan of Time-domain optical coherence 
tomography (OCT) (axons) (bottom) for Sectors 1 and 14 of the right (left column) and 
left (right column) eyes of the individuals with open angle glaucoma and of the normal 
individuals. Filled circles represent individuals with bi-lateral glaucomatous visual field 
loss; filled triangles, individuals with glaucomatous field loss in the given eye; open 
triangles, individuals with glaucomatous field loss in the fellow eye; and open circles 
represent normal individuals. The line of unity is given for comparison. 
Right Eye Sector One Left Eye 
Right Eye Sector Fourteen Left Eye 
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Figure ‎4-23: Scatter plots illustrating the association between the estimated number of 
retinal ganglion cells derived from standard automated perimetry (SAP) (cell soma) and 
that derived by Time-domain optical coherence tomography (OCT) (axons) for Sectors 6 
and 11 of the right (left side) and left (right side) eyes. Filled circles indicate individuals 
with vigabatrin-associated visual field loss, open squares indicate individuals exposed to 
vigabatrin but with normal visual fields and Filled triangle indicate open angle glaucoma 
individuals, and open circles represent normal individuals. The line of unity is given for 
comparison. Note the scale is different from Figure ‎4-1. 
Right Eye Sector Six Left Eye 
Right Eye Sector Eleven  Left Eye 
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Figure ‎4-24: Scatter plots illustrating the association between the estimated number of 
retinal ganglion cells derived from standard automated perimetry (SAP) (cell soma) and 
that derived by Time-domain optical coherence tomography (OCT) (axons) for Sectors 6 
and 11 of the right (left side) and left (right side) eyes. Filled circles indicate individuals 
with vigabatrin-associated visual field loss, open squares represent individuals exposed to 
vigabatrin but with normal visual fields and Filled triangle represent open angle 
glaucoma individuals. The line of unity is given for comparison. Note the scale is different 
from Figure ‎4-1. 
  
Right Eye   Sector Six   Left Eye 
Right Eye   Sector Eleven  Left Eye 
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The estimated number of remaining retinal ganglion cells derived by standard 
automated perimetry (cell soma) and by the complete circular scan of Time-domain 
optical coherence tomography (axons) against the duration of vigabatrin are given in 
Figure  4-25. The corresponding associations for the superior and inferior quadrants are 
given in Figure  4-26 and Figure  4-27 respectively, and for Sectors 11 and 6 are given in 
Figure  4-28 and Figure  4-29, respectively. 
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Figure ‎4-25: The estimated number of remaining retinal ganglion cells derived by 
standard automated perimetry (cell soma) (top) and by the circular scan of Time-domain 
optical coherence tomography (axons) (bottom) against the duration of exposure to 
vigabatrin for the right eye (left column) and the left eye (right column) eyes of the 
individuals exposed to vigabatrin against. Filled circles represent individuals with 
vigabatrin-associated visual field loss and open squares represent individuals exposed to 
vigabatrin but with normal visual fields. VGB represents vigabatrin.  
Right Eye  Global  Left Eye 
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Figure ‎4-26: The estimated number of remaining retinal ganglion cells derived by 
standard automated perimetry (cell soma) (top) and from the superior quadrant of the 
circular scan of Time-domain optical coherence tomography (axons) (bottom) against the 
duration of exposure to vigabatrin for the right eye (left column) and the left eye (right 
column) eyes of the individuals exposed to vigabatrin against. Filled circles represent 
individuals with vigabatrin-associated visual field loss and open squares represent 
individuals exposed to vigabatrin but with normal visual fields. VGB represents 
vigabatrin. 
  
Right Eye Superior Quadrant  Left Eye 
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Figure ‎4-27: The estimated number of remaining retinal ganglion cells derived by 
standard automated perimetry (cell soma) (top) and from the inferior quadrant of the 
circular scan of Time-domain optical coherence tomography (axons) (bottom) against the 
duration of exposure to vigabatrin for the right eye (left column) and the left eye (right 
column) eyes of the individuals exposed to vigabatrin against. Filled circles represent 
individuals with vigabatrin-associated visual field loss and open squares represent 
individuals exposed to vigabatrin but with normal visual fields. VGB represents 
vigabatrin. 
  
Right Eye Inferior Quadrant  Left Eye 
125 
 
  
  
  
Figure ‎4-28: The estimated number of remaining retinal ganglion cells derived by 
standard automated perimetry (cell soma) (top) and from Sector Six of the circular scan 
of Time-domain optical coherence tomography (axons) (bottom) against the duration of 
exposure to vigabatrin for the right eye (left column) and the left eye (right column) eyes 
of the individuals exposed to vigabatrin against. Filled circles represent individuals with 
vigabatrin-associated visual field loss and open squares represent individuals exposed to 
vigabatrin but with normal visual fields. VGB represents vigabatrin. 
  
Right Eye  Sector Six  Left Eye 
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Figure ‎4-29: The estimated number of remaining retinal ganglion cells derived by 
standard automated perimetry (cell soma) (top) and from Sector Eleven of the circular 
scan of Time-domain optical coherence tomography (axons) (bottom) against the 
duration of exposure to vigabatrin for the right eye (left column) and the left eye (right 
column) eyes of the individuals exposed to vigabatrin against. Filled circles represent 
individuals with vigabatrin-associated visual field loss and open squares represent 
individuals exposed to vigabatrin but with normal visual fields. VGB represents 
vigabatrin. 
Right Eye Sector Eleven  Left Eye 
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4.5 Discussion 
The results demonstrate a strong linear association between the number of residual 
retinal ganglion cell soma derived from standard automated perimetry and the number 
of residual retinal ganglion cell axons derived by Time-domain optical coherence 
tomography. This strong association is compatible with that found in other optic 
neuropathies including open angle glaucoma (Hood et al., 2007; Hood and Kardon, 
2007; Medeiros et al., 2012a; Medeiros et al., 2012b) and ischaemic optic neuropathy 
(Hood et al., 2008) and would suggest that vigabatrin toxicity causes an optic 
neuropathy. However, it not known whether the vigabatrin-associated optic neuropathy 
is of a primary or of a secondary origin.  
The degree of association is remarkable given that the data was obtained from 
individuals with severe epilepsy, many of whom had related cognitive difficulties. It is 
also remarkable given the considerable between-subject variation in the topography of 
the retinal nerve fibre layer at the entry to the optic nerve head (Strouthidis et al., 2006; 
Ferreras et al., 2008). 
The associations for the global, inferior and, superior quadrants are linear in each eye 
both for those with vigabatrin-associated visual field loss and for those exposed to 
vigabatrin but a with normal field; however, the trends lie above the line of unity. In 
general, the data points for those exposed to vigabatrin but with normal fields, and those 
of the normal individuals, lie closer to the line of unity than those for the individuals 
with vigabatrin-associated visual field loss and for the individuals with open angle 
glaucoma (Figure  4-6). 
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 A linear association is also present both for the nasal and the temporal quadrants. The 
trend for the nasal quadrant lies considerably below the line of unity. This trend can be 
explained by an under sampling of the perimetric stimulus locations within this region. 
The under-sampling of the stimulus locations in the nasal quadrant results in an overlap 
of apparent residual ganglion cell soma between those with and without vigabatrin-
associated visual field loss. This overlap is attributable to the fact that the nasal quadrant 
of the optic nerve head represents the temporal visual field which is the least affected in 
vigabatrin-associated visual field loss. The trend for the temporal quadrant lies 
considerably above the line of unity. This trend can be explained by an under sampling 
of the perimetric stimulus locations within the region but also by the fact that the 
temporal quadrant contains the papillomacular bundle, the visual field of which is 
seemingly only affected in severe cases of vigabatrin toxicity. The nasal and temporal 
quadrants contain 5 and 3 stimulus locations, respectively, compared to the 23 and 21 
stimulus locations, for the superior and inferior quadrants respectively.  
Similarly, the associations for each of the optic nerve head sectors are linear but the 
numbers of calculated residual ganglion cell soma are markedly influenced by the 
number of available perimetric stimulus locations and this disparity interacts with the 
topographical characteristics of the toxicity. Clearly, one approach, in any future study, 
would be to increase the number of stimulus locations within the nasal and temporal 
quadrants and within each of the under-sampled sectors. However, such an approach 
would not overcome the lack of stimulus locations beyond the grid utilised by Program 
24-2, i.e., that for the peripheral field. Indeed, the formulae for calculating residual 
retinal ganglion cell soma, developed by Harwerth and colleagues (Harwerth et al 2010; 
Medeiros et al., 2012a; Medeiros et al., 2012b; Tatham et al., 2013) should be extended 
to include more peripheral stimulus locations. However, the accuracy of the calculation 
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of the more peripheral ganglion cell soma would be influenced by the increased within- 
and between-subject variability associated with the estimation of threshold which 
increases with increase in eccentricity and which is well established in clinical 
perimetry (Heijl et al., 1987a). Interestingly, a novel stimulus configuration has been 
proposed by Garway-Heath and colleagues (Asaoka et al., 2012) which utilised four 
stimulus locations for each of the 12 sectors of the optic nerve head and which 
contained proportionately more stimulus locations in the nasal sectors and in the 
papillomacular region compared to the grid of Program 24-2. Such stimulus locations 
exhibited higher structure-function correlations than those derived with Program 24-2. 
However, the utility of this novel stimulus grid will be limited until an accompanying 
date base of age-corrected normal values of sensitivity can be offered by the 
manufacture together with the accompanying statistical analysis package. 
The greater number of residual ganglion cell soma, compared to the number of residual 
ganglion cell axons, in the individuals exposed to vigabatrin, in those regions with an 
adequate sampling of stimulus locations, may also arise from a lack of consideration of 
normal age-related changes. The number of residual ganglion cell soma is calculated 
from the measured differential sensitivity without any correction for age (Harwerth et 
al., 2010). It is well accepted that sensitivity declines with increase in age (Jaffe, 
Alvarado and Juster, 1986; Heijl et al., 1987a). Consequently, the number of residual 
ganglion cell soma will decrease with increase in age. The younger age of the 
individuals exposed to vigabatrin compared to that of those with open-angle glaucoma, 
in whom the formulae were developed, may account for some of the discrepancy 
between the retinal ganglion cell soma and axon counts. In contrast, the formula for the 
calculation of ganglion cell axons does compensate for the effect of age (Harwerth et 
al., 2010). The traditional perimetric approach for overcoming the effect of age is to 
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compare the measured sensitivity at any given location with that of corresponding age-
corrected normal value of sensitivity. Such a comparison is displayed, with the 
Humphrey Field Analyzer, in terms of the Total Deviation map. Notwithstanding such 
an approach, it is still not possible to differentiate between a normal reduction in 
sensitivity due to a loss of clarity of the ocular media from that due to normal ‘neural’ 
changes. Several studies have attempted to correlate the reduction in the differential 
light sensitivity with the increased absorption and/ or increased forward intra-ocular 
light scatter arising from a loss of clarity of the ocular media (Wood, Wild and Crews, 
1987; Dengler-Harles et al., 1990; Moss, Wild and Whitaker, 1995) but with varying 
success. Furthermore, the use of the Total Deviation map compares the measured 
sensitivity with the ‘average’ normal sensitivity: the ‘average’ value declines with 
increase in age but may not be linear as currently computed (Bengtsson et al., 1997; 
Artes et al., 2005).  
Quantification of the trend line in terms of the slope and intercept using univariate 
regression was not undertaken since neither the residual ganglion cell soma nor the 
residual ganglion cell axons could be considered to be the dependent variable and each 
exhibit measurement errors of different magnitude. Univariate regression analysis using 
the least squares techniques can only be undertaken with a pre-defined dependent 
variable which does not exhibit a measurement error. Previous studies have considered 
structure to be the independent variable and function to be the dependent variable 
(Harwerth et al., 2007; Racette et al., 2007) and the validity of this approach has been 
debated (Marin-Franch et al., 2013; Redmond et al., 2013b). Alternative techniques 
such as Passing-Bablock regression (Passing and Bablock 1983) which has been used in 
other studies of the structure-function relationship (Redmond et al., 2013a) have also 
been debated (Marin-Franch et al., 2013; Redmond et al., 2013b). Indeed, the gradient 
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of a linear fit can change by factor of 10 for the same structure-function data depending 
upon the type of regression applied (Marin-Franch et al., 2013).  
Assuming a one-to-one relationship between a ganglion cell soma and a ganglion cell 
axon, alternative techniques such as that proposed by Bland and Altmann (1995), 
whereby the difference in the magnitude between the two variables are plotted against 
the mean of the two magnitudes, could have been used; however, the potential linearity 
of the association is more easily recognisable by the comparison with a series of linear 
trend lines. In the current study, a linear trend line of unity constrained to pass through 
the origin, was adopted for the comparison. 
Evaluation of the number of retinal ganglion cells is receiving considerable attention in 
open angle glaucoma. For example, the relationship between the estimated retinal 
ganglion cell count and the cup-to-disc ratio suggests that assessment of change in the 
ratio is an insensitive method for evaluating progressive damage in glaucoma as a small 
change in the ratio can be associated with a large loss of ganglion cells particularly in 
large cup-to-disc ratios (Tatham et al., 2013b). The combination of retinal ganglion cell 
counts from both structural and functional assessments also identifies progressive 
glaucomatous loss earlier than conventional measures of either structure, alone, or 
function, alone (Meira-Freitas et al., 2014). It can be anticipated, therefore, that a 
combined estimate of the retinal ganglion cells will provide a more sensitive tool in the 
evaluation of individuals receiving vigabatrin. 
Given the clear implication of the retinal ganglion cells in vigabatrin toxicity, it is 
perhaps surprising that the pattern electroretinogram (PERG) does not identify the 
dysfunction. However, the PERG (in contrast to the flash ERG) is a local response and 
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reflects the integrity of the optics, photoreceptors, bipolar cells and retinal ganglion cells 
(Bach et al., 2013). The standard stimulus field for clinical pattern electroretinography, 
recommended by the International Society for Clinical Electrophysiology for Vision is 
15° (±3°) which lies within the region of the visual field which is normal even in those 
with severe vigabatrin-associated visual field loss. A larger stimulus field, such as 30°, 
is also recommended but this, at best, would only identify those with severe vigabatrin-
associated visual field loss.  
It also can be seen from Figure  4-1 to Figure  4-6 that a combined structure and function 
measure is able to differentiate individuals with vigabatrin-associated visual field loss 
from those exposed to vigabatrin with a normal visual field. Similarly, as would be 
expected from other studies (Medeiros et al., 2012a; Medeiros et al., 2012b) the 
combination is also able to distinguish individuals with open angle glaucoma from 
normal individuals. The presence of outliers within each grouping, and, therefore, the 
magnitude of the sensitivity and specificity, are not merely due to the presence of 
variability associated with given measurement but is also dependent upon the correct 
clinician-based diagnosis. As mentioned above, the estimation of ganglion cells from 
perimetry is based upon the absolute measure of sensitivity, i.e., the height of the visual 
field, which, itself, is influenced by optical as well as neural factors e.g., forward 
intraocular light scatter arising from cataract.  
In addition, it should never be forgotten that the visual field examination is a subjective 
test. Close inspection of the data sets suggest that, in general, individuals exposed to 
vigabatrin performed ‘better’ in the second eye examined, most likely due to a 
refreshment of the perimetric experience, and that individuals with open angle glaucoma 
and normal individuals performed ‘worse’ in the second eye examined most likely due 
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to the perimetric fatigue effect. Indeed, normal individuals do not always produce 
perimetrically normal results. 
As might be expected from the findings of the previous chapter, Chapter Three, the 
individuals with vigabatrin associated visual field loss had longer exposures and higher 
cumulative doses than those with a normal field (mean cumulative dose 8.9kg [SD 4.3] 
compared to 3.9kg [4.5]; and 10.3 years [3.5] compared to 7.3 years [5.8]). A weak 
negative association was present between the residual ganglion cell axons derived by 
optical coherence tomography and the duration of exposure to vigabatrin Figure  4-25 to 
Figure  4-29 both for those with vigabatrin-associated visual field loss and, surprisingly, 
for those exposed to vigabatrin but with normal fields. No association was present 
between ganglion cell soma derived from standard automated perimetry and duration of 
exposure to vigabatrin. 
As stated previously, the strong topographical association, in general, between the 
residual ganglion cells counts derived from standard automated perimetry and from 
optical coherence tomography suggests that a combined outcome measure would be of 
use in the management of individuals exposed to vigabatrin. One approach is to overlay 
the Pattern Deviation probability map of the visual field with that of the probability map 
from optical coherence tomography arranged according to the axonal configuration of 
the optic nerve head such as that described by Wirtschafter et al (1982) and used 
throughout the study. The combined probability maps are illustrated in the Appendix at 
the end of this Chapter. The maps for the visual field were based upon the Pattern 
Deviation analysis, i.e. that reflecting localised abnormality, whilst those for optical 
coherence where based upon overall loss. It can be envisaged that at some point in the 
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future, resolution permitting, the retinal nerve fibre probability analysis will be divided 
into overall loss and localised loss commensurate with that for periemetry. 
Optical coherence tomography was undertaken using the Time-domain StratusOCT. 
The time for image capture for the StratusOCT is slower than that of its successor, the 
Spectral-domain Cirrus OCT, manufactured by the same company. The Cirrus OCT, 
acquires data approximately 70 times faster and with better resolution (5μm compared 
to 8–10μm axial resolution) (Jeoung et al., 2010). The faster acquisition, together with 
automated compensation for misalignment, of Spectral-domain optical coherence 
tomography should reduce the variability associated with the acquisition of the given 
scan. Despite careful selection of each scan, 11 of the 24 individuals with vigabatrin-
associated visual field loss, and 8 of the 17 individuals exposed to vigabatrin but with 
normal fields, exhibited disparities in the probability level between the two vertical 
hemifields due to scan misalignment. 
In summary, vigabatrin toxicity is associated with retinal ganglion cell axonal and/ or 
soma loss; however, it is not known whether the optic neuropathy occurs as a result of 
the direct or the indirect action of the toxicity. The use of a combined structural and 
functional assessment based upon estimations of residual retinal ganglion cells 
calculated from optical coherence tomography and from standard automated perimetry 
may provide a more sensitive tool for detecting and monitoring vigabatrin toxicity.  
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Chapter 5. The outcome of the visual field 
following long-term withdrawal of vigabatrin 
5.1 Introduction 
It was shown in Chapter One that the visual field seemingly remains stable, in those 
individuals with vigabatrin-associated visual field loss, and also in those with normal 
visual fields, who have withdrawn from vigabatrin for periods of up to 9 months 
(Johnson et al., 2000), 18 months (Newman et al., 2002), 24 months (Hardus et al 
2000a;b), 38 months (Nousiainen et al 2001), 4 years (Hardus et al 2003 and between 4 
and 6 years (Kjellström et al 2008). However, the outcome of the visual field 
examination following longer-term withdrawal from vigabatrin has not received any 
attention and, therefore, it is not known as to whether the vigabatrin-associated visual 
field loss remains stable or exhibits a capacity either for further deterioration or, less 
likely, for improvement.  
Similarly, it was also shown in Chapter One that the visual field of those with 
vigabatrin-associated visual field loss who continue on treatment with vigabatrin 
remains stable over follow-up periods of 11 months (Lawden et al 1999), 12 months 
(Paul et al 2001), 18 months (Graiewski-Wijnands and van der Torron 2002), 24 months 
(Schmidt et al 2002), between 4 and 38 months (Nousiainen et al 2001), between 18 and 
43 months (Best and Acheson 2005), between 18 and 66 months (Kinirons et al 2006) 
and between 4 and 72 months (Johnson et al., 2000; Newman et al., 2002; Kjellström et 
al., 2008). However, the longer-term status of vigabatrin-associated visual field loss in 
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those individuals continuing on vigabatrin and also of those with normal visual fields 
who remain on vigabatrin has received little attention. The one report evaluating the 
outcome of long-term vigabatrin therapy was published during the compilation of this 
thesis (Clayton et al., 2013). Fourteen individuals treated with vigabatrin (including the 
individual described in the case report by (Clayton et al., 2010) initially underwent 
kinetic perimetry after a mean duration of 65 months (mean cumulative dose 4.7kg) and 
were subsequently followed for a mean period of 128 months whilst remaining on the 
drug (final cumulative dose 11.6kg). Thirteen of the 14 individuals exhibited a reduction 
in the extent of the I4e isopter which, itself, was correlated with increasing cumulative 
dose. 
In the data set described in Chapter Three, all individuals had withdrawn from 
vigabatrin either following, or immediately after, the initial visual field examination. 
Such an outcome provided an opportunity, by means of introducing a further visual field 
examination, to determine the status of the visual field following long-term withdrawal 
from vigabatrin.  
5.2 Aim 
The aim of the study was to determine, by the addition of a long-term follow-up visual 
field examination in individuals withdrawn from vigabatrin, the capacity for 
deterioration or for improvement in those with vigabatrin-associated visual field loss or 
for a deterioration in those with previously normal fields. The outcome was to be 
evaluated in relation to two aspects: the interval between the baseline and follow-up 
visual field examinations and the severity of the baseline visual field loss. If either a 
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worsening or an improvement in the fields was found, the extent of the alteration would 
be investigated with respect to the time since withdrawal from vigabatrin and to the 
duration and cumulative dose of vigabatrin.  
5.3 Methods  
5.3.1 Cohort 
The study was a prospective cohort study. The case series comprised 42 individuals 
with epilepsy who had attended the Alan Richens Unit, Welsh Epilepsy Centre at the 
University Hospital of Wales, Cardiff, who had a history of treatment with vigabatrin 
and who had previously undergone visual field examination using the standard protocol 
described in Chapter Three. All individuals had volunteered to undertake the follow-up 
visual field examination.  
5.3.2  Visual field examination  
Each individual was re-examined with Program 30-2 and the FASTPAC strategy of the 
Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) in an identical manner to 
that described in Chapter 4. Each individual wore the distance refraction corrected, 
where necessary, for the viewing distance of the perimeter bowl. The field of the right 
eye was always examined before that of the left eye. A rest period of between 
approximately 30 seconds and two minutes was given approximately every three 
minutes for any given individual. A further rest period of between 10 to 30 minutes 
depending upon the individual was given between the examinations of each eye.  
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Fixation was monitored using the gaze tracker and the Heijl-Krakau blind spot 
technique. Reliability was also monitored in terms of the number of incorrect responses 
to the false-positive and the false-negative catch trials in an identical manner to that 
used in Chapter Four. Visual field examinations which had yielded greater than 15% 
incorrect responses to the false-positive and/ or greater than 20% incorrect responses to 
the fixation loss catch trials and/ or poor quality outcomes to the gaze tracking were 
repeated on a separate occasion. A similar approach was adopted for incorrect responses 
to the false-negative catch trials: the repeat criterion was greater than 30% incorrect 
responses but the tolerance widened with increase in severity of the field loss 
(Bengtsson and Heijl, 2000). 
5.3.3 Statistical Analysis 
The difference in the outcome of the visual field between the follow-up and baseline 
examinations in relation to the interval between the respective examinations was 
evaluated by scattergraph in terms of the visual field indices Mean Deviation and 
Corrected Pattern Standard Deviation.  
The difference in the outcome of the visual field between the follow-up and baseline 
examinations in relation to the severity of the field loss at the baseline examination was 
evaluated in two ways. Firstly, in terms of the visual field indices Mean Deviation and 
Corrected Pattern Standard Deviation using the technique of Bland and Altman (Bland 
and Altman, 1995) whereby the difference in the given index between the two 
examinations was plotted against that of the mean of the two indices and the outcome 
described in terms of the Mean and ±2SD of the differences. Secondly, and in tabular 
format, in terms of the Pattern Deviation probability values.  
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5.4 Results 
5.4.1 Cohort  
Of the 42 individuals, 15 were excluded from the analysis on the basis of the appearance 
of the visual field recorded at the follow-up examination. Of these 15 individuals, one 
was excluded due to the emergence of repeatable visual field loss of differing 
appearance between the two eyes but of unknown aetiology; five due to a fatiguing 
artefact present in the fields from one or both eyes; three due to grossly unreliable visual 
fields; and six due to end-stage visual field loss and the accompanying gross 
unreliability.  
The distribution of the remaining 27 individuals by vigabatrin treatment and by visual 
field outcome at the baseline examination is given in Table  5-1.  
Vigabatrin therapy Normal fields VAVFL Total 
 
Withdrawn 6 6 12 
On-going 2 13 15 
Total 8 19 27 
Table ‎5-1: The number of individuals by vigabatrin treatment and visual field 
outcome at the baseline examination. VAVFL indicates vigabatrin-associated visual 
field loss. 
The age of the 27 individuals at the follow-up visual field examination ranged from 26.2 
to 72.5 years (mean 50.9 years SD 13.9; median 54.7 years IQR 40.7, 60.2). The 
interval between the follow-up and the baseline examination ranged from 5.5 to 8.6 
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years (mean 7.0, SD 0.8 years; median 7.0 years IQR 6.5, 7.6). The biographical 
characteristics, at the time of follow-up, are shown in Table  5-2. 
Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of VGB (yr)  9.4 (3.7) 11.1 (6.0, 12.1) 1.16 18.2 
Cumulative dose of VGB at  
follow-up (kg)  
8.7 (4.8) 8.4 (5.2, 12.7) 0.69 19.0 
Daily dose (g)  2.5 (0.9) 2.1 (1.8, 3.2) 1.41 4.04 
Interval between onset of  
VGB and baseline perimetry (yr) 
10.2 (3.2) 11.6 (8.8, 12.2) 0.9 14.4 
Interval between perimetry (yr)  7.0 (0.8) 7.0 (6.5, 7.6) 5.5 8.6 
Age at baseline (yr)  43.9 (13.9) 48.7 (33.7, 53.6) 17.81 65.4 
Age at follow-up (yr)  50.9 (13.9) 54.7 (40.7, 60.2) 26.2 72.5 
Interval between withdrawal of  
VGB and follow-up perimetry (yr) 
7.1 (3.4) 7.1 (5.4, 8.4) 0.89 16.2 
Table ‎5-2: The summary statistics of the biographical characteristics, at the time of 
follow-up, for the 27 individuals.  
Nineteen of the 27 individuals (12 males, 63% and 7 females, 37%) had exhibited 
vigabatrin-associated visual field loss at the initial examination. Of these 19 individuals, 
6 had discontinued vigabatrin prior to the baseline examination.  
The duration of vigabatrin exposure, and the magnitude of the cumulative dose of 
vigabatrin, at the follow-up examination for the 19 individuals with vigabatrin-
associated visual field loss ranged from 4.0 to 17.0 years (mean 10.8 years, SD 3.2; 
median 11.1 years IQR 9.7, 12.8) and from 2.2 to 19.0 kg cumulative dose (mean 9.9 kg 
SD 4.5; median 8.7 kg, IQR 6.4, 7.7), respectively. The biographical characteristics, at 
the time of follow-up, are shown in Table  5-1 to Table  5-5. Four of the 19 individuals 
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exhibited homonymous quadrantic loss at both the follow-up and the baseline 
examinations in addition to vigabatrin-associated visual field loss. A fifth individual 
exhibited homonymous quadrantic loss at the follow-up examination as a result of 
neurosurgery undertaken during the interval between the two visual field examinations. 
In these latter five cases, the visual fields were evaluated in terms the remaining three 
quadrants. The remaining 8 of the 27 individuals had manifested normal visual fields at 
the baseline examination. Of these 8 individuals, 6 had discontinued vigabatrin prior to 
the baseline examination. None of these 8 individuals manifested any quadrantic or 
hemianopic loss. 
In clinical terms, no individual ‘converted’ from manifesting normal fields at the 
baseline examination to vigabatrin-associated visual field loss at the follow-up 
examination.  
The duration of vigabatrin exposure, and the magnitude of the cumulative dose of 
vigabatrin, at the follow-up examination for the 8 individuals with normal visual fields 
ranged from 1.16 to 13.60 years (mean 8.2 years, SD 5.9; median 6.9 years, IQR 2.8, 
13.0), and from 0.69 to 14.22kg (mean 6.11kg SD 4.9; median 4.37kg IQR 1.92, 10.74). 
The biographical characteristics, at the time of follow-up, are shown in Table  5-5 to 
Table  5-8. 
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  10.8 (3.2) 11.1 (9.7, 12.8) 4.0 17.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
9.9 (4.5) 8. 7 (6.4, 7.7) 2.2 19.0 
Daily dose (g)  2.7 (0.9) 2.8 (1.8, 3.7) 1.5 4.0 
Interval between onset of  
vigabatrin and baseline perimetry (yr)  
9.9 (3.4) 11.6 (9.4, 12.1) 0.9 12.9 
Interval between perimetry (yr)  7.3 (0.8) 7.4 (6.5, 7.7)  5.8 8.6 
Age at baseline (yr)  42.9 (15.2) 49.3 (24.9, 53.6) 17.8 65.4 
Age at follow-up (yr)  50.3 (15.2) 57.0 (32.7, 61.5) 26.2 72.5 
Interval between withdrawal of 
vigabatrin and follow-up perimetry (yr)  
6.2 (2.4) 6.9 (5.3, 7.2) 0.86 11.1 
Table ‎5-3: Summary statistics of the individual characteristics, at the time of follow-up, 
for the 19 individuals with vigabatrin-associated visual field loss.  
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  7.91 (3.5) 7.3 (4.6, 12.0) 4.0 12.1 
Cumulative dose of vigabatrin at  
follow-up (kg)  
9.11 (2.2) 8.8 (5.22, 13.4) 2.2 16.1 
Daily dose (g)  2.8 (1.0) 3.03 (1.7, 3.7) 1.5 3.8 
Interval between onset of  
vigabatrin and baseline perimetry (yr) 
9.9 (2.8) 10.9 (7.0, 12.3) 5.9 12.6 
Interval between perimetry (yr)  7.3 (0.8) 7.4 (6.5, 7.7) 5.8 8.6 
Age at baseline (yr)  42.9 (15.2) 49.3 (1.7, 3.7) 17.8 65.4 
Age at follow-up (yr)  50.4 (15.1) 57.0 (32.7, 61.5) 26.2 72.5 
Interval between withdrawal of  
vigabatrin and follow-up perimetry (yr)  
7.8 (1.9) 7.7 (6.5, 9.1) 5.3 11.1 
Table ‎5-4: The summary statistics of the individual characteristics, at the time of follow-
up, for the 6 individuals with vigabatrin-associated visual field loss who were 
withdrawn from vigabatrin prior to the baseline examination. 
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  10.7 (2.4) 11.1 (10.2, 12.1) 3.50 12.8 
Cumulative dose of vigabatrin at  
follow-up (kg)  
10.2 (4.4) 8.7 (6.9, 12.9) 2.52 19.0 
Daily dose (g) 2.7 (0.9) 2.0 (1.9, 3.6) 1.6 4.0 
Interval between onset of  
vigabatrin and baseline perimetry (yr)  
9.9 (3.8) 11.6 (9.8, 12.0) 0.9 12.9 
Interval between perimetry (yr)  7.3 (0.8) 7.4 (6.5, 7.7) 5.8 8.6 
Age at baseline (yr)  42.9 (15.2) 49.3 (24.9, 53.6) 17.8 65.4 
Age at follow-up (yr)  50.3 (15.1) 57.0 (32.7, 61.5) 26.2 72.5 
Interval between withdrawal of  
vigabatrin and follow-up perimetry (yr)  
5.5 (2.3) 6.0 (4.7, 7.1) 0.86 9.3 
Table ‎5-5: The summary statistics of the individual characteristics, at the time of follow-
up, for the 13 individuals with vigabatrin-associated visual field loss who were 
withdrawn from vigabatrin between the initial and the follow-up visual field 
examinations.  
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  8.2 (5.9) 6.9 (2.8, 13.0) 1.1 18.2 
Cumulative dose of vigabatrin at  
follow-up (kg)  
6.11.( 4.9) 4.37 (1.9, 10.7) 0.7 14.2 
Daily dose (g)  2.02 (0.5) 1.95 (1.7, 2.4) 1.4 2.9 
Interval between onset of  
vigabatrin and baseline perimetry (yr) 
11.0 (2.6) 11.8 (8.1, 13.3) 7.3 14.4 
Interval between perimetry (yr)  6.32 (0.6) 6.23 (5.7, 6.8) 5.5 7.3 
Age at baseline (yr)  46.3 (10.2) 46.26 (1.7, 2.4) 28.5 62.4 
Age at follow-up (yr)  52.6 (10.2) 53.27 (1.7, 2.4) 35.4 68.9 
Interval between withdrawal of  
vigabatrin and follow-up perimetry (yr)  
8.9 (4.5) 8.4 (6.4, 11.9) 1.0 16.2 
Table ‎5-6: Summary statistics of the individual characteristics, at the time of follow-up, 
for the 8 individuals with normal visual fields. 
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  5.8 (4.0) 5.7 (1.7, 9.0) 1.2 12.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
4.2 (3.8) 3.3 (1.3, 6.7) 0.7 11.2 
Daily dose (g)  1.9 (0.4) 1.8 (1.6, 2.2) 1.4 2.5 
Interval between onset of  
vigabatrin and baseline perimetry (yr) 
10.3 (2.7) 10.2 (7.7, 12.6) 7.3 14.4 
Interval between perimetry (yr)  6.3 (0.6)  6.2 (5.9, 6.8) 5.5 7.3 
Age at baseline (yr)  46.3 (10.3) 46.3 (1.6, 2.2) 28.5 62.4 
Age at follow-up (yr)  52.6 (10.2) 53.3 (45.9, 59.5) 35.4 68.9 
Interval between withdrawal of  
vigabatrin and follow-up perimetry (yr) 
10.8 (3.1) 10.2 (8.2, 13.0) 8.2 16.2 
Table ‎5-7: The summary statistics of the individual characteristics, at the time of follow-
up, for the 6 individuals with normal fields who were withdrawn from vigabatrin prior 
to the baseline examination. 
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Characteristics Individual 1 Individual 2 
Duration of vigabatrin (yr)  13.0 12.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
14.2 9.5 
Daily dose (g)  2.9 2.1 
Interval between onset of  
vigabatrin and baseline perimetry (yr) 
13.6 12.7 
Interval between perimetry (yr)  6.9 6.6 
Age at baseline (yr)  28 39 
Age at follow-up (yr)  35 45 
Interval between withdrawal of  
vigabatrin and follow-up perimetry (yr) 
1.0 5.9 
Table ‎5-8: The summary of the individual characteristics, at the time of follow-up, for 
the 2 individuals with normal visual fields who were withdrawn from vigabatrin 
between the initial and the follow-up visual field examinations. 
All 15 individuals (two with normal fields and 13 with vigabatrin-associated visual field 
loss) who were receiving vigabatrin at the time of the baseline examination had been 
withdrawn from vigabatrin by the time of the follow-up examination.  
5.4.2 Interval between the follow-up and baseline examinations 
5.4.2.1 Mean Deviation 
The difference in the Mean Deviation between the follow-up and the baseline 
examinations, averaged across the fields of the two eyes for an individual, against the 
interval between the two examinations, for the 19 individuals with vigabatrin-associated 
visual field loss is illustrated in Figure  5-1. 
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The corresponding plots for the field of the right eye and of the left eye are given in 
Figure  5-2 and Figure  5-3. 
 
Figure ‎5-1: The difference in the Mean Deviation (MD), averaged across the two eyes 
for an individual, between the follow-up and the baseline examinations against the 
interval between the two examinations for the 6 individuals with vigabatrin-associated 
visual field loss withdrawn from vigabatrin prior to the baseline examination (filled 
symbols) and for the 13 individuals with vigabatrin-associated visual field loss 
receiving vigabatrin at the time of the baseline examination (open symbols).   
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Figure ‎5-2: The difference in Mean Deviation (MD), for the right eye of an individual, 
between the follow-up and the baseline examinations against the interval between the 
two examinations for the 6 individuals with vigabatrin-associated visual field loss 
withdrawn from vigabatrin prior to the baseline examination (filled symbols) and for 
the 13 individuals with vigabatrin associated visual field loss receiving vigabatrin at 
the time of the baseline examination (open symbols). 
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Figure ‎5-3: The difference in Mean Deviation (MD), for the left eye of an individual, 
between the follow-up and the baseline examinations against the interval between the 
two examinations for the 6 individuals with vigabatrin-associated visual field loss 
withdrawn from vigabatrin prior to the baseline examination (filled symbols) and for 
the 13 individuals with vigabatrin associated visual field loss receiving vigabatrin at 
the time of the baseline examination (open symbols). 
The difference in the MD between the follow-up and the baseline examinations, 
averaged across the fields of the two eyes for each individual, was independent of the 
interval between the two examinations for the 27 individuals (R
2
 = 0.001). Similarly, 
the differences in the MD for the right eye and for the left eye were also each 
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independent of the interval between the two examinations (R
2
 = 0.003 and R
2
 = 0.0, 
respectively) (Table  5-9).  
No relationship was present between the change in the respective MDs from the 
baseline to the follow-up examination and the corresponding interval between the two 
visual field examinations for those with vigabatrin-associated visual field loss, 
regardless of whether the individuals were receiving (R
2
 = 0.01, R
2
 = 0.08, and R
2
 = 
0.02, respectively), or had been withdrawn from, vigabatrin(R
2
 = 0.05, R
2
 = 0.12, and 
R
2
 = 0.00, respectively) (Table  5-9). 
The difference in the MD at the follow-up examination, averaged across the fields of the 
two eyes for an individual, against that at the baseline examination for the 8 individuals 
with normal fields is illustrated in Figure  5-4. The corresponding plots for the field of 
the right eye and of the left eye are given in Figure  5-5 and Figure  5-6.  
 No 
Mean of both eyes 
MD 
Right eye 
MD 
Left eye 
MD 
Total 27 0.00 0.00 0.00 
VAVFL 19 0.00 0.00 0.00 
Off drug (VAVFL) 13 0.05 0.12 0.00 
On drug (VAVFL) 6 0.01 0.08 0.02 
All (Normal field) 8 0.00 0.00 0.00 
Off drug (Normal field) 6 0.00 0.00 0.01 
On drug (Normal field) 2 -   
Table ‎5-9: The Coefficients of Determination, (R2) for the change in the Mean Deviation 
(MD) between the follow-up and the baseline examinations against the interval between 
the two examinations. 
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Figure ‎5-4: The difference in the Mean Deviation (MD), averaged across the two eyes 
for an individual, between the follow-up and the baseline examinations against the 
interval between the two examinations for the 6 individuals with a normal field 
withdrawn from vigabatrin prior to the baseline examination (filled symbols) and for 
the 2 individuals with a normal field receiving vigabatrin at the time of the baseline 
examination (open symbols). 
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Figure ‎5-5: The difference in the Mean Deviation (MD), for the right eye between the 
follow-up and the baseline examinations against the interval between the two 
examinations for the 6 individuals with normal field withdrawn from vigabatrin prior 
to the baseline examination (filled symbols) and for the 2 individuals with a normal 
field receiving vigabatrin at the time of the baseline examination (open symbols). 
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Figure ‎5-6: The difference in the Mean Deviation (MD), for the left eye between the 
follow-up and baseline examinations against the interval between the two 
examinations for the 6 individuals with a normal field withdrawn from vigabatrin 
prior to the baseline examination (filled symbols) and for the 2 individuals with a 
normal field receiving vigabatrin at the time of the baseline examination (open 
symbols). 
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The magnitudes of the Coefficients of Determination were similar, within the remit of 
the limited numbers of individuals, to those for the 6 individuals with normal fields 
(Table  5-9) who had been withdrawn from vigabatrin prior to the first examination and 
who would not, normally, be expected to exhibit any such relationship. 
5.4.2.2 Corrected Pattern Standard Deviation 
The difference in the mean Corrected Pattern Standard Deviation (CPSD) between the 
follow-up and the baseline examinations, averaged across the fields of the two eyes for 
each individual, against the interval between the two examinations, for the 19 
individuals with vigabatrin-associated visual field loss is illustrated in Figure  5-7. The 
corresponding plots for the field of the right eye and of the left eye are given in Figure 
 5-8 and Figure  5-9. 
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Figure ‎5-7: The difference in the Corrected Pattern Standard Deviation (CPSD), 
averaged across the two eyes for an individual, between the follow-up and the baseline 
examinations against the interval between the two examinations for the 6 individuals 
with vigabatrin associated visual field loss withdrawn from vigabatrin prior to the 
baseline examination (filled symbols) and for the 13 individuals with vigabatrin 
associated visual field loss receiving vigabatrin at the time of the baseline examination 
(open symbols).  
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Figure ‎5-8: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the right eye, between the follow-up and the baseline examinations against the interval 
between the two examinations for the 6 individuals with vigabatrin associated visual 
field loss withdrawn from vigabatrin prior to the baseline examination (filled symbols) 
and for the 13 individuals with vigabatrin associated visual field loss receiving 
vigabatrin at the time of the baseline examination (open symbols). 
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Figure ‎5-9: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the left eye, between the follow-up and the baseline examinations against the interval 
between the two examinations for the 6 individuals with vigabatrin associated visual 
field loss withdrawn from vigabatrin prior to the baseline examination (filled symbols) 
and for the 13 individuals with vigabatrin associated visual field loss receiving 
vigabatrin at the time of the baseline examination (open symbols). 
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Figure ‎5-10: The difference in the Corrected Pattern Standard Deviation (CPSD), 
averaged across the two eyes for an individual, between the follow-up and the baseline 
examinations against the interval between the two examinations for the 6 individuals 
with a normal field withdrawn from vigabatrin prior to the baseline examination 
(filled symbols) and for the 2 individuals with a normal field receiving vigabatrin at 
the time of the baseline examination (open symbols).  
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Figure ‎5-11: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the right eye between the follow-up and the baseline examinations against the interval 
between the two examinations for the 6 individuals with a normal field withdrawn 
from vigabatrin prior to the baseline examination (filled symbols) and for the 2 
individuals with normal field receiving vigabatrin at the time of the baseline 
examination (open symbols). 
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Figure ‎5-12: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the left eye between the follow-up and the baseline examinations against the interval 
between the two examinations for the 6 individuals with a normal field withdrawn 
from vigabatrin prior to the baseline examination (filled symbols) and for the 2 
individuals with normal field receiving vigabatrin at the time of the baseline 
examination (open symbols). 
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No relationship was present between the change in the Corrected Pattern Standard 
Deviation between the follow-up and the baseline examinations and the interval 
between the visual field examinations for those with vigabatrin-associated visual field 
loss regardless of whether the individuals were receiving (R
2
 = 0.00, R
2
 = 0.29, and R
2
 
= 0..27, respectively), or had been withdrawn from, vigabatrin (R
2
 = 0.01, R
2
 = 0.00, 
and R
2
 = 0.04, respectively), (Table  5-10). 
Characteristics  No 
Mean of both eyes 
CPSD 
Right eye 
CPSD 
Left eye 
CPSD 
Total 27 0.02 0.03 0.02 
VAVFL 19 0.00 0.01 0.00 
Off drug (VAVFL) 13 0.01 0.00 0.04 
On drug (VAVFL) 6 0.00 0.29 0.27 
All (Normal field) 8 0.27 0.02 0.21 
Off drug (Normal field) 6 0.22 0.14 0.30 
On drug (Normal field) 2 - 
Table ‎5-10: The Coefficients of Determination, (R2) for the change in the Corrected 
Pattern Standard Deviation (CPSD) between the follow-up and the baseline examinations 
against the interval between the two examinations. 
The magnitudes of the Coefficients of Determination were similar, within the remit of 
the limited numbers of individuals, to the 6 with normal fields (Table  5-10) who had 
been withdrawn from vigabatrin prior to the first examination and who would not, 
normally, be expected to exhibit any such relationship. 
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5.5 Severity of vigabatrin-associated visual field loss 
5.5.1 Mean Deviation 
As a consequence of the lack of a relationship between the change in the MD and the 
interval between examinations, the influence of the severity of the field loss was 
considered in terms of the absolute difference between examinations irrespective of the 
interval between examinations. The Mean Deviation at the follow-up examination, 
averaged across the fields of the two eyes for an individual, against that at the baseline 
examination for those with vigabatrin associated visual field loss is illustrated in Figure 
 5-13. 
The corresponding plots for the field of the right eye and of the left eye are given in 
Figure  5-14 and Figure  5-15. 
The Mean ±2SD of the difference in the Mean Deviation, averaged across the fields of 
the two eyes for an individual, between the follow-up and the baseline examinations, 
against that of the mean of the two examinations for the two eyes, for the 19 individuals 
with vigabatrin associated visual field loss, is given in Figure  5-16.  
The corresponding plots for the field of the right eye and of the left eye are given in 
Figure  5-17 and Figure  5-18. 
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Figure ‎5-13: The mean of the Mean Deviation (MD) between the two eyes at the 
follow-up examination against that at the baseline examination for the 19 individuals 
with vigabatrin-associated visual field loss. Open symbols represent those individuals 
receiving vigabatrin at the baseline examination and the filled symbols those 
withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎5-14: The Mean Deviation (MD) for the right eye at the follow-up examination 
against that at the baseline examination for the 19 individuals with vigabatrin 
associated visual field loss. Open symbols represent those individuals receiving 
vigabatrin at the baseline examination and the filled symbols those withdrawn from 
vigabatrin prior to the baseline examination. 
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Figure ‎5-15 : The Mean Deviation (MD) for the left eye at the follow-up examination 
against that at the baseline examination for the 19 individuals with vigabatrin 
associated visual field loss. Open symbols represent those individuals receiving 
vigabatrin at the baseline examination and the filled symbols those withdrawn from 
vigabatrin prior to the baseline examination. 
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Figure ‎5-16 : The difference in the Mean Deviation (MD), averaged across the fields of 
the two eyes for an individual, between the follow-up examination and the baseline 
examination against the mean of these examinations for the 19 individuals with 
vigabatrin associated visual field loss. Open symbols represent those individuals 
receiving vigabatrin at the baseline examination and the filled symbols those 
withdrawn from vigabatrin prior to the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean. 
The corresponding values for the 8 individuals with normal fields are illustrated in red 
(however, for clarity, the data points have been omitted). 
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Figure ‎5-17 : The difference in the Mean Deviation (MD), for the right eye, between 
the follow-up examination and the baseline examination against the mean of these 
examinations for the 19 individuals with vigabatrin associated visual field loss . Open 
symbols represent those individuals receiving vigabatrin at the baseline examination 
and the filled symbols those withdrawn from vigabatrin prior to the baseline 
examination. The solid lack line represents the mean of the differences and the dotted 
black lines +/- 2SD of the mean. The corresponding values for the 8 individuals with 
normal fields are illustrated in red (however, for clarity, the data points have been 
omitted). 
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Figure ‎5-18: The difference in the Mean Deviation (MD), for the left eye, between the 
follow-up examination and the baseline examination against the mean of these 
examinations for the 19 individuals with vigabatrin associated visual field loss. Open 
symbols represent those individuals receiving vigabatrin at the baseline examination 
and the filled symbols those withdrawn from vigabatrin prior to the baseline 
examination. The solid lack line represents the mean of the differences and the dotted 
black lines +/- 2SD of the mean. The corresponding values for the 8 individuals with 
normal fields are illustrated in red (however, for clarity, the data points have been 
omitted). 
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The Mean Deviation at the follow-up examination, averaged across the fields of the two 
eyes for an individual, against that at the baseline examination for the 8 individuals with 
a normal field is illustrated in Figure  5-19. 
The corresponding plots for the field of the right eye and of the left eye are given in 
Figure  5-20 and Figure  5-21, respectively. 
 
Figure ‎5-19: The mean of the Mean Deviation (MD) between the two eyes at the 
follow-up examination against that at the baseline examination for the 8 individuals 
with normal fields. Open symbols represent those individuals receiving vigabatrin at 
the baseline examination and the filled symbols those withdrawn from vigabatrin 
prior to the baseline examination. Note the difference in scaling of both the abscissa 
and the ordinate compared to Figure 5-13. 
171 
 
 
Figure ‎5-20: The Mean Deviation (MD) for the right eye at the follow-up examination 
against that at the baseline examination for the 8 individuals with normal fields. Open 
symbols represent those individuals receiving vigabatrin at the baseline examination 
and the filled symbols those withdrawn from vigabatrin prior to the baseline 
examination. Note the difference in scaling of both the abscissa and the ordinate 
compared to figure 5-13. 
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Figure ‎5-21: The Mean Deviation (MD) for the left eye at the follow-up examination 
against that at the baseline examination for the 8 individuals with normal fields. Open 
symbols represent those individuals receiving vigabatrin at the baseline examination 
and the filled symbols those withdrawn from vigabatrin prior to the baseline 
examination. Note the difference in scaling of both the abscissa and the ordinate 
compared to figure 5-13. 
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The Mean ±2SD of the difference in the Mean Deviation, averaged across the fields of 
the two eyes for an individual, between the follow-up and the baseline examinations, 
against that of the mean of the two examinations for the two eyes, for the 8 individuals 
with normal fields, is given in Figure  5-22. The corresponding plots for the field of the 
right eye and of the left eye are given in Figure  5-23 and Figure  5-24, respectively. 
 
Figure ‎5-22: The difference in Mean Deviation (MD), averaged across the fields of the 
two eyes for an individual, between the follow-up examination and the baseline 
examination against the mean of these examinations for the 8 individuals with normal 
fields. Open symbols represent those individuals receiving vigabatrin at the baseline 
examination and the filled symbols those withdrawn from vigabatrin prior to the 
baseline examination. The solid black line represents the mean of the differences and 
the dotted black lines +/- 2SD of the mean.  
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Figure ‎5-23: The difference in Mean Deviation (MD) for the right eye between the 
follow-up examination and the baseline examination against the mean of these 
examinations for the 8 individuals with normal fields. Open symbols represent those 
individuals receiving vigabatrin at the baseline examination and the filled symbols 
those withdrawn from vigabatrin prior to the baseline examination. The solid black 
line represents the mean of the differences and the dotted black lines +/- 2SD of the 
mean.  
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Figure ‎5-24: The difference in Mean Deviation (MD) for the left eye between the 
follow-up examination and the baseline examination against the mean of these 
examinations for the 8 individuals with normal fields. Open symbols represent those 
individuals receiving vigabatrin at the baseline examination and the filled symbols 
those withdrawn from vigabatrin prior to the baseline examination. The solid black 
line represents the mean of the differences and the dotted black lines +/- 2SD of the 
mean.  
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5.5.2 Corrected Pattern Standard Deviation 
As a consequence of the lack of a relationship between the change in the CPSD and the 
interval between examinations, the CPSD was also subsequently considered in terms of 
the absolute difference between examinations irrespective of the interval between 
examinations. The Corrected Pattern Standard Deviation at the follow-up examination, 
averaged across the fields of the two eyes for an individual, against that at the baseline 
examination for the two eyes, for the 19 individuals with vigabatrin associated visual 
field loss is illustrated in Figure  5 25. The corresponding plots for the field of the right 
eye and of the left eye are given in Figure  5 26 and Figure  5 27, respectively. 
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Figure ‎5-25: The mean of the Corrected Pattern Standard Deviation (dB) between the 
two eyes at the follow-up examination against that at the baseline examination for the 
19 individuals with vigabatrin associated visual field loss. Open symbols represent 
those individuals receiving vigabatrin at the baseline examination and the filled 
symbols those withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎5-26: The Corrected Pattern Standard Deviation (CPSD) for the right eye at 
the follow-up examination against that at the baseline examination for the 19 
individuals with vigabatrin associated visual field loss. Open symbols represent those 
individuals receiving vigabatrin at the baseline examination and the filled symbols 
those withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎5-27: The Corrected Pattern Standard Deviation (CPSD) for the left eye at the 
follow-up examination against that at the baseline examination for the 19 individuals 
with vigabatrin associated visual field loss. Open symbols represent those individuals 
receiving vigabatrin at the baseline examination and the filled symbols those 
withdrawn from vigabatrin prior to the baseline examination. 
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The Mean ±2SD of the difference in the Corrected Pattern Standard Deviation, averaged 
across the fields of the two eyes for an individual, between the follow-up and the 
baseline examinations, against that of the mean of the two examinations for the two 
eyes, for the 19 individuals with vigabatrin associated visual field loss, is given in 
Figure  5-28. The corresponding plots for the field of the right eye and of the left eye are 
given in Figure  5-29 and Figure  5-30, respectively. 
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Figure ‎5-28: The difference in the Corrected Pattern Standard Deviation (CPSD), 
averaged across the fields of the two eyes for an individual, between the follow-up 
examination and the baseline examination against the mean of these examinations for 
the 19 individuals with vigabatrin associated visual field loss. Open symbols represent 
those individuals receiving vigabatrin at the baseline examination and the filled 
symbols those withdrawn from vigabatrin prior to the baseline examination. The solid 
black line represents the mean of the differences and the dotted black lines +/- 2SD of 
the mean. The corresponding values for the 8 individuals with normal fields are 
illustrated in red (however, for clarity, the data points have been omitted). 
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Figure ‎5-29: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the right eye, between the follow-up examination and the baseline examination against 
the mean of these examinations for the 19 individuals with vigabatrin associated visual 
field loss. Open symbols represent those individuals receiving vigabatrin at the 
baseline examination and the filled symbols those withdrawn from vigabatrin prior to 
the baseline examination. The solid lack line represents the mean of the differences 
and the dotted black lines +/- 2SD of the mean. The corresponding values for the 8 
individuals with normal fields are illustrated in red (however, for clarity, the data 
points have been omitted). 
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Figure ‎5-30: The difference in the Corrected Pattern Standard Deviation (CPSD), for 
the left eye, between the follow-up examination and the baseline examination against 
the mean of these examinations for the 19 individuals with vigabatrin associated visual 
field loss. Open symbols represent those individuals receiving vigabatrin at the 
baseline examination and the filled symbols those withdrawn from vigabatrin prior to 
the baseline examination. The solid lack line represents the mean of the differences 
and the dotted black lines +/- 2SD of the mean. The corresponding values for the 8 
individuals with normal fields are illustrated in red (however, for clarity, the data 
points have been omitted). 
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Figure ‎5-31: The difference in the Corrected Pattern Standard Deviation (CPSD), 
averaged across the fields of the two eyes for an individual, between the follow-up 
examination and the baseline examination against the mean of these examinations for 
the 8 individuals with normal fields. Open symbols represent those individuals 
receiving vigabatrin at the baseline examination and the filled symbols those 
withdrawn from vigabatrin prior to the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean.  
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Figure ‎5-32: The difference in Corrected Pattern Standard Deviation for the right eye, 
between the follow-up examination and the baseline examination against the Mean of 
these examinations for the 8 individuals with normal fields. Open symbols represent 
those individuals receiving vigabatrin at the baseline examination and the filled 
symbols those withdrawn from vigabatrin prior to the baseline examination. The solid 
black line represents the mean of the differences and the dotted black lines +/- 2SD of 
the mean. 
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Figure ‎5-33: The difference in Corrected Pattern Standard Deviation for the left eye, 
between the follow-up examination and the baseline examination against the Mean of 
these examinations for the 8 individuals with normal fields. Open symbols represent 
those individuals receiving vigabatrin at the baseline examination and the filled 
symbols those withdrawn from vigabatrin prior to the baseline examination. The solid 
black line represents the mean of the differences and the dotted black lines +/- 2SD of 
the mean. 
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5.5.3 Pattern Deviation Probability value 
The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and baseline 
examinations for those with vigabatrin associated visual field loss is shown in Table 
 5-13 and Table  5-14 for the 6 individuals receiving vigabatrin at the baseline 
examination and in Table  5-11 and Table  5-12 for the 13 individuals withdrawn from 
vigabatrin prior to the baseline examination. The vertical shading in each table indicates 
the number of stimulus locations exhibiting identical probability values at the two 
examinations. The number of locations exhibiting an improvement, by the number of 
probability levels, at the follow-up examination is shown to the left of the shading and 
the number of locations exhibiting a deterioration, by the number of probability levels, 
is shown to the right of the shading. The numerator indicates the number of locations 
exhibiting normality, and the denominator indicates the number of locations exhibiting 
abnormality at the given probability value, at the baseline examination. A reduction of 
the data, in terms of the number of locations exhibiting either an improvement or a 
deterioration over two and up to three or more probability levels is shown in Table  5-11 
to Table  5-18, respectively. The latter Tables also include the number of locations in the 
extreme outer annulus (1
st
) and in the immediate inner annulus (2
nd
) (Figure  5-34) 
exhibiting either an improvement or a deterioration by three or more probability levels. 
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Figure ‎5-34: The stimulus locations in the outer (filled rectangles) and inner (open 
rectangles) annuli used in the analysis of the change in the Pattern Deviation 
Probability values between the follow-up and baseline examinations. 
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Improvement▲ 
Number of Probability Levels 
 
Deterioration▼ 
Number of Probability Levels 
No Eye 
Visual Field 
Grade 
4 3 2 1 Same 1 2 3 4 
1 
R 
Mild 
0/0 0/4 0/2 0/18 23/4 4/3 4/1 8/0 3/4 
L 0/1 0/5 0/3 0/9 25/6 8/2 2/2 5/1 1/0 
2 
R 
Mild 
0/2 0/1 0/2 0/1 38/13 1/2 0/0 1/1 3/0 
L 0/6 0/5 0/5 0/2 35/11 1/3 1/2 1/0 4/0 
3 
R 
Moderate* 
0/2 0/0 0/1 0/2 28/25 1/4 2/0 4/0 7/0 
L 0/2 0/0 0/2 0/2 26/25 2/1 2/5 5/0 6/0 
4 
R 
Mild 
0/0 0/0 0/0 0/9 52/4 9/0 0/2 0/0 0/0 
L 0/2 0/1 0/2 0/5 48/2 7/2 1/0 2/1 3/0 
5 
R 
Severe* 
0/1 0/3 0/2 0/6 15/20 1/10 1/5 0/2 11/0 
L 0/2 0/0 0/0 0/2 26/31 3/0 1/2 2/1 5/0 
6 
R 
Mild 
0/0 0/3 0/3 0/5 40/6 9/3 3/2 2/0 2/0 
L 0/1 0/2 0/0 0/6 50/5 6/1 3/0 0/0 2/0 
Table ‎5-11: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 6 individuals with vigabatrin associated visual field loss and 
withdrawn from vigabatrin prior to the baseline examination. The shading indicates the 
number of locations exhibiting identical probability values at the two examinations. The 
number of locations exhibiting an improvement, by the number of probability levels, at 
the follow-up examination is shown to the left of the vertical shading and the number of 
locations exhibiting a deterioration, by the number of probability levels, is shown to the 
right of the vertical shading. The numerator indicates the number of locations exhibiting 
normality, and the denominator indicates the number of locations exhibiting 
abnormality, at the given probability value, at the baseline examination. *indicates an 
individual considered by clinical evaluation to exhibit progressive visual field loss in both 
eyes. 
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Annulus 
≥3  
Improvement 
▲Number of 
Probability 
Levels 
 
 
Deterioration▼ 
Number of 
Probability Levels 
 
Annulus 
 ≥3 
No Eye 
Visual Field 
 Grade 
1st 2nd ≥3 2 
Same 
 ±1 
2 ≥3 1st 2nd 
1 
R 
Mild 
3/0 0/0 0/4 0/2 23/4 4/1 11/4 0/0 0/1 
L 1/0 0/0 0/6 0/3 25/6 2/2 6/1 1/2 2/0 
2 
R 
Mild 
0/1 0/0 0/3 0/2 38/13 0/0 4/3 1/0 0/1 
L 1/0 1/0 0/11 0/5 35/11 1/2 5/0 2/0 5/0 
3 
R 
Moderate* 
1/0 0/0 0/2 0/1 28/25 2/0 11/0 2/3 3/0 
L 0/0 0/0 0/2 0/2 26/25 2/5 11/0 0/2 1/5 
4 
R 
Mild 
0/0 0/0 0/0 0/0 52/4 0/2 0/0 1/0 0/0 
L 1/0 0/0 0/3 0/2 48/2 1/0 5/1 2/0 1/0 
5 
R 
Severe* 
1/0 1/0 0/4 0/2 15/20 1/5 11/2 1/0 2/0 
L 0/0 0/0 0/2 0/0 26/31 1/2 7/1 2/0 2/0 
6 
R 
Mild 
1/0 2/0 0/3 0/3 40/6 3/2 4/0 0/0 2/0 
L 0/0 0/0 0/3 0/0 50/5 3/0 0/2 3/0 2/0 
Table ‎5-12: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 6 individuals with vigabatrin associated visual field loss and 
withdrawn from vigabatrin prior to the baseline examination. The shading indicates the 
number of locations exhibiting identical probability values at the two examinations. The 
number of locations exhibiting an improvement, by two or by three or more probability 
levels, respectively, at the follow-up examination is shown to the left of the vertical 
shading and the number of locations exhibiting a deterioration, by two or by three or 
more probability levels, respectively, is shown to the right of the vertical shading. The 
numerator indicates the number of locations exhibiting normality, and the denominator 
indicates the number of locations exhibiting abnormality at the given probability value, 
at the baseline examination. An identical analysis for the outer two annuli (1st or 2nd) of 
stimulus locations, by three or more probability levels, at the follow-up examination is 
shown to the left (improvement) and right (deterioration) of the vertical shading. 
*indicates an individual considered by clinical evaluation to exhibit progressive visual 
field loss in both eyes. 
  
191 
 
   
Improvement▲ 
Number of Probability Levels 
 
 
Deterioration ▼ 
Number of Probability Levels 
 
No Eye 
Visual Field 
 Grade 
4 3 2 1 Same 1 2 3 4 
1 
R 
Severe 
0/1 0/1 0/3 0/7 35/15 2/1 0/0 1/9 0/0 
L 0/1 0/3 0/2 0/9 25/12 1/10 3/4 3/2 0/0 
2 
R 
Severe* 
0/5 0/5 0/4 0/7 18/27 1/1 2/1 0/0 6/0 
L 0/4 0/3 0/0 0/5 25/32 0/2 0/1 0/0 1/0 
3 
R 
Severe 
0/2 0/4 0/7 0/8 18/18 2/3 3/3 1/3 3/0 
L 0/1 0/2 0/3 0/9 22/21 2/7 1/5 3/1 1/0 
4 
R 
Severe 
0/2 0/2 0/3 0/5 21/37 2/1 1/0 0/1 1/0 
L 0/0 0/6 0/4 0/1 21/27 2/6 0/8 0/0 1/0 
5 
R 
Severe* 
0/1 0/2 0/0 0/3 28/21 2/7 2/6 0/2 3/0 
L 0/0 0/3 0/3 0/2 25/9 4/5 5/3 3/0 14/0 
6 
R 
Severe* 
0/0 0/0 0/1 0/2 18/22 2/9 4/3 3/7 5/0 
L 0/0 0/0 0/2 0/2 27/30 2/4 1/3 1/3 1/0 
7 
R 
Mild 
0/0 0/2 0/4 0/7 55/3 2/1 0/0 0/0 2/0 
L 0/0 0/1 0/1 0/7 59/1 3/0 1/2 1/0 0/0 
8 
R 
Severe 
0/4 0/0 0/4 0/4 42/10 2/3 1/2 0/2 2/0 
L 0/2 0/4 0/2 0/3 39/10 4/3 4/2 1/0 2/0 
9 
R 
Moderate 
0/5 0/3 0/4 0/2 45/4 7/1 4/0 0/0 1/0 
L 0/1 0/3 0/7 0/14 33/7 5/2 2/0 2/0 0/0 
10 
R 
Mild 
0/0 0/1 0/2 0/4 62/0 1/0 2/1 3/0 0/0 
L 0/0 0/0 0/0 0/0 70/0 3/0 1/0 1/0 1/0 
11 
R 
Severe 
0/0 0/0 0/1 0/1 40/24 4/0 2/0 3/0 1/0 
L 0/5 0/1 0/3 0/5 32/22 0/2 1/1 1/1 3/0 
12 
R 
Severe* 
0/0 0/0 0/0 0/5 21/10 2/5 7/5 3/4 14/0 
L 0/1 0/0 0/3 0/5 27/8 2/3 2/10 1/4 10/0 
13 
R 
Severe* 
0/0 0/0 0/0 0/2 37/22 3/5 7/3 0/4 3/0 
L 0/0 0/0 0/0 0/3 37/17 1/6 4/1 1/4 2/0 
Table ‎5-13: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 13 individuals with vigabatrin associated visual field loss 
receiving vigabatrin at the baseline examination. The shading indicates the number of 
locations exhibiting identical probability values at the two examinations. The number of 
locations exhibiting an improvement, by the number of probability levels, at the follow-
up examination is shown to the left of the vertical shading and the number of locations 
exhibiting a deterioration, by the number of probability levels, is shown to the right of the 
vertical shading. The numerator indicates the number of locations exhibiting normality, 
and the denominator indicates the number of locations exhibiting abnormality at the 
given probability value, at the baseline examination. *indicates an individual considered 
by clinical evaluation to exhibit progressive visual field loss in both eyes. 
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Annulus 
≥3  
Improvement  
▲ 
 
Deterioration 
▼ 
Annulus 
 ≥3 
No Eye 
Visual Field 
 Grade 
1st 2nd ≥3 2 
Same 
 ±1 
2 ≥3 1st 2nd 
1 
R 
Severe 
0/0 1/0 0/2 0/3 35/15 0/0 1/9 1/2 1/1 
L 0/0 0/1 0/4 0/2 25/12 3/4 3/2 1/2 1/0 
2 
R 
Severe* 
1/0 0/0 0/10 0/4 18/27 2/1 0/6 0/1 0/0 
L 0/0 0/0 0/7 0/0 25/32 0/1 1/0 0/0 1/0 
3 
R 
Severe 
0/0 0/0 0/6 0/7 18/18 3/3 4/3 0/1 1/1 
L 1/0 1/0 0/3 0/3 22/21 1/5 4/1 0/1 1/2 
4 
R 
Severe 
0/0 0/0 0/4 0/3 21/37 1/0 1/1 0/0 0/1 
L 1/0 0/0 0/6 0/4 21/27 0/8 1/0 0/0 0/1 
5 
R 
Severe* 
0/0 0/0 0/3 0/0 28/21 2/6 3/2 0/0 4/0 
L 0/0 0/0 0/3 0/3 25/9 5/3 17/0 3/0 3/0 
6 
R 
Severe* 
1/1 0/0 0/0 0/1 18/22 4/3 8/7 0/3 0/3 
L 0/0 0/0 0/0 0/2 27/30 1/3 2/3 2/1 2/0 
7 
R 
Mild 
0/0 1/0 0/2 0/4 55/3 0/0 2/0 0/0 0/1 
L 0/1 0/1 0/1 0/1 59/1 1/2 1/0 0/0 0/0 
8 
R 
Severe 
2/0 2/0 0/4 0/4 42/10 1/2 2/2 1/1 3/0 
L 1/0 1/1 0/6 0/2 39/10 4/2 3/0 0/0 0/0 
9 
R 
Moderate 
0/0 1/0 0/8 0/4 45/4 4/0 1/0 0/0 0/1 
L 0/0 1/0 0/4 0/7 33/7 2/0 2/0 0/0 0/0 
10 
R 
Mild 
1/0 0/0 0/1 0/2 62/0 2/1 3/0 4/0 /00 
L 0/0 0/0 0/0 0/0 70/0 1/0 2/0 0/0 1/0 
11 
R 
Sever 
1/0 0/0 0/0 0/1 40/24 2/0 4/0 1/0 0/0 
L 3/0 1/0 0/6 0/3 32/22 1/1 4/1 6/0 0/0 
12 
R 
Severe* 
0/0 0/0 0/0 0/0 21/10 7/5 17/4 6/0 1/5 
L 0/0 0/0 0/1 0/3 27/8 2/10 11/4 1/5 0/6 
13 
R 
Severe* 
0/0 0/0 0/0 0/0 37/22 7/3 3/4 1/1 1/2 
L 0/0 0/0 0/0 0/0 37/17 4/1 3/4 0/2 1/1 
Table ‎5-14: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 13 individuals with vigabatrin associated visual field loss 
receiving vigabatrin at the baseline examination. The shading indicates the number of 
locations exhibiting identical probability values at the two examinations. The number of 
locations exhibiting an improvement, by two or by three or more probability levels, 
respectively, at the follow-up examination is shown to the left of the vertical shading and 
the number of locations exhibiting a deterioration, by two or by three or more 
probability levels, respectively, is shown to the right of the vertical shading. The 
numerator indicates the number of locations exhibiting normality, and the denominator 
indicates the number of locations exhibiting abnormality at the given probability value, 
at the baseline examination. An identical analysis for the outer two annuli (1st or 2nd) of 
stimulus locations (as indicated in Table 6-13), by three or more probability levels, at the 
follow-up examination is shown to the left (improvement) and right (deterioration) of the 
vertical shading. *indicates an individual considered by clinical evaluation to exhibit 
progressive visual field loss in both eyes.  
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The difference for each individual in the magnitudes of the Pattern Deviation 
probability levels, across all stimulus locations, between the follow-up and the baseline 
examination for the 6 individuals with normal visual fields and withdrawn from 
vigabatrin prior to the baseline examination is shown in Table  5-15 and Table  5-16. 
 
  
Improvement▲ 
Number of Probability Levels 
 
Deterioration▼ 
Number of Probability Levels 
No Eye 4 3 2 1 Same 1 2 3 4 
1 
R 0/0 0/0 0/0 0/1 68/0 4/0 2/0 0/0 0/1 
L 0/0 0/0 0/0 0/0 64/0 0/8 2/0 1/0 1/0 
2 
R 0/0 0/0 0/1 0/3 66/0 4/0 1/0 0/0 1/0 
L 0/0 0/0 0/2 0/3 66/0 5/0 0/0 0/0 0/0 
3 
R 0/0 0/0 0/0 0/1 74/0 1/0 0/0 0/0 0/0 
L 0/0 0/0 0/0 0/3 70/0 3/0 0/0 0/0 0/0 
4 
R 0/0 0/0 0/1 0/3 67/1 1/0 0/0 1/0 1/1 
L 0/0 0/0 0/0 0/1 71/0 2/0 1/0 1/0 0/0 
5 
R 0/0 0/0 0/0 0/4 70/0 2/0 0/0 0/0 0/0 
L 0/0 0/1 0/2 0/3 60/0 8/1 1/0 0/0 0/0 
6 
R 0/0 0/0 0/0 0/1 72/0 3/0 0/0 0/0 0/0 
L 0/0 0/0 0/0 0/2 71/0 3/0 0/0 0/0 0/0 
Table ‎5-15: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 6 individuals with normal visual fields and withdrawn from 
vigabatrin prior to the baseline examination. The shading indicates the number of 
locations exhibiting identical probability values at the two examinations. The number of 
locations exhibiting an improvement, by the number of probability levels, at the follow-
up examination is shown to the left of the vertical shading and the number of locations 
exhibiting a deterioration, by the number of probability levels, is shown to the right of the 
vertical shading. The numerator indicates the number of locations exhibiting normality, 
and the denominator indicates the number of locations exhibiting abnormality at the 
given probability value, at the baseline examination.  
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Improvement  
▲ 
 
Deterioration  
▼ 
No Eye ≥2 
Same 
±1 
≥2 
1 
R 0/0 72/1 2/1 
L 0/0 64/8 4/0 
2 
R 0/1 70/3 2/0 
L 0/2 71/3 0/0 
3 
R 0/0 75/1 0/0 
L 0/0 73/3 0/0 
4 
R 0/1 68/4 2/1 
L 0/0 73/1 2/0 
5 
R 0/0 72/4 0/0 
L 0/3 68/4 1/0 
6 
R 0/0 75/1 0/0 
L 0/0 74/2 0/0 
Table ‎5-16: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
the examination for the 6 individuals with normal visual fields and withdrawn from 
vigabatrin prior to the baseline examination. The shading indicates the number of 
locations exhibiting identical probability values at the two examinations. The number of 
locations exhibiting an improvement, by two or more probability levels, respectively, at 
the follow-up examination is shown to the left of the vertical shading and the number of 
locations exhibiting a deterioration, by two or more probability levels, respectively, is 
shown to the right of the vertical shading. The numerator indicates the number of 
locations exhibiting normality, and the denominator indicates the number of locations 
exhibiting abnormality at the given probability value, at the baseline examination.  
The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
examination for the two individuals with normal fields and receiving vigabatrin at the 
baseline examination is shown in Table  5-17 and Table  5-18. 
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Improvement▲ 
Number of Probability Levels 
 
Deterioration▼ 
Number of Probability Levels 
No Eye 4 3 2 1 Same 1 2 3 4 
1 
R 0/1 0/2 0/1 0/8 58/0 3/1 1/0 0/0 1/0 
L 0/2 0/0 0/1 0/10 59/0 2/1 0/0 0/0 0/0 
2 
R 0/0 0/2 0/0 0/4 69/0 1/0 0/0 0/0 0/0 
L 0/0 0/0 0/2 0/3 68/0 3/0 0/0 0/0 0/0 
Table ‎5-17: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
examination for the 2 individuals with normal visual fields and receiving vigabatrin at 
the baseline examination. The shading indicates the number of locations exhibiting 
identical probability values at the two examinations. The number of locations exhibiting 
an improvement, by two or more probability levels, respectively, at the follow-up 
examination is shown to the left of the vertical shading and the number of locations 
exhibiting a deterioration, by two or more probability levels, respectively, is shown to the 
right of the vertical shading. The numerator indicates the number of locations exhibiting 
normality, and the denominator indicates the number of locations exhibiting abnormality 
at the given probability value, at the baseline examination.  
 
  
Improvement ▲ 
Number of Probability Levels 
 
Deterioration▼ 
Number of Probability Levels 
No Eye ≥2 2 Same ±1 2 ≥2 
1 
R 0/3 0/4 61/9 2/0 1/0 
L 0/2 0/3 61/11 0/0 0/0 
2 
R 0/2 0/2 70/4 0/0 0/0 
L 0/0 0/2 71/3 0/0 0/0 
Table ‎5-18: The difference for each individual in the magnitudes of the Pattern Deviation 
probability value, across all stimulus locations, between the follow-up and the baseline 
examination for the two individuals with normal fields and receiving vigabatrin at the 
baseline examination. The shading indicates the number of locations exhibiting identical 
probability values at the two examinations. The number of locations exhibiting the given 
improvement in the probability level at the follow-up examination is shown to the left of 
the shading and the number of locations exhibiting the given deterioration to the right of 
the shading. The numerator indicates the number of locations exhibiting normality, and 
the denominator indicates the number of locations exhibiting abnormality at the given 
probability value, at the baseline examination. 
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5.6 Discussion 
The outcome of any study of visual field progression is influenced by the number of 
visual field examinations within the given time period and by the length of the time 
period, itself (Casas-Llera et al., 2009). Clearly, the conclusions that can be obtained 
from a time period which involves only two visual field examinations are limited due to 
the inherent within- and between-examination variability arising from the subjective 
nature of the examination, itself.  
If no alteration occurred in the visual field between the two examinations, the outcomes 
would be identical. However, given the between-examination variability inherent in 
perimetry, and given that only two examinations were undertaken for each individual, it 
could be hypothesized that, if ‘no change’ was present across the case series, one half of 
individuals would exhibit an apparent deterioration between the two examinations and 
one half would exhibit an apparent improvement at the follow-up examination. Clearly, 
either a ‘true’ deterioration or a ‘true’ improvement would be indicated by a greater 
proportion of individuals exhibiting the particular trend/ direction.  
Clearly, no recovery of the visual field to normality, or near normality, was uniformly 
manifest across all individuals with vigabatrin-associated visual field loss in the case 
series. Such an outcome would be unlikely given the catastrophic retinal damage 
associated with vigabatrin associated visual field loss, albeit in one individual, at post-
mortem (Ravindran et al., 2001) and with the mounting evidence for retinal nerve fibre 
layer thinning, identifiable by optical coherence tomography, associated with vigabatrin 
toxicity and with vigabatrin-associated visual field loss (Lawthom et al., 2009; Clayton 
et al., 2011).  
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The difference in the Mean Deviation and in the Corrected Pattern Standard Deviation 
between the follow-up and the baseline examinations for those with vigabatrin-
associated visual field loss was considered in the context of the magnitude of two SDs 
of the distribution of the mean of the corresponding difference for the 8 individuals with 
normal fields. Given that the between-examination variability should be greater for 
those with vigabatrin-associated visual field loss, it was remarkable to note that 12 of 
the 19 individuals with vigabatrin-associated visual field loss exhibited a difference in 
the Mean Deviation which lay within two SDs of the corresponding distribution for the 
individuals with normal fields. Of the remaining 7 individuals, 4 exhibited an apparent 
deterioration and 3 an apparent improvement.  
The visual field loss associated with vigabatrin is absolute, or near absolute, for the 
Goldmann size III stimulus used in static perimetry and is also characterised by a steep 
border. The inherent variability in perimetry exhibits a minimum at normal levels of 
sensitivity but increases to a maximum at a measured sensitivity, for the Humphrey 
Field Analyzer, of approximately 15-19dB (Wall, Kutzko and Chauhan, 1997; Gardiner 
et al., 2014) after which it declines as the measured sensitivity approaches zero.  
The study shows that there is no clinical significant reversibility of vigabatrin-
associated visual field loss in individuals who had withdrawn from the drug between 
0.86 and 11.1 years prior to the follow-up examination. This finding provides further 
evidence that vigabatrin-associated visual field loss is not reversible after 
discontinuation of the drug. 
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5.7 Conclusion 
Within the limited number of individuals in, and the duration of follow-up of, the study, 
it is clear that, following long-term withdrawal from the drug, vigabatrin-associated 
visual field loss does not recover and that individuals exposed to the drug with normal 
fields do not subsequently manifest field loss.  
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Chapter 6. The outcome of the retinal nerve 
fibre layer following long-term withdrawal of 
vigabatrin 
6.1 Previous work  
It was shown in Chapter 5 that no consistent trend was present either for an 
improvement or for a deterioration in the visual field, for those with vigabatrin-
associated visual field loss and for those exposed to vigabatrin with a normal field, who 
had been withdrawn from vigabatrin for a period of up to 11 years. However, only two 
visual field examinations had been undertaken per individual. The outcome of the visual 
field examination is affected by within- and between-visit variability associated with the 
threshold estimate and it is possible that these factors could have masked any trend. 
Optical coherence tomography also exhibits within- and between-examination 
variability but is an objective test. However, it is not known whether the peripapillary 
nerve fibre layer thickness remains stable or exhibits a capacity either for further 
deterioration or for improvement following long-term withdrawal from vigabatrin.  
6.2 Aim  
The aim of the study was to determine the long-term outcome of the peripapillary retinal 
nerve fibre layer thickness in individuals withdrawn from vigabatrin with particular 
reference either for further deterioration or for improvement in those with an attenuated 
thickness or for a deterioration in those with a previously normal thickness. 
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The outcome for the study was to be evaluated in terms of two aspects: the interval 
between the retinal nerve fibre layer examinations and the thickness of the retinal nerve 
fibre layer at the initial assessment. If either a worsening or an improvement in the 
retinal nerve fibre layer thickness was found, the extent of the alteration would be 
investigated with respect to the time since withdrawal from vigabatrin and to the 
duration and cumulative dose of vigabatrin.  
6.3 Methods  
6.3.1 Cohort 
The study was a prospective cohort study. The cohort comprised 17 consecutively 
presenting individuals with refractory complex partial (focal) seizures who were 
attending the Alan Richens Unit, Welsh Epilepsy Centre, University Hospital of Wales, 
Cardiff. Each individual had been exposed to vigabatrin, had previously undergone 
measurement of the retinal nerve fibre layer thickness by Time-domain optical 
coherence tomography and had volunteered to take part in the follow-up study. No 
individuals manifested concomitant visual field loss of any type.  
6.3.2 Optical Coherence Tomography 
All individuals underwent measurement of the peripapillary retinal nerve fibre layer in 
the right eye, only, using an identical protocol to that undertaken at the initial 
examination; namely, the standard 3.4 Scan protocol of the StratusOCT (Software 
Version 3.0) (Carl Zeiss, Meditec, Dublin, CA). The procedures were as described in 
Chapter 4. 
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6.3.3 Visual field examination  
Each individual was re-examined with Program 30-2 and the FASTPAC strategy of the 
Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) in an identical manner to 
that described in Chapters 4 and 5. 
6.3.4 Statistical Analysis 
Global and quadrants retinal nerve fibre layer thicknesses, automatically calculated for 
each scan using the commercially available StatusOCT analysis software (Version 3.0), 
were extracted from the print-out for each individual and inputted into an Excel 
spreadsheet.  
6.4 Results 
The age of the 17 individuals at the follow-up examination ranged from 30.0 to 68.9 
years (mean 52.5 years SD 9.9; median 54.4 years; IQR 45.1, 58.6).  
The interval between the baseline and follow-up examination ranged from 2.8 to 7.4 
years (mean 6.1 years, SD 1.3; median 6.5 years IQR 5.8, 6.9).  
Thirteen of the 17 individuals (6 males; 46 % and 7 females; 54%) had exhibited 
vigabatrin-associated visual field loss and corresponding retinal nerve fibre layer 
thinning at the baseline examination Table  6-1. Of these 13 individuals, 11 had 
withdrawn from vigabatrin prior to the baseline examination and 2 were receiving 
vigabatrin at the baseline examination. All 13 individuals had withdrawn from 
vigabatrin by the time of the follow-up examination.  
202 
 
The remaining 4 individuals, all with a normal visual field and a normal retinal nerve 
fibre layer thickness, had withdrawn from vigabatrin prior to the baseline examination 
Table  6-3. 
The 17 individuals by gender and by visual field outcome at the baseline examination 
are given in Table 6.1. 
Characteristics 
Visual Field Outcome 
Normal  VAVFL Total 
Gender 
Female 4 7 11 
Male 0 6 6 
Total 4 13 17 
Table ‎6-1: The 17 individuals by gender and by visual field outcome at the baseline 
examination. VAVFL indicates vigabatrin-associated visual field loss. 
The duration of vigabatrin exposure for the 13 individuals with vigabatrin-associated 
visual field loss ranged from 1.9 to 17.0 years with a mean (SD) of 10.7 years (4.3). The 
cumulative dose ranged from 2.1 to 12.83kg with a mean (SD) of 8.0kg (3.5) (Table 
 6-2). 
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  10.7 (4.3) 12.0 (7.8, 12.8) 1.9 17.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
8.0 (3.5) 7.4 (5.6, 11.7) 2.1 12.8 
Daily dose (g)  2.1 (0.7) 1.8 (1.5, 2.8) 1.4 3.2 
Interval between onset of  
vigabatrin and baseline OCT (yr)  
13.2 (2.7) 13.1 (11.1, 15.6) 8.4 17.5 
Interval between OCT (yr)  6.1 (1.4) 6.5 (5.7, 7.2) 2.7 7.4 
Age at baseline (yr)  44.9 (9.8) 45.8 (39.3,51.2) 23.0 61.0 
Age at follow-up (yr)  50.5 (9.8) 50.9 (42.1, 55.7) 29.9 67.2 
Interval between withdrawal of  
vigabatrin and follow-up OCT (yr) 
6.6 ( 3.9) 7.0 (4.9, 8.9) 3.3 12.6 
Table ‎6-2: The summary statistics of the demographic information for the 13 individuals 
with vigabatrin-associated visual field loss and corresponding attenuation of the 
peripapillary retinal nerve fibre layer thickness at the follow-up examination.  
  
204 
 
The duration of vigabatrin exposure for the 4 individuals with normal fields ranged 
from 2.0 to 12.0 years with a mean (SD) of 6.9 years (4.2). The cumulative dose ranged 
from 1.5 to 11.1kg with a mean (SD) of 5.3kg (4.1) (Table  6-3). 
Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  6.9 (4.2) 6.7 (2.8, 11.0) 2.0 12.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
5.3 (4.1) 4.3 (2.0, 9.7) 1.5 11.1 
Daily dose (g)  2.0 (0.3) 1.9 (1.8, 2.4) 1.8 2.6 
Interval between onset of  
vigabatrin and baseline OCT (yr) 
12.9 (3.4) 12.4 (10.0, 16.4) 9.2 17.7 
Interval between OCT (yr)  6.0 (0.3) 5.9 (5.8, 6.4) 5.8 6.5 
Age at baseline (yr)  55.2 (8.0) 53.9 (48.1, 63.4) 46.8 65.9 
Age at follow-up (yr)  58.8 (7.5) 57.3 (52.5, 6.7) 51.9 68.9 
Interval between withdrawal of  
vigabatrin and follow-up OCT (yr) 
10.0 (2.2) 9.9 (8.0, 11.9) 8.0 12.0 
Table ‎6-3: The summary statistics of the demographic information for the 4 individuals 
with a normal visual field at the follow-up examination. 
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Characteristics Mean (SD) Median (IQR) Min. Max. 
Duration of vigabatrin (yr)  9.7 (4.5) 11.0 (6.6, 12.5) 1.9 17.0 
Cumulative dose of vigabatrin at  
follow-up (kg)  
7.4 (3.7) 6.5 (4.3, 11.4) 1.5 12.8 
Daily dose (g)  2.1 (0.6) 1.9 (1.5, 2.7)  1.4 3.2 
Interval between onset of  
vigabatrin and baseline OCT (yr) 
13.1 (2.8) 12.8 (11.1, 15.6) 8.4 17.7 
Interval between OCT (yr)  6.1 (1.3) 6.5 (5.8, 6.9) 2.8 7.4 
Age at baseline (yr)  48.0 (10.0) 51.4 (40.9, 53.2) 23.5 65.9 
Age at follow-up (yr)  52.5 (9.9) 54.4 (45.1, 58.6) 29.9 68.9 
Age at onset of vigabatrin therapy 
(yr)  
11.3 (2.1) 12.1 (9.4, 12.6) 7.0 14.0 
Interval between withdrawal of  
vigabatrin and follow-up OCT (yr) 
7.4 8.0 (5.3, 10.2) 3.3 12.6 
Table ‎6-4: The summary statistics of the demographic information for the 17 
individuals exposed to vigabatrin at the follow-up examination.  
 
The difference between the baseline and follow-up peripapillary retinal nerve fibre layer 
thickness against the interval between the two examinations is shown in Figures  6-1 to 
 6-4 for the global value and for the inferior, superior nasal and temporal quadrants, 
respectively. 
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Figure ‎6-1: The difference in the global peripapillary retinal nerve fibre layer 
thickness between the follow-up and the baseline examinations against the interval 
between the two examinations for the 13 individuals with vigabatrin-associated visual 
field loss and an attenuated retinal nerve fibre layer. The filled symbols indicate each 
of the 11 individuals who had withdrawn from vigabatrin prior to the baseline 
examination and the open symbols each of the 2 individuals who were receiving 
vigabatrin at the time of the baseline examination.  
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Figure ‎6-2: The difference in the inferior quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up and the baseline examinations against the 
interval between the two examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. 
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Figure ‎6-3: The difference in the superior quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up and the baseline examinations against the 
interval between the two examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination.  
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Figure ‎6-4: The difference in the nasal quadrant peripapillary retinal nerve fibre layer 
thickness between the follow-up and the baseline examinations against the interval 
between the two examinations for the 13 individuals with vigabatrin-associated visual 
field loss and an attenuated retinal nerve fibre layer. The filled symbols indicate each 
of the 11 individuals who had withdrawn from vigabatrin prior to the baseline 
examination and the open symbols each of the 2 individuals who were receiving 
vigabatrin at the time of the baseline examination.  
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Figure ‎6-5: The difference in the temporal quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up and the baseline examinations against the 
interval between the two examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination.  
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The difference between the follow-up and baseline peripapillary retinal nerve fibre layer 
thickness against the difference between the baseline and follow-up MD and the 
difference between the baseline and follow-up CPSD are shown in Figure  6-6 and 
Figure  6-7, respectively. 
 
Figure ‎6-6: The difference in the Mean Deviation between the follow-up and the 
baseline examinations against the corresponding change in the global peripapillary 
retinal nerve fibre layer thickness for the 13 individuals with vigabatrin-associated 
visual field loss and an attenuated retinal nerve fibre layer. The filled symbols indicate 
each of the 11 individuals who had withdrawn from vigabatrin prior to the baseline 
examination and the open symbols each of the 2 individuals who were receiving 
vigabatrin at the time of the baseline examination.  
212 
 
 
Figure ‎6-7: The difference in the Corrected Pattern Standard Deviation between the 
follow-up and the baseline examinations against the corresponding change in the 
global peripapillary retinal nerve fibre layer thickness for the 13 individuals with 
vigabatrin-associated visual field loss and an attenuated retinal nerve fibre layer. The 
filled symbols indicate each of the 11 individuals who had withdrawn from vigabatrin 
prior to the baseline examination and the open symbols each of the 2 individuals who 
were receiving vigabatrin at the time of the baseline examination. 
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 No Global Inferior Superior Nasal Temporal MD CPSD 
All vigabatrin 17 0.012 0.01 0.04 0.06 0.06 0.07 0.14 
VAVFL 13 0.04 0.02 0.11 0.11 0.02 0.07 0.16 
Off drug 
(VAVFL) 
11 0.13 0.03 0.11 0.08 0.14 0.22 0.19 
On drug 
(VAVFL) 
Only two individuals 
Off drug (normal 
field) 
4 0.07 0.08 0.06 0.21 0.24 0.43 0.19 
Table ‎6-5: The Coefficients of Determination, (R2) for the global, and the inferior, 
superior, nasal, and temporal peripapillary retinal nerve fibre layer thickness and for 
the Mean Deviation and Corrected Pattern Deviation visual field indices, between the 
follow-up and the baseline examinations against the interval between the two 
examinations. 
The lack of relationship between the change in the retinal nerve fibre layer between the 
follow-up and the baseline examinations and the interval between the optical coherence 
tomography for those with vigabatrin-associated visual field loss was present regardless 
of whether the individuals had been withdrawn from, or were receiving vigabatrin, at 
baseline (R
2
 = 0.04, R
2
 = 0.02, R
2
 = 0.11, R
2
 =0.11, and R
2
 =0.02 for the global, 
inferior, superior, nasal and temporal quadrants, respectively) (Table  6-5). 
The mean (SD) of the difference in the peripapillary retinal nerve fibre layer thickness, 
globally and by quadrant, between the baseline and follow-up examinations for the 13 
individuals with vigabatrin-associated visual field loss and for the 4 individuals with a 
normal visual field are given in Table  6-6 (Top and Bottom). 
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Characteristics of individuals with 
vigabatrin-associated visual field 
loss  
Mean (SD) Median (IQR) Min. Max. 
Global (µm) -4.8 (8.8) -3.3 (-10.5, 0.9) -22.7 6.1 
Inferior quadrant (µm) -10.1 (18.0) -8.0 (-21.5, 7.0) -48.0 1.0 
Superior quadrant (µm) -8.8 (9.2) -8.0 (-15.5, 0.0) -24.0 2.0 
Nasal quadrant (µm) 1.6 (19.1) 6.0 (-5.0, 12.0) -42.0 36.0 
Temporal quadrant (µm) -1.4 (8.1) -3.0 (-7.0, 3.5) -15.0 17.0 
Mean Deviation MD (dB) -0.8 (2.5) -0.8 (-2.3, 0.7) -6.6 3.8 
Corrected Pattern Standard 
Deviation (dB) 
0.3 (2.0) 0.7 (-1.2, 1.3) -3.2 4.7 
Characteristics of individuals with 
a normal field 
Mean (SD) Median (IQR) Min. Max. 
Global (µm) 4.9 (20.4) -2.8 (-8.3, 25.8) -9.9 35.0 
Inferior quadrant (µm) 5.5 (29.2) -7.0 (-12.0, 35.0) -13.0 49.0 
Superior quadrant (µm) -1.7 (19.8) -6.0 (-17.7, 18.5) -21.0 26.0 
Nasal quadrant (µm) 20.3 (20.0) 13.0 (6.3, 41.5) 6.0 49.0 
Temporal quadrant (µm) -0.5 (15.7) -1.0 (-15.3, 14.7) -17.0 17.0 
Mean Deviation MD (dB) -0.04 (1.4) 0.1 (-1.5, 1.2) -1.9 1.5 
Corrected Pattern Standard 
Deviation (dB) 
0.9 (1.2) 1.2 (-0.4, 1.8) -0.9 1.9 
Table ‎6-6: The summary statistics of the differences in the peripapillary retinal nerve 
fibre layer thickness between the follow-up and baseline examination, globally, and by 
quadrant; and of the differences in the Mean Deviation and Corrected Pattern Standard 
Deviation visual field indices for the 13 individuals with vigabatrin-associated visual field 
loss (top) and for the 4 individuals with a normal field and a normal retinal nerve fibre 
layer (bottom). 
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The retinal nerve fibre layer thickness at the follow-up examination against that at the 
baseline examination for the 13 individuals with vigabatrin associated visual field loss is 
illustrated in Figure  6-8 to Figure  6-12 for global, inferior, superior, nasal and, temporal 
quadrants, respectively.  
 
Figure ‎6-8: The global retinal nerve fibre layer thickness at the follow-up examination 
against that at the baseline examination for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. 
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Figure ‎6-9: The inferior quadrant retinal nerve fibre layer  thickness at the follow-up 
examination against that at the baseline examination for the 13 individuals with 
vigabatrin-associated visual field loss and an attenuated retinal nerve fibre layer. The 
filled symbols indicate each of the 11 individuals who had withdrawn from vigabatrin 
prior to the baseline examination and the open symbols each of the 2 individuals who 
were receiving vigabatrin at the time of the baseline examination. 
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Figure ‎6-10: The nasal quadrant retinal nerve fibre layer thickness at the follow-up 
examination against that at the baseline examination for the 13 individuals with 
vigabatrin-associated visual field loss and an attenuated retinal nerve fibre layer. The 
filled symbols indicate each of the 11 individuals who had withdrawn from vigabatrin 
prior to the baseline examination and the open symbols each of the 2 individuals who 
were receiving vigabatrin at the time of the baseline examination. 
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Figure ‎6-11: The superior quadrant retinal nerve fibre layer thickness at the follow-up 
examination against that at the baseline examination for the 13 individuals with 
vigabatrin-associated visual field loss and an attenuated retinal nerve fibre layer. The 
filled symbols indicate each of the 11 individuals who had withdrawn from vigabatrin 
prior to the baseline examination and the open symbols each of the 2 individuals who 
were receiving vigabatrin at the time of the baseline examination. 
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Figure ‎6-12: The temporal quadrant retinal nerve fibre layer  thickness at the follow-
up examination against that at the baseline examination for the 13 individuals with 
vigabatrin-associated visual field loss and an attenuated retinal nerve fibre layer. The 
filled symbols indicate each of the 11 individuals who had withdrawn from vigabatrin 
prior to the baseline examination and the open symbols each of the 2 individuals who 
were receiving vigabatrin at the time of the baseline examination.  
  
220 
 
The Mean ±2SD of the difference in the global, the inferior, superior, nasal and 
temporal retinal nerve fibre layer thickness, between the follow-up and the baseline 
examinations, for the 13 individuals with vigabatrin-associated visual field loss, are 
given in Figure  6-13 to Figure  6-17 global, respectively. 
 
Figure ‎6-13: The difference in the global peripapillary retinal nerve fibre layer 
thickness between the follow-up examination and the baseline examination against the 
mean of the two examinations for the 13 individuals with vigabatrin-associated visual 
field loss and an attenuated retinal nerve fibre layer. The filled symbols indicate each 
of the 11 individuals who had withdrawn from vigabatrin prior to the baseline 
examination and the open symbols each of the 2 individuals who were receiving 
vigabatrin at the time of the baseline examination. The solid black line represents the 
mean of the differences and the dotted black lines +/- 2SD of the mean.  
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Figure ‎6-14: The difference in the inferior quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up examination and the baseline examination 
against the mean of these examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean.  
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Figure ‎6-15: The difference in the superior quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up examination and the baseline examination 
against the mean of these examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean.   
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Figure ‎6-16: The difference in the nasal quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up examination and the baseline examination 
against the mean of these examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean.   
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Figure ‎6-17: The difference in the temporal quadrant peripapillary retinal nerve fibre 
layer thickness between the follow-up examination and the baseline examination 
against the mean of these examinations for the 13 individuals with vigabatrin-
associated visual field loss and an attenuated retinal nerve fibre layer. The filled 
symbols indicate each of the 11 individuals who had withdrawn from vigabatrin prior 
to the baseline examination and the open symbols each of the 2 individuals who were 
receiving vigabatrin at the time of the baseline examination. The solid black line 
represents the mean of the differences and the dotted black lines +/- 2SD of the mean.  
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The difference between the follow-up and baseline peripapillary retinal nerve fibre layer 
thickness for 4 individuals with a normal field against the interval between the two 
examinations are shown in Figure  6-18 to Figure  6-22 for the global value and for the 
inferior, superior nasal, temporal quadrants respectively. 
 
 
Figure ‎6-18: The difference in the global retinal nerve fibre thickness between the 
follow-up and the baseline examinations against the interval between the two 
examinations for the 4 individuals with normal fields. All individuals were withdrawn 
from vigabatrin prior to the baseline examination.  
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Figure ‎6-19: The difference in the retinal nerve fibre thickness of the inferior 
quadrant between the follow-up and the baseline examinations against the interval 
between the two examinations for the 4 individuals with normal fields. All individuals 
were withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎6-20: The difference in the retinal nerve fibre thickness of the superior 
quadrant between the follow-up and the baseline examinations against the interval 
between the two examinations for the 4 individuals with normal fields. All individuals 
were withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎6-21: The difference in the retinal nerve fibre thickness of the nasal quadrant 
between the follow-up and the baseline examinations against the interval between the 
two examinations for the 4 individuals with normal fields. All individuals were 
withdrawn from vigabatrin prior to the baseline examination. 
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Figure ‎6-22: The difference in the retinal nerve fibre thickness of the temporal 
quadrant between the follow-up and the baseline examinations against the interval 
between the two examinations for the 4 individuals with normal fields. All individuals 
were withdrawn from vigabatrin prior to the baseline examination. 
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The Mean of the retinal nerve fibre layer at the follow-up examination, for an 
individual, against that at the baseline examination for the 4 individuals with vigabatrin-
associated visual field loss is illustrated in Figure  6-23 to Figure  6-29 for the global, 
inferior, superior, nasal and, temporal quadrants, respectively. 
 
Figure ‎6-23: The mean of the global retinal nerve fibre thickness at the follow-up 
examination against that at the baseline examination for the 4 individuals with normal 
fields. All individuals were withdrawn from vigabatrin prior to the baseline 
examination. 
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Figure ‎6-24: The mean of the retinal nerve fibre thickness of the inferior quadrant at 
the follow-up examination against that at the baseline examination for the 4 
individuals with normal fields. All individuals were withdrawn from vigabatrin prior 
to the baseline examination. 
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Figure ‎6-25: The mean of the retinal nerve fibre thickness of nasal quadrant at the 
follow-up examination against that at the baseline examination for the 4 individuals 
with normal fields. All individuals were withdrawn from vigabatrin prior to the 
baseline examination. 
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Figure ‎6-26: The mean of the retinal nerve fibre thickness of superior quadrant at the 
follow-up examination against that at the baseline examination for the 4 individuals 
with normal fields. All individuals were withdrawn from vigabatrin prior to the 
baseline examination. 
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Figure ‎6-27: The mean of the retinal nerve fibre thickness of temporal quadrant at the 
follow-up examination against that at the baseline examination for the 4 individuals 
with normal fields. All individuals were withdrawn from vigabatrin prior to the 
baseline examination. 
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6.5 Discussion 
The outcome of any study of retinal nerve fibre layer is influenced by the number of 
optical coherence tomography examinations within the given time period and by the 
length of the time period, itself. Clearly, the conclusions that can be obtained from a 
time period which involves only two optical coherence tomography examinations are 
limited.  
If no alteration occurred in the retinal nerve fibre layer thickness between the two 
examinations, and given that it would be unlikely that the given pairs of measurements 
would exhibit identical values, one half of the individuals would exhibit an apparent 
deterioration at the follow-up examination and one half would exhibit an apparent 
improvement at the follow-up examination. Clearly, either a ‘true’ deterioration or a 
‘true’ improvement would be indicated by a greater proportion of individuals exhibiting 
the particular trend/ direction.  
In the current study, the median of the difference in the global retinal nerve fibre layer 
thickness between the two examinations for the 13 individuals with vigabatrin-
associated visual field loss was -3.3μm, i.e., an apparent thinning at the follow-up 
examination. The corresponding value for each of the four quadrants ranged between 
6μm (i.e., an apparent increase in thickness) and -8μm. These values lie within the 
corresponding test-retest variability, using the same protocol as the current study for 5 
sessions over a two month period, for the retinal nerve fibre layer thickness of 
individuals with stable open angle glaucoma (Budenz et al., 2008) and within the axial 
resolution of approximately 8-10μm of Time-domain optical coherence tomography. 
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Similar, or slightly smaller, values were also obtained for the individuals exposed to 
vigabatrin but with normal fields. 
Interestingly, only three of the thirteen individuals exhibited an apparent deterioration in 
both the Mean Deviation of the visual field and the retinal nerve fibre layer. Of the three 
individuals, two exhibited a worsening in the MD of approximately 2.8dB, which is 
inside the value of 3.0dB often used as an empirical cut-off value for visual field 
progression, and a reduction in the retinal nerve fibre layer thicknesses of approximately 
20μm and of approximately 5μm, respectively. The remaining individual exhibited only 
a modest worsening of the Mean Deviation, of 0.9dB, and a reduction in the retinal 
nerve fibre layer thickness of approximately 23μm.  
Clearly, there is no recovery of the attenuated retinal nerve fibre layer arising from 
vigabatrin and no recovery of the visual field following long-term withdrawal from 
vigabatrin for up to 8 years, i.e., the damage is irreversible.  
It is highly unlikely that an improvement would occur in the retinal nerve fibre layer 
without an improvement in the visual field and vice versa. 
 It has been suggested that measurement of the retinal nerve fibre layer thickness using 
optical coherence tomography provides a highly sensitive and specific technique for the 
detection of vigabatrin ocular toxicity (Lawthom et al., 2009; Clayton et al., 2011; 
Clayton et al., 2012). The medians of the respective differences in the retinal nerve fibre 
layer between examinations conducted approximately six years apart were remarkably 
small. This  suggests that prospective optical coherence tomography of the retinal nerve 
fibre layer would provide a sensitive marker for the emergence of vigabatrin ocular 
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toxicity, particularly with spectral-domain optical coherence tomography which exhibits 
better test-retest reliability than Time-domiain optical coherence tomography used in the 
current study (Budenz et al., 2008; Tzamalis et al., 2009; Garcia-Martin et al., 2012; 
Polo et al., 2014). Such an approach would be undertaken in conjunction with standard 
automated perimetry and could be facilitated by a joint probability analysis. 
6.6 Conclusion 
Overall, and within the limits both of the number of examinations and of the limited 
number of individuals within the cohort, no convincing evidence was found for either a 
deterioration or for an improvement in either the visual field or the retinal nerve fibre 
layer thickness following long-term (median 8 years) withdrawal from vigabatrin, i.e., 
the damage associated with vigabatrin is irreversible. 
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Chapter 7. The Macular Complex thickness of 
individuals exposed to vigabatrin 
7.1 Introduction  
The integrity of the macula in vigabatrin ocular toxicity has received little attention 
particularly in regard to high resolution imaging. The presence of an epi-retinal 
membrane at the macula in those with vigabatrin-associated visual field loss has been 
noted in several reports but does not appear to be a common manifestation (Krauss and 
Miller, 1999; Suarez-Baraza and Suarez-Parra, 2007).  
Conventional high contrast visual acuity in those with vigabatrin-associated visual field 
loss is considered to be within the normal range (Nousiainen, Kalviainen and 
Mantyjarvi, 2000b; Hilton et al., 2002). However, in one study, spatial contrast 
sensitivity, measured with the Pelli-Robson chart, was positively correlated with the 
extent of the remaining temporal field in individuals treated with vigabatrin 
monotherapy (Nousiainen et al 2000). In another study, eight of 12 individuals exposed 
to vigabatrin exhibited non-specific but predominantly higher spatial frequency 
attenuation in contrast sensitivity when measured with the CSV-1000 test which 
consists of four rows of eight paired circular test patches (one of the pair does not 
contain a grating) that decrease in contrast from left to right and increase in spatial 
frequency from top to bottom; however only 2 of the 12 individuals had received 
vigabatrin monotherapy (Hilton et al 2002).  
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Several studies have reported the presence of colour vision abnormalities in some 
individuals exposed to vigabatrin; such abnormalities are either non-specific (Hilton et 
al., 2002) or along the tritanopic axis (Nousiainen, Kalviainen and Mantyjarvi, 2000a). 
The latter, although interesting, is confounded by the fact that a tritanopic defect can 
also be found after a single 2000mg exposure to vigabatrin in normal individuals 
(Nousiainen et al., 2000b) and also in individuals with epilepsy treated with 
carbamazepine (Nousiainen et al., 2000b). 
Given, the presence, and the equivocal nature, of the above studies, it seemed 
reasonable to undertake an assessment of the macular complex thickness in individuals 
exposed to vigabatrin.  
In addition, during the evolution of the study, several studies implicated damage to the 
macular ganglion cells in primary open angle glaucoma, manifested as a reduction in the 
thickness of the macular ganglion cell/ inner plexiform layer complex (Tan et al., 2009; 
Hood et al., 2012; Hood et al 2013). The association between vigabatrin toxicity and 
retinal ganglion cell dysfunction, described in Chapter 4, together with these recent 
findings in glaucoma, provided further rationale for the investigation of macular 
complex thickness. 
7.2 Aim 
The primary aim of the study, therefore, was to compare the macular thickness of 
individuals with vigabatrin-associated visual field loss to the macular thickness of those 
exposed to vigabatrin but exhibiting a normal visual field. 
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The secondary aim of the study was to determine any association between the macular 
thickness and the peripapillary retinal nerve fibre layer thickness in those exhibiting 
vigabatrin-associated visual field loss and in those exposed to vigabatrin but exhibiting 
a normal visual field. 
7.3 Methods 
The study was a prospective cross-sectional cohort study. 
7.3.1 Cohort  
The cohort comprised 52 consecutively presenting individuals with refractory complex 
partial (focal) seizures who had been exposed to vigabatrin and who were attending the 
Alan Richens Unit, Welsh Epilepsy Centre, University Hospital of Wales, Cardiff.  
7.3.2 Optical Coherence Tomography 
All individuals underwent measurement of the peripapillary retinal nerve fibre layer in 
each eye using the standard 3.4 Scan protocol and the Fast Macular Thickness Map 
protocol of the StratusOCT (Software Version 3.0) (Carl Zeiss, Meditec, Dublin, CA).  
The scan pattern for the Fast Macular Thickness Map protocol consists of six equally 
separated radial line scans, centred on the fovea, which each covering a diameter of 
6mm. TD-OCT defines retinal thickness as the distance from the surface of the inner 
limiting membrane to the boundary between the inner and outer seqments of the 
photoreceptors. The Fast Macular Thickness Map protocol was used since, although the 
resolution is lower compared to the Macular Thickness Map (128 A/B-scan compared to 
512 A/B-scan), the scan time is faster (1.92 seconds for the entire scan compared to 1.28 
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seconds for each radial line). The analysis software provides a thickness for each of 
three annuli (within 1.0mm diameter, between 1.0 and 3.0mm diameter and between 3.0 
and 6.0mm diameter, respectively) which are further divided into inferior, superior, 
nasal and temporal quadrants, respectively thereby enabling nine separate 
measurements. This division has become a standard following its use in the Early 
Treatment of Diabetic Retinopathy Study (ETDRS) (Huang et al., 2011) (Figure  7-1). 
7.3.3 Visual Field Examination 
Each individual underwent visual field examination with Program 30-2 and the 
FASTPAC strategy of the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) 
in an identical manner to that described in Chapters 4, 5, and 6. 
 
Figure ‎7-1: The sectors of the Fast Macular Thickness scan of the StratusOCT. SQ 
indicates the superior quadrant, IQ indicates the inferior quadrant, NQ indicates the 
nasal quadrant, and TQ indicates the temporal quadrant. 
The pupil was dilated, if necessary, with one drop of 0.5% tropicamide and one drop of 
2.5% phenylephrine hydrochloride. Individuals were instructed to fixate the external 
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fixation target which was suitably positioned by the operator to ensure optimum 
centration of the scan on the optic nerve head. The polarization and Z-axis offset were 
optimised to gain maximum reflection of the signal. Between three and six images were 
retained for each individual. The retained images were free from blink or movement 
artefacts and had a signal to noise ratio of ≥ 33dB. All images were acquired by a senior 
medical photographer highly experienced in optical coherence tomography.  
The image exhibiting the best placement of the scan centre, compatible with the 
maximum signal to noise ratio, was then selected for each individual by the Author and 
by Professor Wild independently of each other. In cases of discordance between, the 
images for the given individual a consensus was reached following a discussion.  
7.3.4 Statistical Analysis  
Global and quadrant retinal nerve fibre layer thicknesses and the 9 separate macular 
thicknesses, automatically calculated for each given scan using the commercially 
available StatusOCT analysis software (Version 3.0), were extracted from the print-out 
for each individual and inputted into an Excel spreadsheet.  
The difference in the outcome of the macular thickness at each of the 9 sectors between 
those with vigabatrin-associated visual field loss and those exposed to vigabatrin but 
with normal fields was undertaken using a two-tailed Student’s t test for independent 
samples. Given that the study was observational in nature, no correction was made for 
the possibility of a Type I error arising amongst the 9 comparisons for each eye. 
Similarly, no correction was made for the inclusion of the two eyes from each 
individual within the study. 
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The linearity of any association between the sectorial macular thickness and the 
peripapillary retinal nerve fibre layer thickness was expressed by the Pearson 
correlation coefficient, r. Similarly, the linearity of any association between the macular 
thickness, averaged across the 9 sectors, and the Mean Deviation visual field index was 
expressed by the Pearson correlation coefficient, r. 
7.4 Results 
Thirty two of the 52 individuals exhibited vigabatrin-associated visual field loss (17 
females [53.1%], 15 males [46.9%] p<0.24). Six individuals exhibited additional 
homonymous quadrantic loss and were excluded from the analysis. Fourteen individuals 
exhibited a normal field.  
The demographic characteristics of the remaining 46 individuals are given in Table  7-1. 
The 46 individuals comprised 27 females (58.7%) and 19 males (41.3) aged 19 to 72 
years with a mean (SD) age of 47 years (11.3) and a median (IQR) of 47.6 years (41.4, 
57.4). 
The macular thickness in each eye for those with and without vigabatrin-associated 
visual field loss is given in Table  7-2. None of the paired comparisons, in either eye, 
between those with and those without vigabatrin-associated visual field loss reached 
statistical significance. 
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Characteristic 
Visual field outcome  
Normal VAVFL Combined 
Number of 
individuals  
14 32 46 
Gender 
Male 4 15 19 
Female 10 17 27 
Age (yrs) 
Mean (SD) 
Median (IQR) 
Range 
45.2 (9.5) 
43.9 (39.5, 49.9) 
32.3-65.5 
48.7 (11.9) 
50.0 (41.8, 57.7) 
22.8-72.5 
47.6 (11.3) 
47.6 (41.4, 57.4) 
22.8-72.5 
Cumulative dose of 
vigabatrin (kg) 
Mean (SD) 
Median (IQR) 
Range 
4.7 (4.7) 
2.7 (1.2, 8.1) 
0.06-14.2 
7.2 (5.0) 
7.3 (2.3, 11.6) 
0.3-19.0 
6.4 (5.0) 
6.2 (1.4, 10.5) 
0.06-19.0 
Duration of  
vigabatrin 
(yrs) 
Mean (SD) 
Median (IQR) 
Range 
5.9 (4.6) 
5.7 (1.3, 9.8) 
0.08-13.6) 
8.1 (4.1) 
8.7 (4.9, 11.6) 
0.3-16.0 
7.5 (4.4) 
8.1 (3.5, 11.3) 
0.08-16.05 
Interval from  
withdrawal 
of vigabatrin (yrs) 
Mean (SD) 
Median (IQR) 
Range 
10.0 (4.9) 
9.0 (5.7, 14.5) 
4.5-18.8 
7.7 (2.9) 
7.2 (6.3, 8.5) 
3.0-17.6 
8.4 (3.7) 
7.4 (5.9, 7.3) 
3.0-18.8 
MD average of both 
eyes (dB) 
Mean (SD) 
Median (IQR) 
Range 
-0.8 (1.3) 
-0.4 (-1.5, 0.04) 
-4.9-0.4 
-10.5 (5.5) 
-11.4 (-14.3, -4.9) 
-21.7—2.1 
-7.6 (6.4) 
-5.2 (-13.6, -1.5) 
-21.7-0.39 
PSD averaged of both 
eyes (dB) 
Mean (SD) 
Median (IQR) 
Range 
2.0 (0.6) 
2.1 (1.8, 2.4) 
1.1-2.8 
9.1 (3.6) 
10.0 (5.2, 12.2) 
2.5-14.7 
6.9 (4.4) 
5.7 (2.4, 11.6) 
1.1-14.7 
Table ‎7-1: The summary statistics, mean, standard deviation (SD) median, interquartile 
range (IQR) and range, for the demographic characteristics of the 46 individuals exposed 
to vigabatrin by visual field outcome (VAVFL indicates vigabatrin-associated visual field 
loss. MD indicates Mean Deviation, PSD indicates Pattern Standard Deviation). 
The Coefficient of Determination for the association between each sectoral macular 
thickness and the corresponding peripapillary retinal nerve fibre layer thickness for the 
32 individuals with vigabatrin-associated visual field loss and for the 14 individuals 
exposed to vigabatrin but exhibiting normal fields in is given in Table  7-3. 
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The strongest associations were present, as might be expected, between the temporal 
quadrant of the optic nerve head and the 3 and 6mm annuli nasal sectors of the macular 
thickness in the right eye (R
2 
=0.291 and R
2 
=0.20, respectively, for those with 
vigabatrin-associated visual field loss; and R
2 
=0.27 and R
2 
=0.18 for those with normal 
fields). However, surprisingly, no association was present for the left eye. 
The Coefficient of Determination for the association between the macular thickness 
averaged across the 9 sectors and the global peripapillary retinal nerve fibre layer 
thickness was 0.03 and 0.00 for the right and left eyes, respectively, for the 32 
individuals with vigabatrin-associated visual field loss and 0.04 and 0.03, respectively, 
for the 14 individuals exposed to vigabatrin but exhibiting normal fields, i.e., no 
correlation, whatsoever.  
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Right Eye Left Eye 
Visual Field Visual Field 
Region VAVFL Normal p VAVFL Normal p 
Central annulus (within 1.0 mm) 
 200 (29) 188 (20) 0.14 204 (30) 187 (19) 0.09 
Inner annulus (between 1.0mm and 3.0 mm) 
Inferior (µm) 253 (17) 245 (27) 0.98 249 (26) 253 (14) 0.76 
Nasal (µm) 252 (18) 256 (16) 0.21 260 (21) 254 (15) 0.58 
Superior (µm) 255 (20) 256 (18) 0.97 257 (17) 256 (17) 0.77 
Temporal (µm) 240 (21) 241 (17) 0.92 243 (22) 241 (13) 0.67 
Outer annulus (between 3.0mm and 6.0 mm) 
Inferior (µm)   212 (15) 213 (20) 0.49 211 (17) 215 (20) 0.61 
Nasal (µm) 234 (21) 239 (20) 0.79 236 (18) 243 (21) 0.70 
Superior (µm) 223 (17) 226 (18) 0.68 222 (16) 226 (18) 0.50 
Temporal (µm) 205 (15) 208 (16) 0.68 211 (19) 204 (15) 0.61 
Table ‎7-2: Macular thickness (Stratus OCT Fast Macular Thickness scan) in each eye 
for each of the 9 sectors for the 32 individuals with vigabatrin-associated visual field 
loss and for the 14 individuals exposed to vigabatrin but with a normal field and the 
accompanying probability value derived by a two-tailed‎Student’s‎t‎test‎for‎independent‎
samples. 
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VAVFL Normal field 
Right Eye Left Eye Right Eye Left Eye 
R
2
 R
2
 R
2
 R
2
 
1 
Inferior quadrant RNFL 
0.011 0.00 0.28 0.08 
Inferior quadrant 3mm ring  
2 
Inferior quadrant RNFL 
0.012 0.001 0.2 0.12 
Inferior quadrant 6mm ring  
3 
Temporal quadrant RNFL 
0.29 0.10 0.27 0.086 
Nasal quadrant 3mm ring  
4 
Temporal quadrant RNFL 
0.20 0.03 0.18 0.09 
Nasal quadrant 6mm ring  
5 
Superior quadrant RNFL 
0.006 0.00 0.33 0.025 
Superior quadrant 3mm ring  
6 
Superior quadrant RNFL 
0.00 0.01 0.27 0.037 
Superior quadrant 6mm ring  
Table ‎7-3: The Coefficient of Determination, R2, for the association between the 
peripapillary retinal nerve fibre layer thickness and the macular thickness for the 32 
individuals with vigabatrin-associated visual field loss and for the 14 individuals exposed 
to vigabatrin but with a normal field. 
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7.5 Discussion  
Optical coherence tomography (OCT) has become an important technique for detecting 
and monitoring macular changes (Bijlsma and Stilma, 2005) and provides repeatable 
measurements (Massin et al., 2001; Muscat et al., 2002; Virgili et al., 2007).  
The results indicate that there was no difference in the macular thickness between those 
with vigabatrin-associated visual field loss and those exposed to vigabatrin but with a 
normal field for any one of the nine sectors.  
Unfortunately, the manufacturer of the StratusOCT has not produced a database of age-
corrected normative values of the macular thickness. Given the advent of the higher 
resolution Spectral domain optical coherence tomography during the course of this 
Thesis and given the similarity of the thickness values in each sector between those with 
and without vigabatrin-associated visual field loss, it was decided not to undertake the 
time consuming task of establishing an age-corrected normative database for the nine 
sectors in each eye for StratusOCT. The more recent Spectral domain optical coherence 
tomographers, which have superseded the Time-domain optical coherence 
tomographers, all possess normative databases for the macular thickness and for the 
number of macular ganglion cells. 
Three studies describe normative values for macular thickness with the Fast Macular 
Thickness scan of the StratusOCT although one of these (Duan et al., 2010) is from 
Chinese eyes; the values from the other two studies are listed in Table  7-4. The group 
median (Grover et al., 2010) or group mean (SD) (Kelty et al., 2008) macular thickness 
derived from each of the two studies on Caucasian individuals are compared with the 
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group mean from the current study in those with and without vigabatrin-associated 
visual field loss. It can be seen from Table that the normal values for macular thickness 
derived by Kelty et al (2008) are lower than those derived by Grover et al (2010). These 
differences are unlikely to be explained by the differences in age between the two 
cohorts or by the difference between the median and mean. In addition, it can be seen 
from the same Table that the macular thickness of those with vigabatrin-associated 
visual field loss and of those exposed to vigabatrin but with normal fields are 
substantially lower than the normal values of either Kelty et al (2008) or Gover et al 
(2010). 
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  Right eye Left eye 
Sector 
 
Grover. 
et al., 
(2010) 
 
Kelty 
et al., 
(2008) 
 
VAVFL 
VGB 
Normal 
Kelty 
et al., 
(2008) 
 
VAVFL 
VGB 
Normal 
Central annulus (within 1.0 mm) 
 202.3 
219 
(25) 
200 (29) 188 (20) 
217 
(24) 
204 (30) 187 (19) 
Inner annulus (between 1.0mm and 3.0 mm) 
Inferior 
(µm) 
264.7 
290 
(19) 
253 (17) 245 (27) 
288 
(24) 
249 (26) 253 (14) 
Nasal 
(µm) 
265.4 
290 
(23) 
252 (18) 256 (16) 
277 
(29) 
260 (21) 254 (15) 
Superior 
(µm) 
270.8 
290 
(20) 
255 (20) 256 (18) 
290 
(31) 
257 (17) 256 (17) 
Temporal 
(µm) 
255.7 
275 
(23) 
240 (21) 241 (17) 
290 
(24) 
243 (22) 241 (13) 
Outer annulus (between 3.0mm and 6.0 mm) 
Inferior 
(µm) 
268.9 
245 
(31) 
212 (15) 213 (20) 
247 
(19) 
211 (17) 215 (20) 
Nasal 
(µm) 
277.4 
272 
(20) 
234 (21) 239 (20) 
232 
(18) 
236 (18) 243 (21) 
Superior 
(µm) 
269.5 
252 
(19) 
223 (17) 226 (18) 
255 
(28) 
222 (16) 226 (18) 
Temporal 
(µm) 
257.5 
233 
(20) 
205 (15) 208 (16) 
273 
(20) 
211 (19) 204 (15) 
Table ‎7-4: The group median (Grover. et al., 2010) and group mean (SD) (Kelty et al., 
2008) normal values of macular and foveal thickness, by sector, compared to the group 
mean macular and foveal thicknesses for those with vigabatrin-associated visual field 
loss and for those exposed to vigabatrin but with normal fields. 
Given the involvement of the retinal ganglion cells in the pathophysiology of vigabatrin 
ocular toxicity, it can be speculated that the reduction in the macular thickness present 
in both groups can be attributed to a reduction in the number of ganglion cells at the 
macular. 
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The retinal ganglion cells and their axons constitute 30-35% of the macular thickness. 
Approximately 50% of the retinal ganglion cells are located within 4 to 5 mm from the 
centre of the fovea (Curcio and Allen, 1990) and the peak density occurs at an 
eccentricity of between 750 and 1100µm where the cell density may be 4 to 6 soma 
thick (Wässle et al., 1989).  
A reduction in the macular thickness, due to atrophy of the ganglion cells and axons, 
has long been noted in glaucoma (Curcio and Allen, 1990; Zeimer et al., 1998; Guedes 
et al., 2003). Macular thickness measurements in glaucoma, determined by Time- 
domain optical coherence tomography, correlate well with the outcome of the visual 
field (Greenfield, Bagga and Knighton, 2003; Seiji et al., 2011) and with those 
determined by scanning laser ophthalmoscopy and correlate well with other structural 
parameters (Seiji et al., 2011). The advent of Spectral domain optical coherence 
tomography, which enables segmentation of the retinal ganglion cells at the macula, has 
shown that, in early glaucoma, both deep local, and shallow widespread, retinal nerve 
fibre damage of the macular region is present (Hood et al., 2014). The localised retinal 
ganglion cell loss is associated with localised visual field loss, having accounted for the 
displacement of the retinal ganglion cells from the foveal centre (Hood et al., 2013). 
The damage to the retinal ganglion cell layer is typically arcuate and is often associated 
with localised peripapillary nerve fibre layer thinning at a narrow region of the inferior 
quadrant of the disc labelled the macular vulnerability zone (MVZ). A small 
(cecocentral) region of the inferior macula, and all of the superior macula (inferior 
visual field), project to the temporal quadrant, a region that is less susceptible to damage 
(Hood et al., 2013). The damage to the retinal ganglion cell complex can be easily 
overlooked by standard automated perimetry using the 6° square stimulus grid of 
Program 24-2 or 30-2. Reduced ganglion cell attenuation occurs in the presence of a 
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normal MD by Program 24-2 (Hood et al., 2012). The use of Program 10-2 is now 
advocated for the investigation of early glaucoma (Hood et al., 2012; Traynis et al., 
2014) along with combined probability maps of the visual field and ganglion cell layer 
outcomes (Hood et al., 2012) when the stimulus locations are adjusted to account for the 
displacement of the ganglion cell soma around the fovea (Hood and Raza, 2011). From 
a perimetric perspective, more than 50% of the eyes with predominantly mild to 
moderate glaucomatous field loss exhibit abnormality in the immediate superior 
paracentral region within an eccentricity of 3° (Schiefer et al., 2010). In addition, 9% of 
either glaucoma suspects or individuals with early glaucoma will be classified as normal 
when evaluated with Program 30-2 compared to Program (10-2) and the severity of 
glaucomatous damage will be underestimated in 13% of the hemifields (Traynis et al., 
2014).  
Clearly, with the advent of spatially- and time-encoded frequency domain OCT, the 
clinical utility of the dataset recorded by Time domain optical coherence tomography in 
the present study, is limited. However, the similarity of the macular thickness values 
between those with and without vigabatrin-associated visual field loss, the suggestion 
that both sets of values are lower than those found in the normal eye and the findings 
from Chapter Six which indicate that vigabatrin ocular toxicity is associated with a 
bilateral optic neuropathy, indicate the direction of future work. A study should be 
undertaken using Program 10-2, or even a more appropriate customised test for macular 
function, and either Spectral domain optical coherence tomography or swept source 
optical coherence tomography which would evaluate the structural and functional 
outcomes in individuals commencing vigabatrin therapy, in those previously and/ or 
currently exposed to vigabatrin but with apparently normal fields, and in those with 
vigabtrin-associated visual field loss. If it can be shown that the time course of the 
253 
 
vigabtrin toxicity is such as to affect the ganglion cell layer at the macula prior to the 
more immediate periphery, then a macular investigation protocol incorporating both 
perimetry and Spectral domain optical coherence tomography, segemented for ganglion 
cell soma and/ or axonal count, could be used at regular intervals for those newly treated 
with vigabtrin. Any indication of a macular abnormality, either by perimetry or by 
optical coherence tomography, or both, would result in withdrawal from vigabatrin 
without loss of the more peripheral visual field. Such an approach would be of 
considerable benefit to both individuals and clinicians, alike. 
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Chapter 8. Summary of the studies and 
conclusions 
8.1 Modelling the risk of visual field loss arising from long-
term exposure to vigabatrin: a cross-sectional approach 
The study described in Chapter Three was the first to evaluate the visual field outcome 
after long-term therapy with vigabatrin. The risk (frequency) of vigabatrin-associated 
visual field loss was assessed in terms of cumulative dose and duration of vigabatrin. 
The cohort comprised 147 adults with refractory complex partial (focal) seizures. The 
median duration of vigabatrin therapy was 7.9 years (IQR 3.6, 11.0) and the median 
cumulative dose 5.8kg (IQR 2.5, 8.7). 
The frequency of vigabatrin-associated visual field loss increased with increase in 
cumulative dose and in treatment duration, reaching a frequency of 75-80% at 
approximately 5kg dose or 6 years of therapy; however, cumulative dose seemed to 
exert a greater influence than duration.  
The frequency was substantially higher than the ‘consensus’ figure of 30-40% and 
substantially increases the risk-benefit of treatment with vigabatrin and, with the greater 
requirement for more clinical examinations, increases the cost-benefit of the drug (Wild 
et al., 2013).  
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8.2 Topographical variations in the ganglion cell structural 
and functional association in vigabatrin toxicity  
The study described in Chapter Four determined the relationship, in individuals with 
vigabatrin-associated visual field loss and in individuals exposed to vigabatrin but with 
normal fields, between the functional and structural outcomes expressed in terms of the 
number of residual ganglion cell soma derived by standard automated perimetry and of 
the number of residual ganglion cell axons derived by Time-domain optical coherence 
tomography. The cohort comprised 40 consecutively presenting individuals who had 
previously been treated with vigabatrin for refractory complex partial (focal) seizures 
and who had volunteered to take part in the study. Two control groups, namely, 18 
individuals with open angle glaucoma and 22 normal individuals were used for 
comparative purposes.  
A strong linear association was present between the number of residual ganglion cell 
soma derived by standard automated perimetry and the number of residual ganglion cell 
axons derived by the Time-domain optical coherence tomography. The trend lay slightly 
above the line of unity indicating a slightly greater estimate of ganglion cell soma 
compared to ganglion cell axons. A similar strong linear association was present, as 
expected, for the individuals with open angle glaucoma and confirms that found by 
others (Hood et al., 2007; Hood and Kardon, 2007; Hood et al., 2008; Medeiros et al., 
2012a; Medeiros et al., 2012b). Derivation of the association by sector of the optic 
nerve head was limited by the undersampling of the stimulus locations of the Humphrey 
Field Analyzer Program 24-2. 
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The findings indicate that vigabatrin-associated ocular toxicity causes an optic 
neuropathy; however; it is not known whether the mechanism is of primary or 
secondary in nature.  
8.3 The outcome of the visual field following long-term 
withdrawal of vigabatrin 
The study described in Chapter Five determined the outcome of the long-term visual 
field examination in relation to the time-course of exposure to vigabatrin with particular 
reference either for further deterioration or for improvement in those with vigabatrin-
associated visual field loss or for a deterioration in those with previously normal fields. 
The final cohort comprised 27 individuals, 19 of whom had vigabatrin-associated visual 
field loss and 8 who had been exposed to vigabatrin but manifested normal fields. All 
individuals were off-drug at the time of the follow-up visual field examination. The 
median length of withdrawal from vigabatrin, at the time of the follow-up examination 
was 7.1 years (IQR 5.4, 8.4). The median interval between the baseline and follow-up 
examinations was 7.0 years (IQR 6.5, 7.6). 
Within the limits of the size of the cohort, and of the two visual field examinations, i.e., 
at baseline and at follow-up, vigabatrin-associated visual field loss did not appear, 
overall, to show either a worsening or an improvement relative to that at baseline. 
Similarly, those individuals exposed to the drug but with normal fields at baseline did 
not manifest any subsequent deterioration. 
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8.4 The outcome of the retinal nerve fibre layer following 
long-term withdrawal of vigabatrin 
The study described in Chapter Six determined the outcome of long-term Time-domain 
optical coherence tomography imaging in relation to the time-course of exposure to 
vigabatrin with particular reference either for further deterioration or for improvement 
in the retinal nerve fibre layer thickness. The final cohort comprised 17 individuals, 13 
of whom had vigabatrin-associated visual field loss and 4 who had been exposed to 
vigabatrin but manifested normal fields. All individuals were off-drug at the time of the 
follow-up examination. The median  length of withdrawal from vigabatrin, at the time 
of the follow-up examination, was 8.0 years (IQR 5.3, 10.2). The median interval 
between the baseline and follow-up examinations was 6.5 years (IQR 5.8, 6.9). 
Within the limits of the size of the cohort, and of the two optical coherence tomography 
examinations, i.e., at baseline and at follow-up, the retinal nerve fibre layer thickness 
did not appear, overall, to show either a worsening or an improvement relative to that at 
baseline in either those with vigabatrin-associated visual field loss or in those 
individuals exposed to the drug but with normal fields. 
8.5 Macular thickness evaluation  
The study described in Chapter Seven determined the macular thickness by Time-
domain optical coherence tomography of individuals with vigabatrin-associated visual 
field loss and of individuals exposed to vigabatrin but with a normal visual field. The 
cohort comprised 32 individuals with vigabatrin-associated visual field loss and 14 
exposed to vigabatrin but with a normal visual field. 
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The group mean macular thickness was similar between those with and without 
vigabatrin associated visual field loss. Although, no corresponding age-corrected 
normal values are supplied by the StratusOCT, the group means from both groups were 
lower than those in the literature. Even so, there is some difference within the literature 
as to the normal value(s) for macular thickness. Given the advent of the higher 
resolution Spectral-domain optical coherence tomography during the compilation of this 
thesis, it was decided not to undertake the lengthy and costly task of collecting a data 
base of age-corrected normal values for macular thickness. 
8.6 Future work  
One pressing topic for the future study of vigabatrin-ocular toxicity centres upon the use 
of Spectral-domain optical coherence tomography to ascertain the retinal ganglion cell 
axonal count from the peripapillary retinal nerve fibre layer thickness. A combined 
structural and functional index based upon residual ganglion cell soma and ganglion cell 
axonal counts, derived by standard automated perimetry and (Spectral-domain) optical 
coherence tomography appears to be of value in the detection and follow-up of open 
angle glaucoma (Medeiros et al., 2012a; Medeiros et al., 2012b; Marvasti et al., 2013; 
Tatham et al., 2013a) and this approach should be applied to the monitoring of patients 
undergoing treatment with vigabatrin.  
A second pressing topic, centres upon the use of Spectral-domain optical coherence 
tomography to determine the macular ganglion cell inner plexiform layer thickness. The 
thickness is compared to the age-corrected normal values within the database of the 
instrument. Macular ganglion cell thickness has been shown to be abnormal in open 
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angle glaucoma (Hwang and Kim, 2012; Hwang et al., 2014), and to be comparable in 
diagnostic performance to the peripapillary retinal nerve fibre layer thickness and the 
neuroretnal rim area in preperimetric glaucoma (Shin et al., 2013; Kim et al., 2014) and 
to be statistically significantly thinner in normal relatives of individuals with open angle 
glaucoma than in healthy individuals with a negative family history of open angle 
glaucoma (Mwanza et al., 2011; Mwanza et al., 2012; Rolle et al., 2014).  
Given the outcome of the macular thickness study (Chapter Seven) and given the 
concept from Chapter Four that vigabatrin ocular toxicity is an optic neuropathy, 
measurement of macular thickness should also be undertaken in patients undergoing 
treatment with vigabatrin. However, care will need to be exercised in that a reduced 
macular ganglion cell inner plexiform layer thickness, arising from trans-synaptic 
degeneration, has been found in hemianopianopsia or quadrantanopia arising from brain 
lesions due to stroke or surgery (Keller, Sanchez-Dalmau and Villoslada, 2014) and in 
optic pathway glioma (Gu et al., 2014).  
The use of the macular ganglion cell inner plexiform layer thickness, in this way, would 
be supplemented by the use of the Humphrey Field analyzer Program 10-2. The latter 
program comprises 68 stimulus locations with an inter-stimulus separation of 2˚, centred 
upon the fovea, and with the stimuli adjacent to the vertical and horizontal midlines 
offset by 1˚. Such an approach would facilitate the structural and functional outcome 
within the macular region. If the macular ganglion cell soma and or axons exhibited 
abnormality prior to the more peripheral ganglion cells, an individual could be 
withdrawn from vigabatrin prior to the occurrence of more widespread ocular damage. 
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Finally, a national register should be compiled of those undergoing, de novo, vigabatrin 
therapy. Such a register would contain the outputs from the various ophthalmological 
tests etc. and would provide an open access anonymised natural history of the evolution 
of vigabatrin ocular toxicity. 
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